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ABSTRACT

FOKI VITAMIN D RECEPTOR GENE POLYMORPHISMS AND METABOLIC
HEALTH IN PREGNANT SAUDI WOMEN
MAY 2018

MAYSA H. ALZAIM, B.S., KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Associate Professor Richard Wood

Lifestyles have been dynamically changing in the past few years in Saudi Arabia,
and the prevalence of non-communicable diseases (NCDs), such as obesity, diabetes,
hypertension, high cholesterol, and other cardiovascular diseases (CVD), is notably
increasing. In fact, NCDs are affecting a growing number of people in SA, especially
women of childbearing age. Vitamin D deficiency has also become pandemic and a major
public health concern among the Saudi population despite the abundance of sunlight. The
most vulnerable groups are pregnant women and their newborns. Previous studies have
correlated low vitamin D status with a higher risk of adverse short- and long-term health
consequences for both mother and child. Therefore, identification of novel genetic
markers in women at risk of adverse pregnancy outcomes could lead to earlier
identification of at-risk pregnancies and inform possible interventions to reduce adverse
health outcomes.
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The fact that vitamin D receptors (VDR) are present in almost every tissue of the
human body has led to a debate about the extra-skeletal functions of vitamin D. To date,
numerous studies have associated VDR gene polymorphisms to serious chronic illnesses.
One candidate gene that has attracted interest in the literature is FokI VDR
polymorphisms. FokI VDR, is capable of altering the protein structure and produces two
structurally different variants: a longer (f allele) and a shorter (F allele), which is more
effective and has higher transcriptional activity than the long variant (f allele).
Since there is scarce research regarding the potential association between FokI
VDR polymorphism and adverse metabolic health outcomes in pregnant Saudi women,
we hypothesized that Saudi mothers with poorer vitamin D status plus expression of the
longer, less effective f version of the VDR protein would be at greatest risk of any
adverse effects, such as vitamin D deficiency, gestational diabetes mellitus (GDM), and
metabolic syndrome (MS).
We carried out a cross-sectional study in pregnant Saudi women and compared
the association between the FokI VDR genotype and different metabolic health outcomes.
The participants were randomly selected from primary health care centers and
governmental hospitals scattered around the city of Riyadh during their first and second
trimesters check-up between December 2013 and January 2016. The FokI VDR genotype
was assessed, and its association with different variables, including vitamin D status,
GDM, and MS and its components, were also analyzed.
In the first study, we investigated the association between FokI VDR gene
polymorphism and serum 25-hydroxyvitamin D (25(OH)D) levels in 345 pregnant Saudi
women (273 with vitamin D deficiency and 72 non-deficient subjects) in their first
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trimester. About 79% of the women studied were vitamin D deficient (25(OH)D < 50
nmol/L). Our findings indicated that the Ff genotype and the combined variant genotype
(Ff+ ff) showed a significant decrease in the risk of developing vitamin D deficiency (FF
vs. Ff, OR = 0.44, 95% CI = 0.20–0.94, P = 0.035, FF vs. Ff+ff, OR = 0.42, 95% CI =
0.20–0.88, P = 0.022), after adjusting for confounding factors that had significant effect
on altering vitamin D status.
In the second study, we examined whether there was a difference in the risk of
having GDM among the various FokI VDR genotypes in 108 GDM patients and 260
healthy pregnant women in their second trimester. We found no significant difference in
risk. However, within the group of patients carrying the minor ff genotype, we found that
serum 25(OH)D was significantly and inversely associated with fasting serum glucose
and hemoglobin A1C. Vitamin D deficiency was highly prevalent among study
participants amounting to 85.3%. It was also significantly associated with GDM
(P=0.016) and glucose indices such as fasting insulin, HOMA_IR and HOMA_.
In the third study, we investigated the association of the FokI VDR genotype as a
risk factor for MS and its components in 368 pegnant Saudi women (44 with MS and 324
without MS) in their second trimester. We found that the minor ff genotype was a
significant risk factor for MS (P = 0.039; OR = 2.91; 95% CI, 1.05–8.1).
Together, the results of the previous studies suggest that FokI VDR gene
polymorphism could be a risk factor for vitamin D deficiency, poorer glucose
homeostasis, and MS in the Saudi population.
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CHAPTER 1
CHALLENGES FACING PREGNANT SAUDI WOMEN

Saudi Arabia is a high-income country with a well-developed health care system,
including free antenatal care for all pregnant Saudi women at primary healthcare centers
as well as referral to government hospitals.1 Moreover, in the past few years there has
been a significant improvement in the educational and employment status of the Saudi
female population.2 These enhancements in medical care and sociodemographic
characteristics have clearly manifested in overall pregnancy outcomes, including the
maternal mortality ratio, which declined from 23/100,000 in 2000 to less than 13/100,000
in 2015.2 Despite this, epidemiological studies conducted in Saudi Arabia found a high
stillbirth rate of 12/1000 live births, which is high when compared with similar highincome countries, with the reason attributed to a high prevalence of maternal diabetes and
obesity.1
The rapid urbanization and advancement in socioeconomic status has resulted in a
significant change in Saudi lifestyle behaviors, including increased consumption of highenergy dense foods, physical inactivity, and the subsequent emergence of noncommunicable diseases (NCDs) such as obesity, diabetes, hypertension, high cholesterol,
and other cardiovascular diseases (CVD).1 NCDs have thus become a major public health
problem and are now the primary cause of death among adults in Saudi Arabia.3 In fact,
the death toll from NCDs reached 78% during 2014, and CVDs were responsible for
about (46%) of these deaths.4 The most alarming fact is that these risk factors are
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prevalent at younger ages,5 and it is well known that Saudi Arabia has a young
population. More than half of the population is younger than 25 years,6,7 78.3% of
women are under the age of 40,8 and the over-65 group constitutes only 3.7% of the total
population.1 These health challenges are concerning in this specific group of women.
Therefore, prevention and early detection should be prioritized to improve health in the
Kingdom of Saudi Arabia (KSA).
In addition to the previously mentioned health problems, vitamin D deficiency is
highly prevalent in KSA, particularly in females and in the younger age groups.9 Al-Faris
conducted a cross-sectional study of 160 pregnant Saudi women and found that younger
pregnant women (aged 20–34 years) had a significantly higher prevalence of vitamin D
deficiency compared with older women (aged 35–49 years) (P = 0.029).10 The author
attributed this observation to unhealthy dietary patterns among younger women,
characterized by high fast food consumption and less vitamin D intake or
supplementation.10
The fact that the previously mentioned health problems are more common at
younger ages deserves immediate attention and investigation of the underlying
mechanisms. Specifically, according to Al Quaiz et al., Saudi women are at a greater risk
of developing CVD and diabetes compared to a decade ago, with a notable increase in
obesity compared to men.6 Moreover, a report published by the World Health
Organization in 2015 revealed that life expectancy among Saudi Arabian women is still
lower than that observed in many developed countries (Japan = 86.8, Australia = 84.8,
United Kingdom = 83, United States of America = 81.6, United Arab Emirates = 78.6,
KSA = 76 years).11 This chapter will address the health problems prevalent among
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pregnant Saudi women and the risk factors that contribute to adverse health outcomes for
mothers and their newborns.
1.1 Vitamin D Deficiency in Pregnancy
1.1.1

Prevalence and Diagnosis
Vitamin D deficiency is considered a public health problem around the world.12

Vitamin D status has been investigated in numerous countries based on the concentration
of serum 25-hydroxyvitamin D (25(OH)D).13 There is a debate in the literature regarding
the definition of vitamin D deficiency. Most researchers agree that a 25(OH)D
concentration < 50 nmol/L is an indication of vitamin D deficiency, whereas a 25(OH)D
concentration of 51–74 nmol/L is considered to indicate insufficiency; concentrations >
75nmol/L are considered to be sufficient.13 This is based on the observation that intestinal
calcium absorption is maximized above 80 nmol/L, and parathyroid hormone (PTH)
concentrations in adults continue to decline and reach their nadir at ≈75–100 nmol/L.13
As there are no tailored recommendations for the diagnosis and treatment of
vitamin D deficiency in the Middle Eastern region, the Prince Mutaib Chair for
Biomarkers of Osteoporosis (PMCO) in King Saud University (KSU), Riyadh, KSA,
together with local experts and in cooperation with the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), organized a panel to
resolve this issue and established a reference range for the cut-off values of serum
25(OH)D based on the following: Vitamin D sufficiency is defined as circulating serum
25(OH)D ≥ 50 nmol for the general population and vitamin D adequacy as serum
25(OH)D > 75 nmol/L for the frail and osteoporotic elderly. The panel also
recommended vitamin D supplementation of 1000–2000 IU/day (vitamin D2 or vitamin
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D3) for pregnant Saudi women, which it claimed would be feasible, safe, and could
improve maternal and fetal outcomes.14
In KSA, two meta-analyses were conducted to assess the prevalence of vitamin D
deficiency across all demographics of the Saudi population.15,16 Both systematic reviews
used the same cut-off values for determining vitamin D status and were conducted around
the same years. Strangely, however, they reported contentious results. In the first metaanalysis, which included 16 articles and was carried out between 2008 and 2015,15 AlAlyani et al. found that the overall rate of vitamin D deficiency in the healthy Saudi
Arabian population was 63.5%.15 Meanwhile, the other meta-analysis, which was
conducted by Al-Daghri between 2011 and 2016 and included a review of 13 articles,
showed the overall prevalence of vitamin D deficiency to be 81.0%.16 The discrepancy
between these numbers is relatively large and could be due to a non-unified cut-off for
vitamin D deficiency, different diagnostic methodologies, and varying study designs and
qualities. 17
Although this issue seems controversial, no one can deny that KSA, the land of
sunshine, has alarming rates of vitamin D deficiency in most of its population, across all
ages and in both genders. Specifically, Saudi females have higher rates of severe vitamin
D deficiency (< 25 nmol/L) when compared to males (44.6% vs. 28.3%, p < 0.000), as
reported in a retrospective observational study of 10,709 patients.18 This issue needs to be
highlighted and carefully addressed, especially in vulnerable groups that appear to be
more susceptible to developing vitamin D deficiency, such as women of childbearing age,
pregnant women, and pregnant women at risk of GDM.19 Previous studies have shown
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that vitamin D deficiency occurs in up to 90% of pregnant women and depends on many
factors, such as the country of origin and lifestyle.20
In KSA, vitamin D deficiency affects approximately 78% of Saudi females among
various age groups.21,22 Studies of women of childbearing age found a variable
prevalence of vitamin D deficiency, from one-third22 to three-fourths23 of the population
studied. Al-Faris found that over 90% of pregnant Saudi women were either vitamin D
deficient (serum 25(OH)D level < 50 nmol/L) or insufficient (serum 25(OH)D level =
50–74 nmol/L).10 In another study, which was conducted on a larger sample of 1,097
pregnant Saudi women living in Riyadh, the capital city of KSA, Fouda et al. found that
almost 85% of pregnant subjects and 88% of their neonates were vitamin D deficient
(serum 25(OH)D level < 50 nmol/L).17 Similarly, Al-Wassia and Abo-Ouf and Alsheikh
et al. reported a very high prevalence of maternal vitamin D deficiency ranging, from
86.4% to 90.5% in pregnant Saudi women. 24,25 Al-Wassia and Abo-Ouf also found that
86% of infants were vitamin D deficient.24 Although numerous studies have assessed the
prevalence of vitamin D deficiency in KSA, information is still lacking regarding vitamin
D status throughout pregnancy, as most previous studies have measured vitamin D once
in the third trimester or at delivery.
1.1.2

Causes
Maternal vitamin D status varies across different pregnancy trimesters, and the

risk of vitamin D deficiency increases due to the high maternal and fetal demands.25
Aside from this, vitamin D levels are usually affected by several factors. The major risk
factors associated with vitamin D deficiency in KSA have been agreed upon by several
investigators and are related to Saudi customs.10,16,17 KSA receives abundant sunshine
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year round, and in summer months the temperatures often rise above 50C. Therefore,
Saudis avoid sun exposure and limit their outdoor activities during the daytime.10 In
addition, due to cultural and religious reasons, the majority of Saudi women wear dark
veils that cover nearly all their body parts, which block sunlight and necessitate increased
circulating 25(OH)D production from sun exposure.16,23,26 Certainly, there are many other
risk factors that affect vitamin D status in Saudi women, including dietary habits, dark
skin pigmentation, pregnancy, physical inactivity, obesity, and lack of government
regulation for vitamin D fortification of food.18, 25
Interestingly, Hussain et al. found that vitamin D deficiency was more common
and severe in Saudis than in non-Saudis living in the same city of Riyadh.18 This
observation sheds light on the influence of genetic variantiations, such as vitamin D
receptor gene polymorphisms, which might play a role in vitamin D metabolism and
disease susceptibility.25 Sadat-Ali et al. were the first to investigate the genetic influence
on vitamin D status in the Saudi population.27 They found that several single nucleotide
polymorphisms (SNPs) in vitamin D-related genes were significantly associated with
vitamin D deficiency compared to the population with normal vitamin D levels.27
However, there have been no studies to confirm such a relationship in KSA with larger
sample sizes and controlling for different confounders that might mask vitamin D status,
such as the risk factors mentioned earlier in this section.
1.1.3

Adverse Perinatal Outcomes

Vitamin D deficiency during pregnancy has been associated with several maternal
and offspring complications that persist later in life.28 Stores of vitamin D in newborns
are dependent on maternal vitamin D status.20 Maternal serum and cord blood 25(OH)D
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are highly correlated, and both maternal serum and cord blood 25(OH)D levels increase
after maternal vitamin D supplementation.29 Indeed, two recent cross-sectional studies
found a significant association between maternal serum 25(OH)D and neonatal cord
blood Vitamin D levels in pregnant Saudi women.17,24
It has been also suggested that low serum 25(OH)D in the mother might cause
reduced transfer of 25(OH)D to the fetus, leading to impaired growth, low infant birth
weight, delayed bone ossification and congenital rickets, abnormal tooth enamel
formation, and lower bone mineral content.30 Case reports show that neonatal
complications from extreme maternal vitamin D deficiency can be life threatening, e.g.,
severe hypocalcemic fits with high risks of resultant brain damage and neonatal heart
failure.29
Aside from causing adverse skeletal effects, vitamin D deficiency during
pregnancy has also been linked with a number of maternal problems, including infertility,
preeclampsia, gestational diabetes, caesarean section, bacterial vaginosis, postpartum
depression, neonatal hypoglycemia, low birth weight, and preterm birth.10,31-33
Fortunately, a recent study found that supplementing pregnant women with vitamin D
and increasing maternal serum 25(OH)D levels to ≥ 100 nmol/L was associated with a
60% reduction in preterm birth risk in a large, diverse population of women.34
In KSA, Alsheikh et al. studied the effect of hypovitaminosis D on adverse
pregnancy and neonatal outcomes and found that hypertensive pregnancy disorders and a
history of miscarriage were significantly associated with vitamin D deficiency and
insufficiency when compared to women with normal vitamin D levels.25
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1.2 Gestational Diabetes Mellitus
1.2.1

Prevalence and Diagnosis
The American Diabetes Association (ADA) defines GDM as “carbohydrate

intolerance resulting in high blood sugar (hyperglycemia) of variable severity, with onset
or first recognition during pregnancy.”35 It is usually diagnosed between 24 and 28 weeks
of gestation.35 GDM is recognized in the global population as ranging from 1% to 14% of
all pregnancies, depending on the ethnicity and the GDM diagnostic tests used.36 Hence,
GDM is considered to be one of the most common complications of pregnancy.37 When
compared to adverse maternal outcomes, GDM is the most prevalent complication seen
in pregnant Saudi women (11.1%).25 In fact, in their large multicenter cohort study,
Wahabi et al. reported that the prevalence of GDM (24%) and pre-GDM (4.3%) in
pregnant Saudi women is among the highest in the world and is associated with high
maternal and neonatal morbidities and mortalities.1 Another study conducted in KSA
showed that 18.7% of all pregnancies led to a GDM status.38 This alarmingly high rate
exceeds the prevalence that is reported in the United States and Europe.39 In fact, the
prevalence of GDM in the United States is far less than in KSA, ranging from 3.47% to
7.15%.40
Although GDM affects only a sub-group of the population, its prevalence is rising
along with soaring rates of obesity and Type 2 diabetes mellitus (T2DM).41 For example,
In the United States, Getahun et al. reported that the prevalence of GDM increased
gradually between 1989–1990 and 2003–2004 by 122%, from 1.9–4.2%, respectively.42
Considering the high burden of T2DM in the Saudi population and the fact that the
occurrence of GDM is directly related to that of T2DM, a high rate of GDM is
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anticipated to continue to increase in pregnant Saudi women.1 The prevalence of GDM is
expected to increase fourfold in subsequent decades,43 stressing the importance of further
research into its pathophysiology.
1.2.2

Causes
The most commonly reported risk factors for the development of GDM are high

maternal age (> 35 years), obesity, ethnicity, parity, family history of type 2 diabetes
and/or GDM, previous delivery of a macrosomic infant, and diagnosis of polycystic
ovarian syndrome (PCOS).44 However, these well-known risk factors are only
responsible for about 50% to 60% of the risk of future GDM.45 Other factors mentioned
in observational studies that are independently associated with higher GDM risk include
the following: higher triglycerides,46 inflammation,47 gestational weight gain (GWG),48
and low vitamin D levels.19 Studies from KSA reported that the most commonly observed
risk factors were increased maternal age, higher body weight and BMI, previous history
of GDM, macrosomia, and multiparae.49,50 The question remains: Why are certain ethnic
groups, such as pregnant Saudi women, at a higher risk of GDM?
The underlying pathophysiological mechanisms for GDM are poorly understood
and seem to be multi-factorial.51,52 Nevertheless, it is well known that gestational steroid
hormones coupled with placental outcomes (hormones and cytokines) are altered by
insulin secretion and resistance.53 When insulin secretion is unable to meet increased
maternal needs, secondary to increased resistance, GDM occurs.51,53 As a result, an
increased request for insulin during pregnancy places an additional burden on pancreatic
β-cells, which can lead to pancreatic dysfunction.51 Previous data have linked vitamin D
deficiency to GDM, but some studies have not found this association. A recent systematic
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review found that vitamin D deficiency (serum 25(OH)D <50 nmol/L) in pregnancy is
associated with a 1.61-times increased risk of GDM.54 However, this association remains
inconclusive and requires more studies to elucidate the impact of low vitamin D status on
the occurrence of GDM.
1.2.3

Adverse Perinatal Outcomes
Gestational diabetes (GDM) complicates 3–14% of pregnancies, and it is

responsible for an important proportion of fetal and maternal morbidity and mortality in
both the short and long term.42 Short-term effects include maternal GDM complications,
such as pregnancy-induced hypertension, preeclampsia, urinary tract infections, and
cesarean deliveries;55 long-term complications include a 35−80% higher risk of recurrent
GDM,56 a 70% higher risk of developing T2DM within 10 years after delivery,53 and a
higher risk of developing metabolic syndrome.57 In the offspring of GDM mothers, there
can also be short-term complications, such as fetal macrosomia, birth trauma, shoulder
dystocia respiratory distress syndrome, congenital malformation, and neonatal jaundice
as well as an increased risk of neonatal intensive care unit (NICU) admission.42
Meanwhile, long-term complications for the child can include childhood obesity,
metabolic syndrome, T2DM, and CVD.58
According to a study performed in KSA, GDM was a major contributor to
perinatal death, congenital malformation, and neonatal jaundice.59 Similarly, most studies
conducted in KSA reported that GDM affected both the mother and fetus. GDM mothers
were more likely to have cesarean deliveries, and the infants born to such mothers were at
higher risk of developing hypoglycemia, higher birth weight, hyperbilirubinemia,
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macrosomia, and higher NICU admissions when compared to infants born to non-GDM
mothers.49
Interestingly, not only mothers with GDM suffered from perinatal complications;
pregnant Saudi women with pre-GDM also experienced hypertensive disorders during
pregnancy, induction of labor, cesarean section delivery, preterm delivery between 34
and 36 weeks, stillbirth rate, neonatal admission to NICU, macrosomia, low APGAR
scores, and shoulder dystocia when compared to nondiabetic women.1
1.3 Metabolic Syndrome
1.3.1

Prevalence and Diagnosis
Metabolic syndrome (MS) is a cluster of risk factors for T2DM and CVD.25,60 The

National Institutes of Health (NIH) defines MS as having at least three of the following
risk factors: central obesity, elevated triglycerides, low high-density lipoprotein
cholesterol, hypertension, and elevated fasting plasma glucose.61
MS is considered an epidemic of the 21st century and a huge burden that needs to
be carefully addressed in both developed and developing countries.60 According to the
International Diabetes Federation (IDF), a quarter of the adult population worldwide
suffers from MS.62 The prevalence estimates of MS differ depending on which defining
criteria are utilized. Using the IDF’s definition of MS, according to the National Health
and Nutrition Examination Survey (NHANES), the prevalence of MS rose significantly
from 25.3% between 1988 and 1994 to 34.2% between 2007 and 2012 among US
adults.63
In KSA, the prevalence of MS is much higher than in the US, with rates varying
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between 25.5% and 55% when using the same IDF definition.64 After reviewing different
studies and using various defining criteria, Bahijri and Raddadi found that the overall
prevalence of MS in the Saudi population varies from 13.6% to 57%.65 The authors
attributed the difference in prevalence to variations in the targeted populations,
geographical location, gender, age groups, and the criteria used to define MS.62
Irrespective of the defining criteria of MS, the calculated prevalence is very high among
the Saudi population, particularly among Saudi females.62 This issue raises concern for
women of childbearing age and pregnant women in KSA, as the detection and screening
of MS during pregnancy has not been addressed in the literature. Studies on pregnancy
from around the world have shown that women with MS have a higher risk of having
newborns with perinatal adverse outcomes, demanding attention and special care.60
Therefore, diagnosis during pregnancy is essential in terms of determining the women at
risk of cardiovascular and metabolic changes.66
1.3.2

Causes
Despite the fact that the pathogenesis of MS has not been studied thoroughly,67 it

is known to be a multi-factorial disorder influenced by the synergistic effects of genetic
and environmental risk factors.62,65
Environmental components such as changes in diet and lifestyle explain the
increased prevalence of MS in Saudi Arabia. 62,65 As mentioned earlier, the prevalence of
MS is increasing worldwide and is associated with the rising incidence of obesity
epidemic along with population aging and urban housing.57,60 Surprisingly, the overall
prevalence of obesity in adult females in KSA has been previously reported as one of the
highest worldwide.4,6,25 Moreover, obesity rates are higher in Saudi females than in their
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males counterparts.5,68 A large national survey conducted in KSA revealed that 33.5% of
women were obese and 28.7% were overweight.8 These high rates of obesity in this
population are extremely shocking and must be addressed, especially for pregnant Saudi
women.
Over all, it is estimated that maternal obesity complicates 33% of all pregnancies,
having detrimental effects on the metabolic health of the mother and offspring.61 Maternal
obesity has been associated with macrosomia, delivery by cesarean section, pregnancyinduced hypertension, and higher rates of early miscarriage and congenital anomalies,
including neural tube defects, which can lead to fetal death.50,60,69
Most studies have agreed that the high prevalence of obesity among Saudi women
could be attributed to unhealthy dietary patterns and physical inactivity.3,8,62 Al-Quaiz
reported a very high rate of physical inactivity, reaching upwards of 98.1% in Saudi
females.70
The genetic components of MS have been investigated in the Saudi population
with relatively very small study sizes. We will elaborate more on this topic in Chapter 2.
1.3.3

Adverse Perinatal Outcomes
It is vital to identify women with MS, as they are at twice the risk of developing

CVD over the next 5–10 years.57 According to World Health Organization (WHO),
CVDs are the primary cause of death in women worldwide, accounting for 33.2% of
female deaths in 2008.71 In KSA, the estimated prevalence of CVD is around 42%, with a
high proportion of young women aged 30 years and above affected.72 Strangely, the mean
age of CVD incidence was estimated to be ten years younger in the Gulf region when
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compared to that in European countries.72 Women with MS also have a higher risk of
developing GDM,69 and thus they have a 30% risk of developing future T2DM.57,60
There are few studies on metabolic syndrome in pregnancy. Dane et al. found that
pregnant women with MS had significantly higher rates of GDM and preeclampsia when
compared with women with normal pregnancies.66 Moreover, Tavares et al. reported
finding adverse perinatal outcomes in 14.1% of pregnancies with MS.60
Overall, women in KSA face serious health challenges, such as vitamin D
deficiency, GDM, and MS. These conditions are alarmingly widespread, especially at
young ages. To develop strategies for primary prevention, more research is needed on
younger women, and special attention should be focused on pregnancy to prevent the
burden of disease in coming years.
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CHAPTER 2
FOKI VITAMIN D RECEPTOR GENE POLYMORPHISMS AND ITS
ASSOCIATION WITH NON-SKELETAL OUTCOMES

2.1 Vitamin D Metabolism Pathway
It has been long known that the effect of genetic variation in the vitamin D
synthesis and metabolism pathway on circulating concentrations is not clear.1 The two
forms of vitamin D, which is either synthesized in the body from adequate exposure of
the skin to sunlight (vitamin D3; cholecalciferol) or obtained from diet (vitamin D2;
ergocalciferol), are both prohormones that are biologically inactive.2 Both vitamin D3 and
D2 are hydroxylated twice to obtain their biologically active form, calcitriol, or what is
known as 1,25-hydroxyvitamin D (1,25(OH)2D).3 The first hydroxylation occurs in the
liver, where the enzyme 25-hydroxylase (CYP2R1) hydroxylates vitamin D to 25hydroxyvitamin D (25(OH)D; calcidiol), which is the circulating form of vitamin D and
the most reliable indicator reflecting vitamin D status.4 The second hydroxylation occurs
primarily in the kidneys or at the local tissue level and is performed by the enzyme
25(OH)D-1-α-hydroxylase (CYP27B1) to yield 1,25(OH)2D.4 The active hormone,
1,25(OH)2D, is then released in the blood, where it binds to the vitamin D–binding
protein (DBP) and arrives at the targeted cells to apply its endocrine functions through
the vitamin D receptor (VDR; Figure 2.1).5,6 This process is vital in regulating many
genes that play significant roles in controlling cellular growth and differentiation.5,6 Thus,
any genetic variation or mutation in this metabolic pathway has the capability of altering
serum 25(OH)D concentrations.1
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Figure 2.1: Vitamin D metabolism and genes involved in vitamin D metabolic
pathways
(Adapted from Hossein-Nezhad & Holick, 2013)6

2.2 Vitamin D Receptor (VDR) Gene Polymorphisms
VDR, a member of the steroid/thyroid hormone nuclear receptor family, is
ubiquitously expressed in nearly all nucleated human cells at fluctuating concentrations.7
The VDR gene is considered to be a candidate for controlling responses to vitamin D.8 As
mentioned in the previous section, VDR binds to the active form of 1,25(OH)2D and, in
turn, the ligand-activated VDR forms a heterodimer with the retinoid X receptor.9 The
heterodimer binds to vitamin D–response elements in the promoter regions of vitamin D–
dependent target genes and regulates the expression of various genes related to vitamin D
metabolism.9,10 VDR is also known to be involved in bone and calcium homeostasis, cell
differentiation, immunomodulation, and the control of other hormonal systems.11
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The VDR gene, which is at the chromosomal locus of 12q12-14, includes 2
promoter regions, 8 coding exons (namely, 2–9), and 6 untranslated exons (1A–1F).12
Several single nucleotide polymorphisms (SNPs) have been identified in the VDR gene,
including 3 SNPS located at the 3′ untranslated region (3′ UTR) of the gene, namely BsmI
(A > G, rs1544410), ApaI (A > C, rs7975232), and TaqI (T > C, rs731236), as well as
another polymorphism known as FokI (C > T, rs10735810), which is located within the 5′
end of the coding exons near the promoter region (Figure 2.2).13
Since VDR is found in nearly every human tissue, researchers investigated its
functional significance and potential effects on disease susceptibility and the extraskeletal
functions of vitamin D.9 To date, numerous systematic reviews of the literature as well
genome-wide association studies have linked VDR polymorphisms to various disease
outcomes, such as bone mineral density, cardiovascular diseases, metabolic syndrome
(MS), asthma, increased risk of T2D, an unfavorable lipid profile, hypertension, obesity,
periodontitis, risk of multiple sclerosis, and malignancy.14–16 In the next section, we will
focus on FokI polymorphism in VDR and its association with adverse health outcomes in
pregnancy.
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Figure 2.2: Structure of the VDR gene and position of single nucleotide
polymorphisms (Adapted from Uitterlinden et al., 2004)13

2.2.1 FokI VDR Gene Polymorphism
The FokI SNP (rs10735810 merged into rs2228570), which is defined by the
restriction enzyme, is located in exon 2 of the coding region of the VDR gene (Figure
2.3).17 It is uniquely different from the other SNPs for two reasons. First, it is the only
polymorphism that is not linked to any of the other VDR variants.18 Second, it is the only
known VDR polymorphism, in contrast to other variants, that is translated into two
different VDR protein products, thus affecting the VDR protein structure and function.11
In regards to this, VDR FokI is considered one of the most important functional
regions of the gene.18 In fact, it is the only known VDR gene polymorphism that leads to
the production of an altered protein.17 In other words, it can generate two structurally
distinct isoforms: a shorter F allele or a longer f allele protein.19 In the ff FokI genotype,
translation initiation occurs at the first ATG site, giving rise to a full length VDR protein
comprised of 427 amino acids.17 On the contrary, in the FF FokI genotype, translation
begins at the second ATG site instead of the first, resulting in a shortened protein with 3
fewer amino acids (427 versus 424 amino acids).17 The mutation in the ff FokI VDR
polymorphism results in a cytosine-to-thymine (C→T) nucleotide change in exon 2 of the
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coding region of the VDR gene and creates a second upstream start site due to a codon
change from ACG → ATG.13 This start codon change causes the expression of a VDR
protein that is 3 amino acids longer and has been shown to reduce transcriptional activity
and to be less responsive to 1,25(OH)2D than the shorter F allele version in activating
target gene expression.20 In fact, the F allele variant is 1.7-fold more active than the f
allele.15,21 However, various studies have shown inconsistent findings regarding the
functional significance of the FokI polymorphism,9 although most data indicate that the F
allele is more effective than the f allele in transactivation of the 1,25(OH)2D signal.13–19
Thus, women with the F allele may have better metabolic outcomes regarding bone
health, glucose homeostasis, and inflammatory response.9 Still, the number of
publications that have examined the role of VDR polymorphisms in pregnancy is very
limited. The aim of this chapter is to review the association of VDR FokI polymorphism
and metabolic disorders in the general population while shedding light on the limited
research that has been done on pregnant women.

Figure 2.3: Location of the VDR gene FokI polymorphism
(Adapted from Colombini et al., 2014)17
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2.2.1.1 FokI VDR Gene Polymorphisms and Vitamin D Deficiency
Twin- and family-based studies have previously found that heritable factors have
a considerable effect on vitamin D status.15,19 Depending on the VDR variant, it could
either increase or decrease the serum 25(OH)D levels.15,19
The VDR FokI polymorphism, either individually or in combination with other
VDR variants, has been investigated in a few studies and showed inconsistent results
regarding their association with serum 25(OH)D levels or vitamin D deficiency. Recent
reports from China,1,22 Saudi Arabia,23 the United States,24 and the United Arab
Emirates25 have failed to detect any significant association between VDR FokI
polymorphism and circulating levels of 25(OH)D. To our knowledge, there is only one
study that assessed the association between VDR FokI polymorphism and vitamin D
status in Iranian women during their gestation periods.26 However, Aslani et al., who
conducted this study, did not detect any significant differences in 25(OH)D levels
between carriers of the F and f alleles among healthy pregnant Iranian women and GDM
patients in their second trimester.26
In contrast, there is consistent evidence that the VDR gene FokI polymorphism is
significantly associated with 25(OH)D levels in adult patients with multiple sclerosis,27–29
systemic lupus erythematosus,30 and autism spectrum disorder in children.18 The unified
finding for all these studies indicated that the mutant ff FokI genotype had significantly
higher levels of serum 25(OH)D compared to FF and Ff carriers.18,27–30 Some of these
authors reported that the reason for higher levels of serum 25(OH)D in mutant f allele
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carriers may be attributed to its compensatory response due to reduced VDR activity and
distorted signaling pathways.18,27
On the other hand, few studies have reported a significant association between ff
genotype carriers and low values of serum 25(OH)D when compared to the FF genotype
in patients with T2DM,8,31 patients with inflammatory bowel disease,32,33 and patients
with chronic kidney disease.34 In fact, two of these studies demonstrated a significant
association between vitamin D deficiency and the combined mutant genotype (Ff + ff) of
FokI in the Chinese patients with Crohn’s disease32 and ulcerative colitis.33 Similarly,
another study reported an increased risk of developing severe vitamin D deficiency (< 38
nmol/L) among chronic kidney disease patients carrying Ff and combined Ff + ff
genotypes compared to healthy participants in the South African population.34
The inconclusive findings of all the studies could be attributed to their modest
sample sizes; variability of the population and ethnic groups studied; and the failure to
adjust for risk factors that alter serum 25(OH)D, such as vitamin D intake, use of
supplements, latitude, seasonal variations, sun exposure, and others.1 Additionally, most
of the research to date has assessed the association between 25(OH)D and the VDR FokI
polymorphism on unhealthy subjects, and the lack of an association could be related to
disease confounders.
Future prospective cohort studies on healthy subjects are required to clarify the
primary genetic predictors of 25(OH)D concentrations, including the assessment of genes
involved in vitamin D metabolism. It is vitally important to consider the proper
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adjustments to be made for important confounders that are known to alter vitamin D
status to appreciate the effects of genotype on vitamin D levels.
2.2.1.2 FokI VDR Gene Polymorphisms and Gestational Diabetes
GDM is considered to be a serious public health problem associated with higher
incidence rates of perinatal mortality and morbidity.35 As previously mentioned, VDR is
expressed in many human tissues, including the ones involved in the regulation of
glucose metabolism, such as pancreatic β cells.8,19 VDR is also known to alter glucose
homeostasis via the insulin-like growth factor system.8,12
Since T2DM and GDM are very much alike in terms of sharing a similar
pathophysiology, polymorphisms in genes that cause a predisposition for T2DM are
closely related to GDM vulnerability.12 Moreover, numerous studies were conducted to
prove an association between VDR FokI polymorphism and T2DM but with rather
equivocal results.36 Studies that have confirmed a significant association between VDR
FokI polymorphism and T2DM were carried out on Chinese37 and Emarati38 populations.
In fact, the latter study found that the mutant f allele and ff genotype of VDR FokI
polymorphism were significantly associated with 85% increased risk of T2DM when
compared to the control group (P = 0.0007),38 whereas no significant association has
been reported in Italian39 or Indian populations.40 According to a meta-analysis, the
inconsistent evidence in the previous studies could be due to strong intra-individual
variability of vitamin D status, which could probably affect the expression of VDR
variants, as well as substantial inter-ethnic variance in the samples studied.36
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Studies have shown a potential role of FokI polymorphism of the VDR gene in
the pathogenesis of GDM, yet they remain scarce and inconclusive. Only three studies
were available, and one was conducted in Saudi Arabia. The first study was conducted by
Aslani and colleagues on 303 Iranian pregnant women (142 GDM patients and 161
healthy subjects) and found that the ff genotype was more common in GDM patients
compared to the healthy subjects (OR = 1.783, 95% CI = 0.774–4.107). 26 Interestingly,
healthy subjects had higher frequencies of the F allele (78.6% vs. 72.2%, [P < 0.06]),
suggesting that the F allele may have a role in decreasing the incidence of GDM.26 The
authors attributed the reason for the association between the mutant ff FokI genotype and
a higher risk of GDM to the dysfunction of the f VDR variant. Because the mutant f allele
is longer in structure and 40% less active than the shorter F allele, f allele carriers are
therefore predisposed to a higher risk for GDM.26 The second recent study, whose results
were in line with Aslani et al., was recently conducted on a population from northeastern
Brazil.42 The investigators examined whether VDR FokI polymorphism was associated
with GDM risk in pregnant women who had spontaneous preterm births (SPTBs).42 The
results showed a significant association between carriers of the mutant ff FokI genotype
and the risk for GDM in SPTB patients compared to patients who had normal deliveries
(OR = 4.71, CI 95% = 1.1–22.30; P = 0.044). The frequency of the ff genotype was
higher in the SPTB group than their counterparts (23% vs. 4.7%). The authors suggested
that FokI VDR could be a biomarker for GDM.42
On the contrary, the third study, which was conducted in Saudi Arabia, did not
show any significant association between VDR FokI polymorphism and the risk of GDM
when the investigators compared 112 GDM patients and 218 controls in their cross-
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sectional study.41 The previous findings of the studies should be interpreted cautiously. It
should be stressed that El-Beshbishy et al.41 and Aslani et al.26 used fasting blood glucose
levels alone to screen for GDM. However, the application of other criteria, such as the
International Association of Diabetes and Pregnancy Study Groups’ criteria, for the
diagnosis of GDM results in an increased prevalence of GDM since it includes pregnant
women with hyperglycemia.43 Therefore, there might be a chance that the authors missed
high-risk patients, and GDM incidence may have been under-reported and could have
affected the study outcomes. It was also not clearly indicated in the previous studies if
investigators controlled for risk factors such as obesity, a family history of diabetes, or a
history of microsomia, as the latter two factors were significantly associated with GDM
patients only in Aslani et al.’s study.26
To conclude, further studies with sufficient statistical power and on different
ethnicities are warranted in order to confirm the potential of genetic biomarkers for the
prediction of GDM in different populations. These prospective studies should take into
consideration the inclusion of GDM risk factors while controlling for them to
independently observe to what extent the FokI VDR gene polymorphism is the culprit in
increasing the risk of GDM.
2.2.1.3 FokI VDR Gene Polymorphisms and Metabolic Syndrome
As mentioned in the previous chapter, MS is a serious health concern, and its
prevalence is rising significantly in Saudi Arabia.44,45 It is also more common in females
than in males.44 Disappointingly, despite the increasing prevalence of MS in Saudi
Arabia, especially in women, no study to date has detected the role of the VDR gene FokI
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polymorphisms in the pathogenesis of maternal MS and its components in MS during
pregnancy. However, a few studies have examined the association between VDR gene
polymorphisms and MS in adults. Aslani et al., for example, found that the frequency of
the ff genotype was twofold more frequent in postpartum Iranian women with MS when
compared to the healthy participants during postpartum follow-ups (P = 0.09, OR = 2.1,
95% CI = 0.90–4.89).26 On the contrary, another recent study from the same population
in Iran by Shab-Bidar and colleagues did not observe any significant association between
FokI and MS in adult males or females.46 Other studies from Brazil,47 north China,48 and
the United Arab Emirates are also in line with the previous findings. This evident
variation and inconsistency between different studies on VDR FokI polymorphism and
MS could be attributed to environmental factors in different populations.25 Moreover, the
frequency distribution of the genotypes and alleles of the VDR gene polymorphisms
differ substantially among different ethnic groups and within the same studied
population, as previously noted in the Iranian population.26,46 Such heterogeneity in the
distribution of alleles and genotypes leads to different susceptibility to specific diseases.49
Iyer et al. explained that in Saudi Arabia, genetic factors such as allele distributions and
the exchange of gene pools through crossbreeding with neighboring countries can have a
large effect on the findings of studies.50 Accordingly, larger and more carefully designed
prospective studies are needed that adjust for factors that might interfere with the
underlying etiology of the disease.
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CHAPTER 3
PURPOSE OF THE STUDY

3.1 Research Aims and Hypotheses
As mentioned in CHAPTER 2, vitamin D receptor (VDR) polymorphism could
be associated with increased risk of chronic disease resulting from defects in gene
activation. The presence of the FokI f allele (mutant) has been shown to reduce
transcriptional activity and affect vitamin D responsiveness. This, in turn, might lead to
vitamin D deficiency and extra-skeletal health complications; yet, there is very limited
research examining the association of the FokI VDR polymorphism with adverse
pregnancy outcomes. The present research will investigate this association; particularly
how maternal FokI VDR gene polymorphism affects metabolic health outcomes in
pregnancy. The following chapter explains the aims and hypotheses of this research in
greater detail.
Aim 1:
The first aim is to investigate the association between FokI VDR gene
polymorphism and serum 25(OH)D levels in first-trimester pregnant Saudi women while
controlling for lifestyle and environmental risk factors that are known to alter vitamin D
status, such as dietary intake of vitamin D, sun exposure indices, physical activity,
educational level, and place of residence.
Hypothesis 1:
We hypothesized that pregnant Saudi women carrying the ff genotype of the FokI
VDR polymorphism will have an increased risk of vitamin D deficiency compared to
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those carrying the FF and Ff genotypes.
Aim 2:
The second aim is to determine whether there was a difference in gestational
diabetes mellitus (GDM) risk factors among the VDR FokI genotypes carried by pregnant
Saudi women in their second trimester, via an oral glucose tolerance test (OGTT)
administered at 24–28 weeks of pregnancy. We will also study the effect of different
FokI VDR genotypes on glucose intolerance by measuring fasting blood glucose, fasting
insulin, and glycated hemoglobin. We will also calculate Homeostasis model of insulin
resistance and of beta cell function using HOMA-IR and HOMA_, respectively.
Hypothesis 2:
We predicted that pregnant Saudi women carrying the ff genotype of the FokI
VDR polymorphism will have increased glucose intolerance and a greater risk of GDM
compared to those carrying the FF and Ff genotypes.
Aim 3:
The final aim is to assess whether the FokI VDR genotypes are associated with
Metaboilc Syndrome (MS), or its components, in pregnant Saudi women. We will also
study the metabolic impact of the ff genotype versus the wild FF genotype on various MS
risk factors by measuring blood pressure, lipid and glycemic profiles, and body mass
index (BMI).
Hypothesis 3:
We expect that pregnant Saudi women carrying the ff genotype of the VDR FokI
polymorphism will be at higher risk of MS; elevated blood pressure; glucose
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intolerance/gestational diabetes; dyslipidemia; and elevated lipid-profile biomarkers, such
as total cholesterol, low-density lipoprotein (LDL), triglycerides (TG), and low highdensity lipoprotein (HDL) cholesterol.
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CHAPTER 4
MANUSCRIPT 1: THE INFLUENCE OF FOKI VITAMIN D RECEPTOR GENE
POLYMORPHISMS ON VITAMIN D STATUS AMONG PREGNANT SAUDI
WOMEN

4.1 Abstract
•

Background: Vitamin D deficiency is highly prevalent among pregnant Saudi
women, ranging from 86.4 % to 90.5%. It has been associated with adverse maternal
and offspring outcomes. Numerous factors, including genetics, play significant roles
in altering vitamin D status. Previous genomic studies have associated vitamin D
receptor (VDR) gene polymorphism with serum 25-hydroxyvitamin D levels in
adults. However, the genetic determinant of VDR gene polymorphisms and maternal
vitamin D status in pregnancy have not been clarified yet.

•

Aim: The objective of this study was to investigate the association between FokI
VDR gene polymorphism and serum 25-hydroxyvitamin D levels in pregnant Saudi
women in their first trimester, while controlling for lifestyle and environmental risk
factors that are known to alter vitamin D status.

•

Materials and Method: A cross-sectional study was conducted on 345 pregnant
Saudi women who visited antenatal clinics of three hospitals in Riyadh, Saudi Arabia
(King Khaled University Hospital [KKUH], King Salman bin Abdulaziz Hospital,
and King Fahad Medical City [KFMC]) between December 2013 and January 2016.
In the first antenatal visit, information was collected regarding socio-economic status
and anthropometric and biochemical data, including serum 25 hydroxy-vitamin D
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(25(OH)D) levels, dietary intake of calcium and vitamin D, physical activity, and sun
exposure indices. The Fokl VDR genotypes of each woman were determined by
allele-specific polymerase chain reaction (PCR).
•

Results: About 79% of the Saudi women studied were vitamin D deficient (25(OH)D
< 50 nmol/L). Full body coverage with clothing, low physical activity, residence in
North Riyadh, indoor work, and timing of sun exposure were found to be the key
factors predisposing pregnant women toward vitamin D deficiency in the Kingdom of
Saudi Arabia. In addition, the risk of being vitamin D deficient was associated with
the FokI VDR genotype. The frequencies of genotypes FF, Ff, ff, and combined Ff+ff
in women with vitamin D deficiency were 60.1%, 33.3%, 6.6%, and 39.9%,
respectively, while in the non-deficient group they were 55.6%, 36.1%, 8.3%, and
44.4%, respectively. Taking the FF genotype as a reference, the Ff genotype and the
combined variant genotype (Ff+ff) showed a significant decrease in the risk of
developing vitamin D deficiency after adjusting for confounding factors (FF vs. Ff,
OR = 0.44, 95% CI = 0.20–0.94, P = 0.035, FF vs. Ff+ff, OR = 0.42, 95% CI = 0.20–
0.88, P = 0.022). Furthermore, individuals carrying the f allele were protected against
vitamin D deficiency (OR = 0.51, 95% CI = 0.29–0.91, P = 0.021).

•

Conclusion: Our study is the first to evaluate the association between FokI VDR
gene polymorphism and vitamin D status in pregnant Saudi women while controlling
for major risk factors. Our findings indicated that the FF genotype and the F allele of
FokI VDR genotype polymorphisms is an important determinant of an individual’s
susceptibility to vitamin D deficiency in pregnant Saudi women after adjusting for
confounding factors that have an effect on vitamin D status, such as age, BMI,

44

physical activity, full body clothing coverage, job status, residential area, and
education.

4.2 Introduction
Vitamin D deficiency during pregnancy is of epidemic proportions, occurring in
nearly 20% to 95% of pregnant women around the world.1,2 There is a substantial body of
evidence in the literature that indicate the serious adverse consequences of low maternal
vitamin D status on maternal and fetal health, including both skeletal and non-skeletal
outcomes.3,4 Aside from the adverse skeletal effects, vitamin D deficiency during
pregnancy has been linked to a number of maternal and fetal problems, including
preeclampsia, gestational diabetes, caesarean section, bacterial vaginosis, postpartum
depression, neonatal hypoglycemia, small-for-gestational age infants, and preterm
birth.1,5-8
It is expected that the Saudi population will have adequate vitamin D status since
cutaneous vitamin D production is primarily determined by sun exposure. Saudi Arabia
has the highest number of sunny days per year, with an average sunlight of 2,200
kWh/m2 and more solar radiation hitting the earth there due to the country’s location
within the earth’s equatorial sun belt.7 Unfortunately, numerous studies have
demonstrated that vitamin D deficiency has become an epidemic among the Saudi
population, specifically in the young and middle-aged groups of healthy Saudi adults, and
in females more than males.6,10 It is estimated that between 80–100% of Saudi women
have suboptimal levels of vitamin D during the reproductive phase of their lives.11-13
Higher prevalence of vitamin D deficiency among Saudi women appears to be a
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predisposition for further deterioration of the vitamin D status, particularly among
pregnant females because of the increased nutritional demands of the growing fetus.14
Two recently published studies found that the prevalence of vitamin D deficiency was
about 86% in pregnant Saudi women 10,15 and 88% among neonates.15 Both of these
studies, as well as other studies, used serum 25-hydroxyvitamin D (25(OH)D) < 50
nmol/L as a cut-off point for vitamin D deficiency.10,15-17 Serum 25(OH)D is the main
circulating metabolite of vitamin D and the most reliable biomarker of vitamin D
adequacy,18 reflecting both dietary vitamin D intake and cutaneous vitamin D
production.19
Factors such as age, race, gender, skin pigmentation, physical activity, sun
exposure, season, geographic location, latitude, obesity, and dietary/supplemental vitamin
D intake have all been previously reported to influence serum 25(OH)D levels.20,21 Other
factors related to Saudi cultural practices and customs, including complete coverage of
the body and limited outdoor activities play an important role in hindering the positive
effect of the abundant sunlight on vitamin D status.10
Obviously, there are many factors that influence the levels of circulating
25(OH)D other than the ones mentioned earlier. Hussain et al. found that the prevalence
of vitamin D deficiency was more common and severe in Saudis than in non-Saudis
living in the same city of Riyadh, Saudi Arabia.12 This observation might be explained by
the influence of genetic variants such as vitamin D receptor polymorphisms that play a
role in vitamin D metabolism and disease susceptibility.10,20,22 In fact, genome wide
association (GWA) studies have revealed that the genetic variation significantly
contributes to variability in serum 25(OH)D concentration, with estimates of heritability
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ranging from 29% to 80%.23-25
Vitamin D receptor (VDR) is one of the candidate genes involved in meditating
the transcription of vitamin D-dependent target genes26 by binding to the active hormonal
form of vitamin D (1,25-dihydroxyvitamin).27 VDR is known to be expressed in almost
every tissue.10 Several single nucleotide polymorphisms (SNPs) have been identified in
the VDR sequence, including a FokI endonuclease site (rs10735810, merged into
rs2228570).28 The FokI VDR variant, which is located in an alternate upstream
transcriptional initiation site of the VDR gene, specifically in exon 2 in the 5′-coding
region, is the only known VDR polymorphism that is not linked to any of the other VDR
variants. In addition, the VDR protein products differ with one variant (f) establishing an
alternate start site resulting in a VDR protein that is 3 amino acids longer than the other
shorter VDR variant (F). The longer f variant form of VDR has been shown to be less
active in some in vitro test systems, thus giving it a potentially unique role. 24,29 The FokI
mutation produces a longer f-VDR protein that is 427 amino acid long and a shorter FVDR protein variant that is 424 amino acids long, which is reported to be more active
and effective than the longer protein variant. 26 However, the functional significance of
the FokI VDR polymorphism as a genetic risk factor in various disease outcomes is
inconsistent.30
While there is increasing evidence in the literature associating FokI VDR gene
polymorphisms with an increased risk of a range of adverse health outcomes, it is not yet
clear whether the FokI VDR polymorphism contributes to maintaining serum 25(OH)D
adequacy. The role of the FokI VDR polymorphism and other genetic variants related to
vitamin D metabolic pathways have been greatly evaluated in regards to the responses of
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serum 25(OH)D levels to vitamin D supplementation, with contradicting results.31 The
first study in the Saudi population that evaluated the genetic influence of FokI VDR as
well as several single nucleotide polymorphisms (SNPs) in vitamin D-related genes on
vitamin D status was reported by Sadat-Ali et al.32 They found that FokI VDR was
significantly associated with vitamin D deficiency, compared to the population with
normal vitamin D levels.32 Moreover, there are a limited number of studies that examined
the effects of dietary vitamin D intake, sun exposure, or other personal characteristics as
probable modifiers that influence serum 25(OH)D concentrations. 20 Additionally, most
of the studies that examined such a relationship were conducted on groups of adults with
different kinds of diseases. Such a correlation was not investigated among pregnant
women in Saudi Arabia, where plentiful sunlight is available throughout the entire year.
Therefore, we conducted a cross-sectional study to investigate the association between
the FokI VDR gene polymorphism and serum 25(OH)D levels in pregnant Saudi women
while controlling for environmental and lifestyle variables linked to Saudi culture that
were previously known to influence vitamin D status.

4.3 Methods
4.3.1 Study Design and Sample Population
This study is part of a large prospective cohort study called “Vitamin D and
Pregnancy in Saudi Women.” Our cross-sectional study is a subset of these study
participants, consisting of 345 pregnant Saudi women who visited an antenatal clinic at
one of three different Saudi hospitals: King Khaled University Hospital (KKUH), King
Salman Bin Abdulaziz Hospital, and King Fahad Medical City (KFMC) in Riyadh, the
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capital of Saudi Arabia, between December 2013 and January 2016. The study has full
ethical approval from the three hospitals to collect samples and patient data and approval
from the Ethics Committee of the College of Science, King Saud University in Riyadh
(Appendix A). Written informed consent was obtained from each patient (Appendix B).
4.3.1.1 Inclusion and Exclusion Criteria
Healthy pregnant Saudi women in their first trimester (8–12 weeks) aged 18 to 40
years, with no previous history of diabetes mellitus (type I or II), were recruited. Subject
exclusion criteria included: non-Saudi subjects; gestational age of over 16 weeks; taking
vitamin D supplements during pregnancy; unwillingness to deliver at any of the three
hospitals; taking oral glucocorticoids; using drugs known to interfere with vitamin D or
calcium absorption or parathyroid disorders; using any cardiac medication or diuretics;
suffering from chronic hypertension or malabsorption syndrome; having chronic medical
conditions or preexisting liver, kidney, calcium, and/or parathyroid conditions; or serious
chronic disease conditions (epilepsy, cancer, or other malignancy).
4.3.1.2 Recruitment and Data Collection
Recruitment banners and brochures were placed in prenatal clinics in all three of
the hospitals. Obstetricians were asked to introduce the research to their pregnant patients
during their first prenatal appointment. Patients who met the criteria and consented to
contribute to the present study were provided the appropriate information. During their
early pregnancy visit, prospective candidates were asked to sign consent forms that
included information about their participation in the study, such as the completion of a
questionnaire regarding demographic data, procurement of blood samples for biomarker
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measurement and DNA for genetic analyses, and anthropometric measurements.
Permission for data collection from their medical records and stored blood stocks from a
bio-bank were also obtained. Additionally, the participants were informed of their right to
withdraw from the study at any point without it affecting their usual medical care.
The study tools included anthropometric measurements, blood biochemical tests,
and an interview questionnaire. The interview questionnaire included questions regarding
socio-economic information, clinical measurements, and past medical and treatment
history. It also contained a food frequency questionaire (FFQ) and questions on sun
exposure and physical activity.
4.3.2 Anthropometric Measurements
Anthropometric measurements were taken in the first antenatal visit. These
measurements included weight (kg) and height (cm), used for calculating body mass
index (BMI) (kg/m2); reported pre-pregnancy weight (kg); and pre-pregnancy BMI
(kg/m2). Body weight, without shoes and in lightweight clothing, was measured to the
nearest 0.1 kg with a stadiometer (Digital Pearson Scale, ADAM Equipment Inc., USA).
Based on pre-pregnancy weight as self-reported during the prenatal visit, the pregnant
women were classified according to the WHO BMI definitions as follows: underweight:
< 18.5 kg/m2; normal weight: 18.5–24.9 kg/m2; overweight: 25.0–29.9 kg/m2; or obese:
≥ 30.0 kg/m2.33 Height, to the nearest 0.5 cm, was measured during the early pregnancy
visit using only (Digital Pearson Scale), with the women standing upright without shoes.
Pre-pregnancy BMI was calculated from pre-pregnancy body weight recall and the
measured height.
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4.3.3 Interview and Physical Activity Questionnaire
The interview questionnaire was adapted from a previously published
epidemiological survey in Saudi Arabia that included questions about socio-economic
details, past medical and treatment history, and sun exposure (Appendix C). 34-37 At the
early pregnancy visit, all socio-economic and clinical measurements were recorded,
including the visit date, age of the subject, place of birth, gestational age, maternal
education status, occupation, and area of residence. Clinical data included date of LMP
and estimated date of delivery (EDD). The participants were asked about parity
(nulliparous or ≥ 1 multiparous). The season of the sampling was recorded. For the
analysis of the season in relation to vitamin D status, the months of the year were divided
into two periods. April to October was classified as summer, and November to March as
winter.38
Furthermore, they were asked about sun exposure (yes/no) and other sun exposure
indices such as exposure to the sun at work (indoor or outdoor work), timing of the
exposure (e.g., noon), clothing (full body coverage vs. some parts of the body exposed),
and the use of sunscreen (yes/no). Noon was defined in this study to be from 10:00 a.m.
to 2:00 p.m.
Physical activity was also assessed through a well-known and validated
questionnaire, namely an Arabic short version of an International Physical Activity
Questionnaire (IPAQ).39 The short IPAQ has been validated in various studies among
different populations, including pregnant subjects.40,41 IPAQ evaluates physical activity
during periods of leisure, work, and commute. It also assesses the intensity of an activity
as vigorous, moderate, low-intensity physical activity/walking, or sitting. Each subject
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was assisted in recalling her physical activities over the previous week. For each type of
activity, frequency and duration were recorded in days per week and minutes or hours per
day. This study excluded moderate and high activity because few women carried out such
activities during pregnancy. The present study analyzed low-intensity physical activity
and minutes spent sitting per week, similar to other studies using IPAQ in pregnancy.42
Low-intensity physical activity in minutes per week was applied as a continuous and
categorical variable at either less than or over 210 minutes/week.43
4.3.4 Dietary Data Collection and Processing
The dietary tool applied for measuring the participants’ food intake was the FFQ,
which has been used previously in Saudi Arabian studies.

35,37

The subjects were

interviewed separately, and the data were gathered by applying a pre-designed
questionnaire to measure aspects of food consumption among the expectant mothers over
the course of one week. The main purpose of this was to assess calcium, vitamin D, fat,
and protein intake, as well as any other nutrients that may affect the absorption or
excretion of vitamin D and calcium. Responses to the dietary questionnaire were
facilitated through food models, cups and spoons of various sizes, cans, and approximate
portions, using hand gestures to help the participants recall the amount of food consumed.
The FFQ consisted of eight parts pertaining to: (1) bran, starch, and grains; (2)
meat and fish; (3) fats and oils; (4) dairy products; (5) fruits and vegetables; (6)
traditional dishes; (7) sweets and soft drinks; and (8) coffee and tea. Starches and grains
mainly referred to any bran food that could have reduced calcium absorption.44 Fruits and
vegetables included those high in calcium and any that may have reduced calcium
absorption.45 Dairy fats (whole fat, low fat, skim milk, or other products) and fat added
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during cooking may also affect calcium absorption.46 Finally, data on supplement intake
(yes/no) were collected, including multivitamins, folic acid, iron, vitamin D, and cod
liver oil.
Nutrient intake was calculated using U.S. Department of Agriculture (USDA)
software (27th edn, 2014), along with Nutribase software (11th edn, 2014), which utilizes
food macro- and micro-nutrient composition. For traditional Saudi food, an Arabic food
analysis program was used (1st version, 2007). The assessment of everyday food intake
was conducted as total intake of macro- and micro-nutrients, especially vitamin D and
calcium. Dietary nutrient values were compared with the dietary reference intake (DRI)
of micro-nutrients during pregnancy, such as vitamin D and calcium.47 Additionally,
vitamin D and calcium intake were presented continuously and categorically as above
600 IU/day and 1,000 mg/day of vitamin D and calcium, respectively.

4.3.5 Biochemical Assessment
Blood samples (10 ml) were collected using a sterile vacutainer blood collection
apparatus. Whole blood, serum, and ethylene diamine tetra-acetic acid (EDTA) plasma
were collected from the participants. All samples were aliquoted and stored in a freezer at
-80 oC to facilitate their availability for subsequent chemical analysis. All the lab tests
were performed on the serum. The plasma was stored if needed for further analysis. The
samples were stored and analyzed in the Biomarkers Research Program (BRP)
laboratory.
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4.3.5.1 Primary Outcome Measures
Our main outcome measure was to investigate the association between FokI VDR
gene polymorphism and serum 25(OH)D levels in pregnant Saudi women while
controlling for confounding factors, which affect vitamin D status.
4.3.5.2 Assessment of Circulating 25(OH)D and Biochemical Parameters
During the first antenatal visit, random blood samples were collected to measure
total 25(OH)D, calcium, phosphorus, and alkaline phosphatase. Total 25(OH)D was
measured in an ECLIA assay, (Cobas e 411; Roche Diagnostics GmbA, Mannheim,
Germany). The BRP laboratory is a participating entity in the Vitamin D External Quality
Assessment Scheme (DEQAS). Since no international consensus exists for vitamin D
deficiency cut-off points during pregnancy, vitamin D was categorized according to
25(OH)D concentrations as follows: < 50 nmol/L considered to be a deficiency and ≥ 50
nmol/L considered to be non-deficient.16,17
Serum calcium and phosphorous were measured using a routine laboratory
chemical analyzer (Konelab, Finland). Meanwhile, bone-specific alkaline phosphatase
(BAP) was measured using the LIAISON XL immunoassay (DiaSorin, Italy).
4.3.5.3 DNA Extraction and Quantification
Genomic DNA was extracted from whole blood using innuPREP blood mini kits
(Analytik Jena, Germany) by following the manufacturer’s instructions. In brief, 200 µl
of the whole blood sample was added to a 1.5 ml reaction tube containing lysis buffer and
Proteinase K. The contents were mixed using a vortex and incubated at 60 0C for 10
minutes. The required amount of binding solution was added to the tube and transferred

54

to a spin filter column with a receiver tube and centrifuged for 1 minute at 12,000 rpm.
The column-bound DNA was washed using the kit’s washing solution C, followed by
washing solution BS. As a final step, the spin filter was placed in a 1.5 ml elution tube,
and 200 µl of elution buffer that was pre-warmed to 60

0

C was added. After

centrifugation, the collected DNA was stored at -20 0C for further analysis. DNA
concentration

and

purity

(260/280)

was

determined

using

a

Nano-Drop

spectrophotometer.
4.3.5.4 FokI VDR SNP Genotyping
The FokI SNP (rs 2228570), previously reported as (rs10735810)20 (Exon 2,
C[F] > T[f]), is located in the VDR coding region and can be evaluated by allelic
discrimination real-time PCR using pre-designed TaqMan genotyping assay from
Applied Biosystems, Foster City, CA, USA (assay ID: C_12060045_20). Amplification
reactions were performed in a volume of 10 µL containing 1X TaqMan genotyping
Master Mix (Applied Biosystems), 1X mix of unlabeled PCR primers and TaqMan MGB
probes, and 30 ng of template DNA. All amplifications and detections were conducted in
96-well PCR plates using a Bio-Rad CFX96 Real-Time PCR Detection System (Bio-Rad,
Milan, Italy). Thermal cycling was initiated with a denaturation step of 10 min at 95 °C,
followed by 45 cycles of 15 s at 95 °C and 90 s at 60 °C. After PCR was completed,
allelic discrimination was analyzed using the Bio-Rad CFX Manager Software (Version
1.6, Bio-Rad). Genotype assignment was determined by plotting the end point relative
fluorescent units (RFU) for one fluorophore (allele 1 on the x-axis) against the RFU for
the other fluorophore (allele 2 on the y-axis) on the allelic discrimination. All PCR
reactions were set up in a dedicated PCR area with dedicated PCR pipettes and reagents.
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4.3.6 Statistical Analysis
The sample size was estimated for adequate statistical power. The significant
differences in serum 25(OH)D levels according to FokI VDR genotype were based on an
expected effect size of 0.25,48 and the required sample size at 95% CI was 243, with 95%
power.
The data were analyzed using SPSS version 21.0 statistical software (SPSS, Chicago, IL,
USA). Quantitative normal variables were expressed as mean ±SD, while quantitative
non-normal variables were expressed as medians (Q1-Q3). Categorical variables were
expressed as frequencies and percentages (%). Pearson’s chi-square test was used to
determine the differences between categorical variables. Comparisons between groups
were performed using the independent sample t-test and the Mann-Whitney U test for
normal and non-normal variables, respectively. Unadjusted and adjusted odds ratios were
determined using logistic regression analysis. P-value < 0.05 is considered significant.
4.4 Results
4.4.1 Demographics and Biochemical Characteristics According to Vitamin D Status
in Early Pregnancy
Table 4.1 presents the characteristics of the deficient and non-deficient groups of
pregnant women. The population sample was categorized into either deficient (< 50
nmol/L) or non-deficient (≥ 50 nmol/L) groups for statistical analysis. 49,50 The
prevalence of vitamin D deficiency (< 50 nmol/L) in early pregnancy was 79.1%
(273/345).
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The mean age of women with vitamin D deficiency was similar to that of nondeficient women (28.7 ± 5.4 vs. 29.4 ± 5.4 years, P = 0.320). Pre-pregnancy BMI, BMI
in early pregnancy, and parity also failed to reveal any differences between the two
groups. The biochemical profile of the pregnant women, such as calcium and alkaline
phosphatase levels, did not show any significant differences between the groups.
However, the non-deficient subjects had significantly higher serum phosphorus and
25(OH)D levels than the deficient subjects, (1.3 ± 0.5 vs. 1.2 ± 0.4 mmol/L, P = 0.029)
and (67.8 ± 12.9 vs. 27.0 ± 10.6 nmol/L, P < 0.001), respectively.
Interestingly, the percentage of women engaged in low-intensity physical activity
such as walking was significantly higher in the non-deficient group than in the deficient
group (78% vs. 43.8%, P < 0.001), respectively. Furthermore, pregnant women who were
non-deficient in vitamin D were more likely to be educated and have a graduate or
postgraduate degree than those in the deficient group (70.4% vs. 56.0%, P = 0.028),
respectively. Moreover, the rate of employment was higher in the non-deficient group
compared to the deficient group, although this was not statistically significant (38.9% vs.
29.5%, P = 0.127). Similarly, vitamin D, calcium, and multivitamin intake did not reveal
any statistically significant differences between the deficient and non-deficient groups.
The percentage of women living in North Riyadh was significantly higher
amongst the non-deficient subjects compared to their counterparts (33.3% vs. 15.9%, P <
0.001). Meanwhile, a higher percentage of pregnant women who were deficient in
vitamin D lived in West Riyadh compared to the non-deficient group, but this figure did
not reach statistical significance (18.8% vs. 29.8%, P = 0.069).
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We did not observe any differences between vitamin D non-deficient and
deficient groups in exposure to sun, use of sunscreen, and blood being drawn in the
summer or winter. Nevertheless, the amount of exposure to the sun at noon was
significantly higher amongst the non-deficient subjects compared to their deficient
counterparts (72.2% vs. 22.7%, P < 0.001), respectively. Likewise, the percentage of
women who tend to work indoors was higher amongst the deficient participants
compared to the non-deficient subjects, (98.5% vs. 66.7%, P < 0.001), respectively.
Moreover, the percentage of subjects covering their whole body with clothing was
significantly higher in the deficient group compared to their counterparts, (33.3% vs.
2.8%, P < 0.001), respectively.
4.4.2 Risk Factors for Vitamin D Deficiency in Pregnancy
We further conducted a multivariate logistic regression analysis to assess the risk
factors for vitamin D deficiency while adjusting for confounding factors (Table 4.2).
Significant independent variables that increased the risk of vitamin D deficiency included
full body coverage with clothing (OR 19.64, 95% CI 2.52-152.68, P = 0.004), and
working indoors (OR 132.0, 95% CI 10.9-1600.7, P < 0.001).
On the contrary, the variables that appeared to confer some protection against
vitamin D deficiency in early pregnancy were higher serum phosphorus levels (OR 0.27,
95% CI 0.10-0.76, P = 0.013), low-intensity physical activity/walking (≥ 210
minutes/week) (OR 0.19, 95% CI 0.08-0.44, P < 0.001), time of sun exposure at noon
(OR 0.13, 95% CI 0.06-0.32, P <0.001), and living in North Riyadh (OR 0.32, 95% CI
0.14-0.75, P = 0.009).
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Moreover, having a graduate or bachelor’s degree, and a higher serum calcium
levels (OR 0.42, 95% CI 0.17-1.02, P = 0.054), (OR 0.11, 95% CI 0.01-1.18, P = 0.068),
respectively, appeared to be protective factors against vitamin D deficiency, but did not
reach significant levels.
4.4.3 FokI VDR Gene Polymorphism and Vitamin D Deficiency
As shown in Table 4.3, the difference in the occurrence of the various FokI VDR
genotypes in vitamin D deficient and non-deficient participants was statistically
significant. The FokI VDR genotypes are normally expressed as homozygous genotype
“FF,” heterozygous genotype “Ff,” and mutant homozygous genotype “ff.” The
frequencies of genotypes FF, Ff, ff, and combined Ff+ff in women with vitamin D
deficiency were 60.1%, 33.3%, 6.6%, and 39.9% respectively, while in the non-deficient
group they were 55.6%, 36.1%, 8.3%, and 44.4%, respectively. We did not observe any
statistically significant associations between FokI VDR polymorphisms and serum
25(OH)D levels, but after adjusting for important covariates such as age, BMI, lowintense physical activity, full body clothing coverage, job status, residential area, and
education, we detected a statistically significant association between VDR genotype and
risk of vitamin D deficiency.
After correcting for the potential confounding variables, and using the FF
genotype as a reference, the Ff genotype and the combined variant genotype (Ff+ff)
showed a significant decrease in the risk of developing vitamin D deficiency (FF vs. Ff,
OR = 0.44, 95% CI = 0.20–0.94, P = 0.035; FF vs. Ff+ff, OR = 0.42, 95% CI = 0.20–
0.88, P = 0.022). Furthermore, individuals with the f allele were protected against vitamin
D deficiency (OR = 0.51, 95% CI = 0.29–0.91, P = 0.021). However, no significant
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association was found between the ff genotype and vitamin D deficiency (FF vs. ff, OR =
0.36, 95% CI = 0.08–1.52, P = 0.163).
4.5 Discussion
In our study, vitamin D deficiency was evident in 79.1% of our study sample.
Although numerous studies have reported a high prevalence of vitamin D deficiency in
the Saudi population across different ages, 35, 51,52 only a limited number of studies have
assessed the prevalence of vitamin D deficiency in pregnant Saudi women. 6,10,15, 53 For
example, Al-Ajlan et al. found that 68% of Saudi pregnant women were vitamin D
deficient.53 Al Foda et al. 15 and Al-Sheikh et al.10 found a higher prevalence of vitamin D
deficiency reaching 86%.10,15 Besides Saudi Arabia, vitamin D deficiency during
gestation seems to be a global health concern, as it has been reported in many other
countries such as the UAE (78%),54 India (62%),55 Korea (77.3%),56 Belgium (44.6%),57
Switzerland (63%),58 and Canada (39%).59
Despite the abundant sunshine all year in Saudi Arabia, our results indicated that
lifestyle patterns and traditional clothing play an important role in decreasing sun
exposure, thus significantly decreasing vitamin D levels and the risk of vitamin D
deficiency. Saudi women wear black veils, or what are known as abaya, to cover their
entire bodies due to religious and cultural beliefs. The present study, supported by others,
indicates that pregnant women who fully cover their body are at greater risk of
developing vitamin D deficiency. 11,60
Moreover, we found higher levels of vitamin D among educated pregnant women
compared to their less educated counterparts. This observation has been stated in
different studies reporting that vitamin D levels vary in adults according to their
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educational acheivement, with a higher level of education decreasing the risk of vitamin
D deficiency.61,62
We also noticed that the area of residence, particulary North Riyadh, had a
significantly positive impact on vitamin D status compared to other areas. In other words,
pregnant women residing in North Riyadh had higher serum 25(OH)D levels than women
residing in other areas such as south, west, and east of Riyadh. We speculate that this part
of the capital city is more likely to be affluent and has highly educated residents.
Pregnant women performing low-intensity physical activity such as walking were
also shown to have higher vitamin D levels compared to those performing low-intensity
physical activity in the deficient group. Similarly, Al-Faris et al. also noted that pregnant
women involved in daily outdoor activity during the early stages of pregnancy were more
likely to have adequate vitamin D levels.6 These observations may be attributed to two
reasons. First, increased physical activity causes greater mobilization of vitamin D from
burned fat deposits.63 Second, engaging in an outdoor asctivity means greater sun
exposure, thus triggering vitamin D synthesis. 64
In our present study, we did not detect any significant associations between
vitamin D levels and the season in which the blood was drawn from the samples when
comparing the deficient and non-deficient pregnant women. However, this result was
expected due to several reasons. Firstly, women tend to cover their whole bodies with
clothing due to cultural and religious reasons.10 Secondly, due to the extreme hot weather
in the summer, Saudis generally avoid sun exposure.6,53 Thirdly, a large proportion of the
workforce works indoors in Saudi Arabia. The latter two explanations confirm our
finding that working indoors and the amount of sun exposure, especially at noon, were
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also critical in determining vitamin D levels and corresponded significantly with risk of
having vitamin D deficiency in our population. Our results were in line with the findings
of Al-Shahrani et al.65 They reported that the time of day plays a major role in vitamin D
production, as they observed that summer production of pre-vitamin D3 increased
between the peak hours of 10:00 a.m. to 12:00 p.m.65
We did not observe a significant difference in dietary intake of vitamin D and
calcium between deficient and non-deficient participants, as they were shown to be very
low in both groups in our study, as well as in other studies conducted in Saudi Arabia.6,66
In the present study, we found that about 25% of the entire sample were taking
multivitamins in their first trimester. Consistently, other studies from various countries
have reported the use of multivitamin supplementation during pregnancy, ranging from
7.5% to 63.1%. 6,57,67
It has been previously noted that vitamin D intake during pregnancy, whether
from food or from supplements, is inadequate for meeting the optimum demands of the
mother and the growing fetus.68 Previous studies have reported that less than 10% of the
daily vitamin D requirement could be met through dietary sources of vitamin D.69,70
In Saudi Arabia, dietary sources of vitamin D tend to be inadequate, and currently
food fortification is extremely scarce.70 In addition, globalization has brought dramatic
changes to dietary and lifestyle patterns, with a shift toward unhealthy diets.6,60 Since our
study was conducted in the capital city of Riyadh, the consumption of vitamin D-rich fish
was usually uncommon due to the geographic nature of the area, which lacks access to
the sea or rivers.11
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Interestingly, in our study we observed the novel finding of an association
between FokI VDR gene polymorphism and the risk of vitamin D deficiency in pregnant
Saudi women after adjusting for lifestyle and environmental factors that are known to
alter vitamin D levels. Our results showed a significant difference in the genotype
distribution between vitamin D deficient and non-deficient pregnant women. Our results
indicated that FF genotype individuals have a significantly higher risk for vitamin D
deficiency compared to those carrying the Ff genotype and the combined genotype
(Ff+ff). Based on our data, subjects carrying the FokI F allele had a significantly higher
prevalence of vitamin D deficiency than subjects with f alleles.
There is consistent evidence that FokI VDR gene polymorphism is significantly
associated with 25(OH)D levels in adult patients with Multiple Sclerosis (MS),18,71,72
Systemic Lupus Erythematosus (SLE),73 Ulcerative Colitis,29 Crohn’s Disease,79 and
Autism Spectrum Disorder (ASD) in children.48
Three studies investigated the association between FokI polymorphism and serum
25(OH)D levels in MS patients and found results that were similar to our findings.
Agnello et al. observed that MS patients with the ff genotype had significantly higher
levels of serum 25(OH)D compared to FF and Ff carriers.71 In addition, Orton et al.
reported the same finding in a study on twins with MS.18 Similarly, another study by
Smolders et al. demonstrated that lower serum 25(OH)D levels were associated with the
homozygous FF genotype compared to the homozygous ff genotype carriers.72 Another
study conducted in Turkey by Coskun et al. reported that the ff genotype was associated
with higher serum 25(OH)D levels in children with ASD compared to the homozygous
FF genotype.48 In addition, two studies conducted in patients with SLE living in Brazil73
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and Egypt74 found that carriers of the wild type homozygous FF genotype in comparison
with the mutant homozygous ff genotype had significantly lower serum 25(OH)D.
Intriguingly, Yao et al. conducted a randomized double-blinded, placebocontrolled trial and found that carriers of the f allele responded better to vitamin D
treatment (2000 IU/d) than F allele carriers in the Chinese population with vitamin D
deficiency.27 In fact, when compared to other common polymorphisms in vitamin D
metabolism genes, ff FokI genotype was associated with a greater increase in 25(OH)D
in week 20 of the treatment, but the treatment was still unable to correct vitamin D
deficiency in 25% of participants who were carrying other mutant genes. 27
These results, as well as our findings regarding the mutant f allele’s protective
role against vitamin D deficiency should be interpreted cautiously. Monticielo et al.
explained that the underlying justification for such an observation could be that the
mutant f allele may be associated with VDR dysfunction since it is longer and less active
than the F allele, thus causing an increased synthesis of serum 25(OH)D from vitamin D.
73

However, there are definitely other described genetic factors along the vitamin D

metabolic pathway that influence the production, elimination, and transportation of serum
25(OH)D concentration, which we did not measure and may contribute to residual
confounding in our study.
If we delve into the underlying mechanism of vitamin D metabolism, we notice
that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) binds to the VDR, and the activated VDR
regulates the rate of transcription of vitamin D-responsive genes.75 VDR-1,25(OH)2 D
complex is considered a negative regulator of vitamin D-25-hydroxylase enzyme (also
known as CYP27A1), which catalyzes the 25-hydroxylation of vitamin D. 71
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Furthermore, it is well known that FokI VDR polymorphism can alter the translation
initiation sites of the VDR gene.48,71 The short VDR variant (F allele) is associated with
a higher transcriptional activity than the long variant (f allele).48 According to this
evidence, the authors attributed the observation of higher vitamin D levels in individuals
with the ff genotype to the following explanation: Since the F allele variant of the FokI
VDR genotype is more active, it is more likely to enhance the inhibitory effect of the
VDR on CYP27A1 than the f allele, causing reduced serum 25(OH)D levels. 71,72
Interestingly, there are other studies that have reported an association between
FokI VDR polymorphism and vitamin D status, but their findings contradict ours. These
studies show that the ff genotype could be a risk factor for vitamin D deficiency based on
the fact that this mutant genotype could alter the metabolic feedback loops or affect the
speed at which 25(OH)D is metabolized.18 Thus, individuals carrying the homozygous
major genotype FF have a significantly better increase in serum 25(OH)D levels than
those who carry the ff genotype.76 This assumption led Al-Daghri and colleagues to
speculate that FokI genotypic variants might require different threshold concentrations of
25(OH)D levels to exhibit feedback effects. The following section will shed light on the
studies that contrast our findings.
Two studies conducted in Egypt found a significant association between ff
genotype carriers and low values of serum 25(OH)D when compared to FF genotype in
type 2 diabetic (T2DM) patients.77,78 In agreement with the previous results, two studies
conducted in China also evaluated the association between FokI VDR polymorphism and
vitamin D status among patients with inflammatory bowel disease (IBD) and found
similar outcomes.79,80 Both studies demonstrated a significant association between
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vitamin D deficiency and the combined mutant genotype (Ff+ff) of FokI in the Chinese
patients with ulcerative colitis (UC)29 and Crohn’s Disease (CD).79 Moreover, the
investigators observed a higher risk of UC 29 and CD 79 in patients when FokI VDR
mutations and vitamin D deficiency were combined. Similarly, a very recent crosssectional study conducted among black and white South Africans found an increased risk
of developing severe vitamin D deficiency (< 38 nmol/L) among chronic kidney disease
(CKD) patients carrying Ff and combined Ff+ff genotypes compared to healthy
participants.80
Furthermore, two vitamin D supplementation studies conducted on type 2 diabetic
(T2DM) patients reported that the lowest increase in serum 25(OH)D levels was detected
in patients with ff genotypes.26,76 With that knowledge, Al Daghri et al. 76 supplemented
their patients with 2,000 IU vitamin D3 daily for 12 months without a control or placebo
group, while Neyestani et al. monitored the daily intake of vitamin D-fortified yogurt
with 500 IU vitamin D/250 mL for 12 weeks.26 Both authors suggested that high-risk
patients carrying ff genotype might be considered “low responders,” as they need higher
doses of vitamin D supplements than their counterparts in order to achieve sufficient
levels and benefit the most from the treatment.26,76
To our knowledge, only one study has explored the effect of FokI VDR
polymorphism on serum 25(OH)D levels in healthy Saudi subjects.32 Sadat-Ali et al.
found that vitamin D deficiency was quite prevalent among 283 Saudis, reaching 87%,
and that carriers of the GG genotype of FokI VDR (which corresponds to FokI ff
genotypes in our study) had an increased risk of both vitamin D insufficiency and
deficiency when compared to controls, 32 a study that contradicts ours. The investigators

66

addressed a major limitation in their study that they did not control for confounders such
as environmental and individual factors that may alter vitamin D levels. 32 It is worth
mentioning that we did not see any significant associations between FokI VDR
polymorphism and vitamin D deficiency in our logistic regression model until we
adjusted for risk factors such as age, BMI, physical activity, clothing, job status,
residential area, and education level. It seems that these factors have masked the genetic
influence on vitamin D status, and this could be the case with Sadat Ali et al.’s findings
as well.
While there is robust evidence linking FokI VDR polymorphism to serum
25(OH)D concentrations, many studies have failed to replicate these finding in different
populations. Neither Li et al. 81 nor Robein et al. 20 found a significant association
between FokI VDR gene polymorphism and vitamin D deficiency in the Chinese
population, even though Robein et al. 20 controlled for confounding factors such as
dietary vitamin D intake and number of hours spent indoors at work. Also, Engelman et
al. did not observe any effect of FokI on vitamin D levels in the African-American or
Hispanic populations.82 Similarly, no association was detected among Saudi 83 and
Emirates 84 participants with Metabolic Syndrome (MS).
Although there is a vast body of literature stating that pregnancy offers a window
of opportunity to prevent adverse fetal programming, we only found one study that
evaluated the association between FokI VDR polymorphism and vitamin D levels in
Iranian pregnant women. 85 Aslani et al. did not detect any significant differences in
25(OH)D levels between carriers of the F and f alleles among healthy pregnant women
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and gestational diabetes mellitus (GDM) patients in their second trimester (17.27 ± 13.56
vs. 16.86 ± 9.79 nmol/L, P = 0.7). 85
Possible explanations for the non-significant association between VDR FokI and
vitamin D status in the previous studies could be attributed to the following reasons:
smaller study populations and the failure to adjust for risk factors that alter serum
25(OH)D, such as vitamin D intake, use of supplements, latitude, seasonal variations, sun
exposure, and other factors that affect vitamin D status. 20 Additionally, most of the
research to date has assessed the association between 25(OH)D and FokI VDR on nonhealthy subjects, and the lack of association could be related to disease state confounders.
To the best of our knowledge, this is the first investigation to assess VDR FokI
polymorphism and vitamin D levels in a group of pregnant women with prevalent
vitamin D deficiency in Saudi Arabia. We also extensively studied important confounders
that have a significant effect on altering vitamin D status.
We acknowledge that there are some limitations to the current study. First, the
cross-sectional nature of the study cannot confirm a causal link between vitamin D levels
and VDR FokI, and further prospective design studies are required to support our
findings. Second, we did not study polymorphisms of other VDR genotypes and other
genes involved in the vitamin D metabolic pathway such as Vitamin D-binding protein,
Vitamin D 25-hydroxylase, and CYP27A1 that are thought to be associated with vitamin
D status.31 Third, despite several adjustments, factors related to sun exposure and the use
of sunscreen were subjected to recall bias.
Despite the aforementioned limitations of this study, the finding in our study may
assist in identifying “at-risk” populations through screening for FokI VDR
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polymorphisms in conjunction with screening vitamin D serum levels in pregnant
women. Moreover, since vitamin D is a potentially modifiable risk factor, these results
encourage a prospective study of the use of vitamin D supplementation in pregnant
women who are vitamin D deficient and the monitoring of its effectiveness in increasing
vitamin D levels while evaluating genes related to the metabolic pathway.
4.6 Conclusion
As far as we know, this is the first cross-sectional study to evaluate the
association between FokI polymorphisms in the VDR gene and serum 25(OH)D levels in
pregnant Saudi women with vitamin D deficiency compared to non-deficient subjects.
We also demonstrated the first association between the f allele and the reduced risk of
vitamin D deficiency when controlling for lifestyle and environmental factors that play a
major role in altering vitamin D status. The observed higher levels of serum 25(OH)D in f
allele carriers may be a compensatory response due to reduced VDR activity and
distorted signaling pathways.
In conclusion, vitamin D deficiency was highly prevalent among 79% of pregnant
Saudi women in their first trimester. Full body coverage with clothing, lower levels of
physical activity, residence in areas other than North Riyadh, work indoors, and the
amount of exposure to sunlight were found to be major risk factors for vitamin D
deficiency in pregnant Saudi women.
Our findings also indicated that the VDR gene FokI FF genotype and the F allele
might be important determinants of an individual’s susceptibility to vitamin D deficiency
in pregnant Saudi women, thus leaving them unprotected with the risk of developing
adverse skeletal and non-skeletal health outcomes. However, allele f and genotype Ff
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seemed to play a protective role, but the role of genotype ff is still unclear because of its
limited frequency.
It is important to take this finding into consideration in future prospective studies
that are targeted to assess 25(OH)D levels. Therefore, possible alterations in vitamin D
intake are needed to ameliorate the untoward effects of VDR FokI polymorphisms on
vitamin D status in this vulnerable vitamin D deficient group carrying a variant of the F
allele. If genotypes are truly associated with vitamin D status, serum concentrations of
25(OH)D required to reduce adverse health outcomes may need to be individualized for
each patient.
Future studies on healthy subjects are required to clarify the primary genetic
predictors of 25(OH)D concentrations, including the assessment of genes involved in
vitamin D metabolism. However, our study indicates the need for proper adjustment for
important confounders that are known to alter vitamin D status to appreciate the effects of
genotype on vitamin D levels.
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Table 4.1: Demographic and biochemical characteristics of vitamin D deficient vs. non-deficient subjects

Parameters
N
Age (years)
BMI (kg/m2)
Pre-pregnancy BMI (kg/m2)
Parity #
Calcium (mmol/L)
Phosphorus (mmol/L)
Alkaline phosphatase (mmol/L)
25(OH) D (nmol/L)
Low-intense PA (<210 mint/wk) (yes)
Sitting (minutes/week)

Vitamin D intake (>600 IU/d)
Calcium intake (>1000 mg/d)
Multivitamin intake
University graduate (or Higher) (yes)
Employment (yes)
Living in north Riyadh (yes)
Living in west Riyadh (yes)
Blood sample collection season

Overall

Non-Deficient
50nmol/L

345
72 (20.9)
28.8 ± 5.4
29.4 ± 5.4
28.2 ± 6.3
28.6 ± 6.6
27.2 ± 6.1
27.5 ± 6.7
1.4 ± 1.7
1.3 ± 1.7
Biochemical Parameters
2.2 ± 0.2
2.2 ± 0.2
1.2 ± 0.4
1.3 ± 0.5
9.5 ± 3.2
9.5 ± 2.8
35.5 ± 20.0
67.8 ± 12.9
Physical Activity
144 (50.9)
46 (78.0)
1200(6001200 (450 – 1500)
1800)
Diet
10 (3.1)
4 (5.8)
21 (6.6)
6 (8.7)
62 (21.9)
13 (24.5)
Education and employment
199 (59.1)
50 (70.4)
107 (31.5)
28 (38.9)
Area of living
64 (19.6)
23 (33.3)
90 (27.5)
13 (18.8)
Sun exposure Indices
111 (32.4)

23 (32.9)
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Deficient
<50 nmol/L
273 (79.1)
28.7 ± 5.4
28.2 ± 6.3
27.1 ± 5.9
1.4 ± 1.7

Pvalues
--0.320
0.626
0.591
0.492

2.2 ± 0.2
1.2 ± 0.4
9.5 ± 3.3
27.0 ± 10.6

0.638
0.029
0.992
0.000

98 (43.8)
1200 (600 –
1800)

<0.001

6 (2.4)
15 (6.0)
49 (21.3)

0.433
0.147
0.609

149 (56.0)
79 (29.5)

0.028
0.127

41 (15.9)
77 (29.8)

<0.001
0.069

88 (32.2)

0.921

0.709

(Summer)
Sun exposure (yes)
Coverage with clothing (whole body)
Use of sun screen (yes)
Nature of work (indoors)
Time of sun exposure (at noon)

91 (26.4)
93 (27.0)
28 (8.1)
317 (91.9)
114 (33.0)

20 (27.8)
2 (2.8)
6 (8.3)
48 (66.7)
52 (72.2)

71 (26.0)
91 (33.3)
22 (8.1)
269 (98.5)
62 (22.7)

Note: Data presented as Mean ± SD for continuous variables and N (%) presented for categorical variables;
# indicates non-normal variables; P-value<0.05 considered significant.
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0.762
<0.001
0.939
<0.001
<0.001

Table 4.2: Predictors of vitamin D deficiency among pregnant women in early pregnancy
Parameters

Univariate Analysis

Adjusted Model

OR (95% CI)

Pvalue

OR (95% CI) *

P-value*

Age (years)

0.98 (0.93 – 1.02)

0.319

1.00 (0.92 – 1.08)

0.909

BMI (kg/m2)

0.99 (0.95 – 1.03)

0.625

0.97 (0.92 – 1.03)

0.288

Pre-pregnancy BMI (kg/m2)

0.99 (0.55 - 1.03)

0.590

0.97 (0.91 – 1.03)

0.283

Parity

1.06 (0.90 – 1.25)

0.491

1.13 (0.85 – 1.50)

0.403

University graduate or postgraduate

0.54 (0.30 - 0.94)

0.030

0.42 (0.17 – 1.02)

0.054

Employment

0.66 (0.38 – 1.13)

0.128

0.67 (0.31 – 1.47)

0.319

Living in North Riyadh

0.38 (0.21 - 0.69)

0.002

0.32 (0.14 - 0.75)

0.009

Living in West Riyadh

1.35 (0.97 - 1.88)

0.072

1.42 (0.91 – 2.22)

0.119

Calcium (mmol/L)

0.70 (0.16 – 3.02)

0.637

0.11 (0.01 – 1.18)

0.068

Phosphorus (mmol/L)

0.42 (0.21 – 0.83)

0.012

0.27 (0.10 – 0.76)

0.013

Alkaline phosphatase (mmol/L)

1.00 (0.92 – 1.09)

0.992

0.96 (0.83 – 1.11)

0.596

Low-intense PA (<210 mint/wk) (yes)

0.22 (0.11 – 0.43)

<0.001

0.19 (0.08 – 0.44)

<0.001

Vitamin D intake (>600 IU/d)

0.40 (0.11 – 1.46)

0.165

0.30 (0.02 – 4.52)

0.383

Calcium intake (>1000 mg/d)

0.67 (0.25 – 1.80)

0.427

2.94 (0.30 – 28.35)

0.351

Blood collection season (Summer)

0.97 (0.56 – 1.70)

0.921

2.49 (0.90 – 6.89)

0.080

Sun exposure (yes)

0.91 (0.51 – 1.64)

0.762

2.23 (0.88 – 5.67)

0.090

Coverage with clothing (whole body)

17.5 (4.20 – 72.98)

<0.001

19.64 (2.52 – 152.68)

0.004

Use of sun screen (yes)

0.96 (0.37 – 2.47)

0.939

1.65 (0.42 – 6.48)

0.474
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Nature of work (indoors)
Time of sun exposure (at noon)

33.63 (11.17 – 101.23)

<0.001

132.0 (10.9 – 1600.7)

<0.001

0.11 (0.06 - 0.20)

<0.001

0.13 (0.06 - 0.32)

<0.001

Note: *P-value adjusted for Age, BMI at visit 1, Low-intense physical activity, Whole body cloth coverage, Job Status,
Residential Area, Education, total-cholesterol-HDL ratio, Calcium intake (mg/day), Vitamin D intake (IU/day).
P-value<0.05 considered significant.
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Table 4.3: The genotype distribution of FokI VDR gene polymorphisms among participants
FokI
Genotype

OR (95 % CI)

164 (60.1)

Non
Deficient
(>50
nmol/L)
40 (55.6)

117 (33.9)

91 (33.3)

26 (36.1)

0.85 (0.50 – 1.49)

0.577

24 (7.0)

18 (6.6)

6 (8.3)

0.73 (0.27 – 1.96)

0.535

FF

204(59.1)

164 (60.1)

40 (55.6)

Ff + ff

141 (40.9)

109 (39.9)

32 (44.4)

F

525 (76.1)

419 (76.7)

106 (73.6)

f

165 (23.9)

127 (23.3)

38 (26.4)

All

Deficient
(<50
nmol/L)

FF

204(59.1)

Ff
ff

Adj. OR
(95%CI)

Adjusted
P-value*

0.44 (0.20 –
0.94)
0.36 (0.08 –
1.52)

0.035

0.42 (0.20 - 0.88)

0.022

P-Value

Reference

0.163

Reference
0.83 (0.49 – 1.40)

0.488

Reference
0.85 (0.56 – 1.29)

0.434

0.51 (0.29 –
0.91)

0.021

Note: *P-value adjusted for Age, BMI, low-intense physical activity, whole body cloth coverage, Job Status, residential Area, and education
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CHAPTER 5
MANUSCRIPT 2: FOKI VITAMIN D RECEPTOR GENE POLYMORPHISMS,
GLUCOSE INTOLERANCE AND GESTATIONAL DIABETES RISK IN SAUDI
WOMEN

5.1 Abstract
•

Background: Gestational diabetes mellitus (GDM) is one of the major complications
of pregnancy. GDM is common in pregnancies around the world (1% to 14%), with
alarmingly high rates among Saudi women (39%). The reported prevalence of
vitamin D deficiency is also higher in pregnant Saudi women (85%). Previous studies
have linked vitamin D deficiency in pregnancy with a 1.6-times increased risk of
developing GDM. The presence of the mutant f allele of the FokI vitamin D receptor
(VDR) polymorphism has been shown to reduce vitamin D responsiveness. We
expect that carriers of the ff genotype have a greater risk of GDM.

•

Aim: This study examined whether there was a difference in GDM risk associated
with the various genotypes of the FokI VDR polymorphism in pregnant Saudi women
during their second trimester.

•

Materials and Methods: A cross-sectional study of 368 pregnant Saudi women,
including 108 GDM patients and 260 healthy subjects, was conducted in the antenatal
clinics of three hospitals in Riyadh, Saudi Arabia (King Khaled University Hospital
[KKUH], King Salman bin Abdulaziz Hospital, and King Fahad Medical City
[KFMC]) between December 2013 and January 2016. The oral glucose tolerance test
(OGTT) was administered at 24–28 weeks’ gestation. We also measured fasting
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blood glucose, insulin, and HbA1C. The homeostasis models of insulin resistance and
beta cell function were calculated using the HOMA-IR and HOMA-, respectively.
The FokI genotype of each woman was determined through allele-specific
polymerase chain reaction (PCR).
•

Results: About 29% of the study sample were diagnosed with GDM. The GDM
patients were older, heavier, and had higher pre-pregnancy BMIs than the healthy
subjects. As expected, the fasting blood glucose (FBG), fasting insulin, HbA1C,
HOMA-IR, and HOMA- levels were also higher in the GDM patients. Among the
GDM patients, the frequencies of the genotypes FF, Ff, ff, and combined Ff+ff were
60.2%, 33.3%, 6.5%, and 39.8%, respectively; among the healthy subjects, the
frequencies of these genotypes were 61.1%, 31.5%, 6.9%, and 38.4%, respectively.
While we could not determine a significant association between the FokI VDR
polymorphism and GDM risk, we found that serum 25-hydroxyvitamin D was
significantly and inversely associated with fasting blood glucose and HbA1C within
the group of patients carrying the ff minor allele genotype (r=-0.49, P=0.014 and r=0.45, P= 0.026, respectively). Vitamin D deficiency was highly prevalent among the
study sample, reaching up to 85.3%. This condition was also significantly associated
with GDM (P=0.016) and glucose indices, such as fasting insulin, HOMA-IR and
HOMA-.

•

Conclusion: Our study suggests that, within the Saudi population, the glucoselowering effects of a higher vitamin D level may be dependent upon the FokI
genotype.
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5.2 Introduction
Gestational Diabetes Mellitus (GDM), defined as “carbohydrate intolerance of
variable severity, with onset or first recognition during pregnancy”,1 is one of the more
common complications of pregnancy. The global prevalence of GDM, which is from 1%
to 14% of all pregnancies, depends on the population studied and the GDM diagnostic
tests applied.2 GDM can cause serious maternal and fetal morbidity and mortality. Shortterm maternal complications of GDM include increased risk of maternal hypertension,
pre-eclampsia, infection, cesarean delivery and premature birth, and in newborns
hypoglycemia, macrosomia, shoulder dystocia or birth injury, increased intensive
neonatal care, hyperbilirubinemia, respiratory distress syndrome, and polycythemia.3,4
Long-term adverse maternal health outcomes of GDM include a 70% increase in the risk
of developing Type 2 Diabetes (T2DM) within 10 years after delivery5, and a 35 to 80%
increased risk of developing GDM in a future pregnancy.6 In addition, offspring of
mothers with GDM are at increased risk of developing obesity, T2DM and cardiovascular
disease during early childhood.7 The pathogenesis of GDM remains unclear, 8 but likely
is attributed to both genetic and lifestyle factors.
The role of vitamin D deficiency as a potentially modifiable nutritional risk factor
for GDM has been highlighted in the literature. For example, a recent meta-analysis
found that reduced vitamin D status was associated with a 45% increase in GDM risk. 8
Further support for a role of vitamin D status in blood glucose control in women with
GDM has been supplied by two vitamin D supplementation studies.9,10 One recent
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randomized, double-blind placebo-controlled clinical trial found that a very high-dose of
vitamin D supplementation (50,000 IU) every 2 weeks significantly reduced levels of
insulin resistance in pregnant Chinese women with GDM .9 Similarly, another
randomized placebo-controlled trial found a significant reduction in fasting plasma
glucose, serum insulin levels and HOMA insulin resistance in 56 Iranian women with
GDM compared with the placebo group after supplementing them with calcium (1,000
mg/d) and vitamin D (50,000 IU/d) twice during the study period.10
In spite of bountiful sunlight in Saudi Arabia, vitamin D deficiency is common
and reported to affect 72% of women of childbearing age.11 A cross-sectional study found
that out of 160 pregnant Saudi women, 90% of the study sample were either vitamin D
deficient (25(OH)D ≤50 nmol/L) or vitamin D insufficient (25(OH)D = 50–74 nmol/L). 12
Similarly, another cross-sectional study of 1000 pregnant Saudi women reported that
86% were vitamin D deficient (mean: 30.5 ± 19.6 nmol/L).13 This alarmingly high rate of
vitamin D inadequacy needs to be carefully evaluated because many studies have linked
vitamin D deficiency with adverse metabolic outcomes for both mother and their
newborns. 14,15,16
In addition, the prevalence of GDM among Saudi women is also exceedingly
high, ranging between 10% to 51% depending on the diagnostic tool.15 Important risk
factors for GDM in Saudi women that have been identified include obesity, and the
tradition of Saudi women to become pregnant at an older age.16 Other commonly
observed risk factors for GDM include: a family history of diabetes, gestational weight
gain, history of GDM in previous pregnancies, a history of delivering a large baby
(macrosomia).15,16
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The suggested physiological mechanism behind the association of vitamin D
status and risk of GDM is that the vitamin D receptor (VDR) is present in almost every
tissue of the human body, including β-cells of the pancreas.9 The active hormonal
metabolite of vitamin D (1,25-dihydroxyvitamin D) binds to the VDR of pancreatic β
cells and promotes insulin secretion and thereby may influence glucose homeostasis.9, 17
Activation of the vitamin D receptor by its ligand can be modulated by many cellular
factors, including single nucleotide polymorphisms (SNP) in the VDR gene itself, such as
the ff FokI SNP (rs 2228570); previously reported as (rs10735810).18 This VDR
polymorphism is of particular interest because in vitro studies indicate that the f allele
results in a nucleotide change in the gene sequence that results in the formation of a
second upstream start site that results in the expression of a VDR protein that is 3 amino
acids longer than the VDR coded by the F FokI VDR allele.19 The longer VDR has been
shown to be less responsive to 1,25-dihydroxyvitamin D than the shorter F allele version
in activating target gene expression.20 Thus, we hypothesized that Saudi mothers with
poorer vitamin D status plus expression of the longer, less effective f version of the VDR
protein would be at greatest risk of any adverse effects of vitamin D deficiency on
glucose intolerance and the risk of GDM.
To our knowledge, only a few studies have investigated the association between
the FokI VDR polymorphisms and GDM in Iran,21 Saudi Arabia,22,23 and most recently in
Brazil,23 but the findings were inconsistent and inconclusive due to the variability of the
population and ethnic groups studied. A significant association was found between
mutant ff FokI genotype carriers and the risk of GDM when compared with healthy
subjects in Iranian and Brazilian population.21,24 Nevertheless, El-Beshbishy et al. and Al-
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Ghamdi failed to observe such an association in Saudi pregnant women.22,23
The current study was designed to determine to what extent the f allele of the FokI
VDR gene polymorphism is a genetic biomarker associated with increased risk of GDM
in Saudi women. We reasoned that the ability of vitamin D status to modulate glucose
metabolism would be impaired in women with the ff FokI genotype. Our working
hypothesis was that Saudi pregnant women carrying the (f) minor allele FokI VDR
genotype will have an increased signs of glucose intolerance and a greater risk of
developing GDM.
5.3 Methods
5.3.1 Study Design and Sample Population
This study is a part of a large prospective cohort study called “Vitamin D and
Pregnancy in Saudi Women”. Our cross-sectional study is a subset of these study
participants and consisted of 368 pregnant Saudi women including 108 GDM patients
and 260 healthy pregnant women who visited an antenatal clinic in their second trimester
(24-28 weeks of gestation) at one of three different hospitals; King Khaled University
Hospital (KKUH), King Salman bin Abdulaziz Hospital and King Fahad Medical City
(KFMC) in Riyadh, the capital city of Saudi Arabia, between December 2013 and
January 2016. The study has full ethical approval from the three hospitals to collect
samples and patients data and also an approval was obtained from the Ethics Committee
of the College of Science, King Saud University in Riyadh (Appendix A). Written
informed consent was obtained from each patient (Appendix B).
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5.3.1.1 Inclusion and Exclusion Criteria
Healthy pregnant Saudi women aged 18 to 40 years with no previous history of
diabetes mellitus (type I or II) were enrolled in the study prior to 16 weeks of gestation.
Subject exclusion criteria included: non-Saudi subjects; gestational age of over 16 weeks;
women were excluded from the study if they were taking vitamin D supplements during
pregnancy; unwillingness to deliver at the three hospitals; taking oral glucocorticoids;
using drugs known to interfere with vitamin D or calcium absorption or parathyroid
disorders; using any cardiac medication or diuretics; suffering from chronic hypertension
or malabsorption syndrome; having chronic medical conditions or preexisting liver,
kidney, calcium, and /or parathyroid conditions; or serious chronic disease conditions
(epilepsy, cancer, other malignancy).
5.3.1.2 Recruitment and Medical Screening
Recruitment banners and brochures were placed in prenatal clinics in all three of
the hospitals. Obstetricians were asked to introduce the research to their pregnant patients
at their first prenatal appointment. Patients who met the criteria and consented to
contribute in the present study were given the appropriate information. At their early
pregnancy visit, prospective candidates were asked to sign consent forms that included
information about their participation in the study, such as answering a questionnaire
about demographic data collection, procurement of blood samples for biomarker
measurement and DNA for genetic analyses, and anthropometric measurements.
Permission for data collection from their medical records and stored blood stocks ifrom a
bio-bank were also obtained (Appendix A). The participants were also informed of their
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right to withdraw from the study at any point, without it affecting their usual medical
care.
5.3.2 Anthropometric Measurements
Anthropometric measurements were taken from the participants between 24 and
28 weeks gestation. These measures included weight (kg) and height (cm), used for
calculating BMI (kg/m2); reported pre-pregnancy weight (kg) and pre-pregnancy BMI
(kg/m2). Body weight, without shoes and wearing lightweight clothing, was measured to
the nearest 0.1 kg (Digital Pearson Scale, ADAM Equipment Inc., USA). Height, to the
nearest 0.5 cm, was measured at the early pregnancy visit only using the Digital Pearson
Scale, while standing upright without shoes. Pre-pregnancy BMI was calculated from
pre-pregnancy body weight recall and measured height.
5.3.3 Interview Questionnaire
At the second trimester visit (24-28 weeks of gestation), clinical data was
collected. Pregnant women were questioned about GDM risk factors, such as parity
(nulliparous or ≥ 1 multiparous), pre-pregnancy weight, previous miscarriage (yes/no),
previous history of GDM, and family history of diabetes or any other family medical
history. Participants were also asked about pregnancy-related symptoms, such as nausea,
vomiting, morning sickness, frequent urination, headaches, abdominal bloating,
constipation, acute respiratory or gastrointestinal viral or bacterial infections, any
hospitalisation or medication prescribed, and the presence of any pregnancy-related
complications.
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5.3.4 Biochemical Assessment
During the antenatal visit between 24 and 28 weeks of gestation, participants were
asked to fast > 10 hours for blood withdrawal. Blood samples (10 ml) were collected
using sterile vacutainer blood collection apparatus. Whole blood, serum, and ethylene
diamine tetra-acetic acid (EDTA) plasma were collected from the participants. All
samples were aliquoted and stored in a -80ºC freezer for subsequent analyses. All the lab
tests were performed on serum, except hemoglobin A1C (HbA1C), which was performed
on whole blood. The blood samples were stored and analyzed at the King Saud University
Biomarkers Research Program (BRP) Laboratory. It should be noted that the Biomarker
Research Program (BRP) Laboratory is a participating entity in the vitamin D External
Quality Assessment Scheme (DEQAS), and Quality Assurance (QA) standards are
maintained by ISO 9000 and 17025. The QA department audits the BRP Laboratory at
regular intervals.
5.3.4.1 Primary Outcome Measures
Our main outcome is the metabolic impact of the mutant ff FokI VDR genotype
versus the wild type FF FokI VDR genotype on glucose intolerance and risk of GDM,
measured by oral glucose tolerance test (OGTT) administered at 24-28 weeks gestation.
For the OGTT, women were asked to fast for at least 10 hours, and a fasting blood
sample was obtained and then a 75 g glucose drink was consumed (within a period of five
minutes). Further blood collections took place at the 60- and 120-minute time points to
assess glucose tolerance. Serum glucose (PG) was measured by using routine laboratory
analysis (Konelab, Finland). The International Association of Diabetes and Pregnancy
Study Groups (IADPSG) guidelines were applied to diagnose GDM based on the (fasting
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≥5.1 mmol/l and or 1 h post glucose ≥10mmol/l h and/or 2 h post glucose load
≥8.5mmol/l) .25
5.3.4.2 DNA Extraction and Quantification
Genomic DNA was extracted from whole blood using innuPREP blood ini kits
(Analytik Jena, Germany) following the manufacturer’s instructions. Briefly, 200µl of
whole blood sample was added to a 1.5 ml reaction tube containing lysis buffer and
Proteinase K. The content was mixed by vortex and incubated at 600C for 10 minutes.
The required amount of binding solution was added to the tube and transferred to a spin
filter column with receiver tube and centrifuged for 1 minute at 12000 rpm. Washing of
the column-bound DNA was performed using the kit’s washing solution C followed by
washing solution BS. In a final step, the spin filter was placed into a 1.5ml elution tube
and 200µl of pre-warmed (at 600C) elution buffer was added. After centrifugation, the
collected DNA was stored at -20◦C for further analysis. DNA concentration and purity
(260/280) was determined using a Nano-Drop spectrophotometer.
5.3.4.3 FokI SNP Genotyping
The Fok-I SNP is in the VDR coding region (rs 2228570); previously reported as
(rs10735810) and can be evaluated by allelic discrimination real-time PCR using predesigned TaqMan genotyping assay from Applied Biosystems, Foster City, CA, USA
(assay ID: C_12060045_20). Amplification reactions was performed in a volume of 10
µL containing 1X TaqMan genotyping Master Mix (Applied Biosystems), 1X mix of
unlabeled PCR primers and TaqMan MGB probes, and 30 ng of template DNA. All
amplification and detection was conducted in 96-well PCR plates using a Bio-Rad
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CFX96 Real-Time PCR Detection System (Bio-Rad, Milan, Italy). Thermal cycling was
initiated with a denaturation step of 10 min at 95 °C, followed by 45 cycles of 15 s at 95
°C and 90 s at 60 °C. After PCR was completed, allelic discrimination was analyzed
using the Bio-Rad CFX Manager Software (Version 1.6, Bio-Rad). Genotype assignment
was determined by plotting the end point relative fluorescent units (RFU) for one
fluorophore (allele 1 on the x-axis) against the RFU for the other fluorophore (allele 2 on
the y-axis) on the allelic discrimination. All PCR reactions were set up in a dedicated
PCR area with dedicated PCR pipettes and reagents.
5.3.4.4 Other Measures
From the whole blood, HbA1C was measured using a point-of-care device (AccuCheck Active, Roche Diagnostics, Mannheim, Germany). Fasting serum insulin was
measured by COBAS e 411 Analyzer (Roche Diagnostics). The homeostasis model of
insulin resistance (HOMA-IR) and homeostasis model of beta cell function (HOMA-β),
were calculated to evaluate insulin resistance and basal pancreatic β-cell function using
the following equations:
(HOMA-IR) = fasting insulin (μU/ml) × fasting FPG (mmol/l)/22.5 14
(HOMA-β) = 20 × fasting insulin(μU/ml)/[FPG(mmol/l) − 3.5] 14
Higher HOMA-IR values indicated greater insulin resistance, while lower HOMA-β
values indicated greater beta-cell dysfunction, as validated against gold standards.26
We also measured serum 25-hydroxyvitamin D (25(OH)D), which is the most
reliable indicator of vitamin D status 27 through an electro-chemiluminescence binding
assay 2012 (ECLIA) (Roche Diagnostics GmbA, Mannheim, Germany) and
commercially available IDS kits (IDS Ltd, Boldon Colliery, Tyne & Wear, UK). The
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inter- and intra-assay coefficients of variation (CV) for the 25(OH)D ELISA is 5.3% and
4.6%, respectively, with 100% cross-reactivity to 25(OH)D3 and 75% cross-reactivity to
25(OH)D2. According to US Endocrine Society guidelines, the cutoff values for vitamin
D deficiency is defined as serum 25(OH)D less than 50nmol/L. 27
5.3.5 Statistical Analysis
The power analysis for this study is based on results from Aslani et al.21 Using the
G*Power Calculator for sample size effect size=0.22 α=0.05, power (1-β) = 0.95 and
degrees of freedom=2, the total estimated sample size=321. Data were analyzed using
SPSS statistical software (version 21.0, IBM). The normality of all quantitative
variables was tested before performing the analysis, using Shapiro-Wilk Test.
Quantitative normally distributed variables were presented as mean ± standard deviation
(SD), while quantitative non-normally distributed variables were presented in median
(25th and 75th) percentiles. Categorical data were presented as frequencies and
percentages (%). Pearson’s chi-square test was used to determine the differences between
categorical variables. Comparisons between groups were performed using the
independent sample t-test and the Mann-Whitney U test for normal and non-normal
variables, respectively. The Pearson’s and Spearman’s rank correlation coefficients were
determined to assess the linear relationship between quantitative variables for normally
and non-normally distributed variables, respectively. Unadjusted and adjusted odds ratios
were determined using logistic regression analysis to identify the risk factors associated
with categorical outcome variables. Generalized multivariate analysis was also done to
compare mean differences adjusted for age, BMI. A P-value of < 0.05 and 95% CI was
finally applied to report statistical significance and the precision of the estimates.
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5.4 Results
5.4.1 Demographic and Biochemical Characteristics of GDM vs. Normal Subjects
Table 5.1 presents the anthropometric and biochemical characteristics of the
GDM and non-GDM groups of pregnant women. The prevalence of GDM was 29.3%
(n=108/368). There was a significant difference in age, current BMI, and pre-pregnancy
BMI between the GDM and normal subjects. GDM patients were significantly older and
heavier than normal pregnant women (P< 0.01 and <0.01, respectively). Moreover, GDM
patients were more obese (53.4%) compared to healthy pregnant women (30.2%),
(P<0.001) (Figure 5.1). Compared with non-GDM group, fasting blood glucose (FBG), 1
h and 2 h OGTT, HbA1C, fasting insulin, HOMA_IR, and HOMA-β in the GDM subjects
were significantly increased. These significant increases remained even after adjusting
for age and BMI. Although, medium serum 25(OH)D was low, but not different in the
GDM and normal subjects (33.9 vs. 32.9 nmol/L, respectively P = 0.686), vitamin D
deficiency however, was significantly higher in GDM group (93.2%) compared to normal
subjects (82.2%) (P =0.013) (Figure 5.1).
Interestingly, there were no significant differences between GDM and normal
subjects in regards to parity, family history of diabetes, and previous history of
miscarriage. However, previous history of GDM was significantly higher in GDM than
non-GDM groups (25.7% vs. 3.1%, respectively P < 0.01) (Figure 5.1).
5.4.2 Risk Factors for GDM in Pregnancy
We further conducted a multivariate logistic regression analysis to assess the risk
factors for GDM while adjusting for confounding factors (Table 5.2). Significant
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independent variables that increased the risk of GDM included previous history of GDM
(OR 9.25, 95% CI 3.14-27.22, P < 0.001), fasting insulin (OR 1.07, 95% CI 1.03-1.11, P
< 0.001), HOMA_IR (OR 1.07, 95% CI 1.03-1.11, P < 0.001), obesity (OR 2.08, 95% CI
1.09-3.95, P =0.026) and vitamin D deficiency (OR 2.96, 95% CI 1.22-7.19, P = 0.016).
Although HbA1C was significantly higher in GDM than non-GDM group, it did
not appear to be a risk factor for GDM. In fact, it lost its significance after adjusting for
confounding factors (OR 1.50, 95% CI 0.74-3.02, P = 0.263).
5.4.3 FokI VDR Polymorphism and GDM
As shown in Table 5.3, the difference in the occurrence of the various FokI VDR
genotypes in GDM and non-GDM participants was not significant. The FokI VDR
genotypes are normally expressed as homozygous genotype “FF,” heterozygous
genotype “Ff,” and mutant homozygous genotype “ff.” The frequencies of FF, Ff, ff, and
combined Ff+ff genotypes were 61.1% (225), 32.1% (118), 6.8% (25), and 39.8% (43)
respectively, in the study population. Taking the FF genotype as a reference, the odds
ratio for the risk of having GDM was not significant among the different FokI VDR
genotypes, even after adjusting for important covariates such as age, BMI, family history
of diabetes, obesity, previous history of GDM, fasting serum insulin, HbA1C and vitamin
D deficiency. The frequencies of genotypes FF, Ff, ff, and combined Ff+ff in women
with GDM were 60.2%, 33.3%, 6.5%, and 39.8% respectively, while in the control group
were 61.1%, 31.5%, 6.9%, and 38.4% respectively. The prevalence of F and f alleles for
the FokI VDR polymorphisms in the two groups was also not significant (allele F vs. f;
P=0.495), even after adjustments of covariates.
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5.4.4 Biochemical Characteristics of the Subjects Depending on FokI VDR
Genotypes and Alleles
Table 5.4 shows that women carrying the f allele had higher OGTT levels at 2
hours than subjects carrying the F allele (P= 0.017). Similarly, OGTT levels at 2 hours
were significantly higher in combined FokI genotype Ff+ff than the FF genotype carriers
(P= 0.019) (data not shown). Yet, we did not detect any significant association between
other different biochemical variables and FokI VDR genotypes in all subjects.
5.4.5 Vitamin D Status and Glucose Indices
Table 5.5 presents the clinical and biochemical characteristics of vitamin D
deficient versus non-deficient subjects. Vitamin D deficient subjects had significantly
higher fasting insulin, HOMA_IR and HOMA1-β (P= 0.024, 0.007, 0.041, respectively).
5.4.6 Correlation Between Vitamin D and Other Parameters in Genotypes
Serum 25(OH)D was significantly and inversely associated with fasting blood
glucose (FBG) (r= -0.49, P=0.014) (Figure 5.2) and HbA1C (r = - 0.45, P=0.026) (Figure
5.3) in women carrying the ff FokI genotype. Moreover, there was a significant and
positive association between serum 25(OH)D and HOMA1-β (r = 0.20, P<0.05) in
patients carrying the f allele.
5.5 Discussion
Vitamin D deficiency was evident in 85.3% of our study sample. Despite the
abundance of sunlight in Saudi Arabia, many previous studies have similarly reported a
high prevalence of vitamin D deficiency among the Saudi population, with a higher rate
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observed in younger females, especially in pregnant women and their offspring.12,13 In
line with our finding, both Al-Sheikh et al.13 and Foda et al.28 found that 86% of pregnant
Saudi women, were vitamin D deficient. Several factors related to Saudi customs may
play a role in vitamin D status, such as limited outdoor activities due to extremely high
temperatures during the daytime as well as the tradition of wearing dark clothing that
covers the whole body, thus preventing sun exposure and blocking the cutaneous
production of vitamin D. Low consumption of foods containing vitamin D may be
another important risk factor for vitamin D deficiency in Saudi Arabia.12,13
Poor vitamin D status is a known risk factor for glucose intolerance and the
development of T2DM.29 VDR gene polymorphisms are candidate single nucleotide
polymorphisms associated with vulnerability to a variety of conditions and diseases,
including glucose intolerance and T2DM.18 Among the most common VDR
polymorphisms studied, only the FokI VDR polymorphism has been shown to affect the
VDR protein structure.30 This polymorphism (denoted by f) results in a cytosine-tothymine (C→T) nucleotide change in exon 2 of the coding region of the VDR gene, thus
creating a second upstream start site due to a codon change from ACG to ATG.19, 20 This
start codon change causes the expression of a VDR protein that is 3 amino acids longer
(427 versus 424 amino acids), which has been shown to have reduced transactivation
ability.19, 20 Therefore, we hypothesized that pregnant women with the ff genotype of the
FokI polymorphism (all long VDR proteins) would be more likely to have impaired
glucose tolerance than those with the FF genotype (all short VDR proteins). We also
predicted that poor vitamin D status, in combination with the ff genotype, would be
associated with a greater degree of glucose intolerance (determined via an OGTT at 24
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weeks’ gestation) and would be more likely to be diagnosed with GDM. However, our
findings showed no significant associations between the FokI VDR polymorphism and
the risk of GDM in pregnant Saudi women. In fact, the frequencies of FokI genotype and
allele variants were almost identical in the wild-type (FF) carriers, ff homozygotes, and
Ff heterozygotes among the GDM and control groups.
While previous studies have demonstrated the potential role of the FokI VDR
polymorphism in the pathogenesis of GDM, they remain scarce and inconclusive. Our
results agree with the following two studies conducted among the Saudi population.22,23
In her small study, Al-Ghamdi did not observe any difference in the FokI VDR
polymorphisms of 50 healthy, pregnant Saudi women and 50 GDM patients. 23 ElBeshbishy et al., using a sample size similar to our own, also did not detect any
significant differences in the FokI VDR polymorphisms of 112 GDM patients and 218
healthy, pregnant Saudi women. 22
In contrast, two studies found a significant association between the FokI VDR
polymorphism and GDM. The first study was conducted by Aslani et al. on 303 pregnant
Iranian women (142 GDM patients and 161 healthy subjects), which found that the ff
genotype was more common in the GDM patients than in the healthy subjects
(OR=1.783; 95% CI=0.774–4.107). 21 Interestingly, the healthy subjects had higher
frequencies of the F allele (78.6% vs. 72.2%; P<0.06), suggesting that the F allele may
contribute to decreasing the incidence of GDM.21 The authors attributed the reason for
this association to the dysfunction of the f VDR variant. As the mutant f allele is longer in
structure and 40% less active than the F allele, carriers of the f allele are therefore
predisposed to a higher risk of GDM.21 The second study, which supports Aslani et al.’s
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results, was recently conducted on a population from northeastern Brazil.24 The authors
examined whether the FokI VDR polymorphism was associated with GDM risk in
pregnant women with a history of spontaneous preterm births (SPTBs).24 The results
revealed a significant association between the presence of the mutant ff genotype and
GDM risk in SPTB patients, compared to patients who experienced normal deliveries
(OR=4.71; CI 95%=1.1–22.30; P=0.044), as the frequency of the ff genotype was higher
in the SPTB group (23% vs. 4.7%).24 The authors therefore suggested that the FokI VDR
polymorphism could be a biomarker for GDM.24
These previous findings should be interpreted with caution, however, as ElBeshbishy et al.22 and Aslani et al.21 measured fasting blood glucose alone to screen for
GDM. The application of other criteria for the diagnosis of GDM, such as those of the
International Association of Diabetes and Pregnancy Study Groups (IADPSG), results in
an increased prevalence of GDM due to the inclusion of pregnant women with
hyperglycemia.25 Therefore, there is a possibility that the authors missed the high-risk
patients, thus under-reporting the incidence of GDM, which may have affected the study
outcomes. It was also not clearly indicated whether the previous investigators controlled
for risk factors such as obesity, a family history of diabetes, or a history of microsomia,
as only Aslani et al.21 found the latter two factors to be significantly associated with
GDM risk. Furthermore, the contradictory evidence of the previous studies could be
explained by the small sample size, the heterogeneity of the analyzed samples, and the
intra-individual variability in vitamin D status, which might have influenced the
expression of VDR gene polymorphisms.30 It should be noted that Aslani et al.21 were the
only investigators who measured the serum 25(OH)D levels; however, they did not study
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the effect of vitamin D deficiency in combination with the genotype of the FokI VDR
polymorphism on the patients’ glucose intolerance or GDM risk.
Although our study did not result in a significant association between the FokI
VDR polymorphism and the risk of GDM, we did find that carriers of the f allele had
higher levels of blood glucose at two hours into the OGTT than carriers of the F allele.
Moreover, in carriers of the ff genotype, serum 25(OH)D was found to be significantly
and inversely associated with fasting blood glucose and HbA1C. These observations might
be explained by the fact that the VDR is expressed in many human tissues, including
those involved in the regulation of glucose metabolism, such as pancreatic β cells.8,19 The
VDR is also known to alter glucose homeostasis via the insulin-like growth factor
system.8,12 Although the role of vitamin D and the VDR in regulating glucose
homeostasis remains unclear, our results in the Saudi population suggest that the glucoselowering effects of a higher vitamin D level may be dependent upon the FokI genotype.
It is well known that vitamin D may enhance insulin sensitivity by stimulating the
expression of insulin receptors, thereby increasing insulin response to facilitate glucose
transport.31 In our results, we found evidence that supports the adverse effect of vitamin
D deficiency on glucose tolerance and insulin sensitivity, as the levels of fasting insulin,
and HOMA-IR were significantly higher in vitamin D-deficient subjects. These
observations are congruent with other published studies reporting an association between
lower serum 25(OH)D levels and higher HOMA-IR, which suggests that vitamin D
deficiency during pregnancy may be related to insulin resistance and could therefore
increase the risk of GDM.32–35 Our findings are also in agreement with a recently
published study that revealed a significant association between poor vitamin D status and
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fasting blood glucose (P=0.002) or insulin sensitivity (P=0.001) in healthy Czech
adults.30
In our study, although there were no observed, significant differences in vitamin
D levels between the GDM and healthy subjects, even after adjusting for the cofounders
of age and BMI, vitamin D deficiency appeared to be a risk factor for GDM. In fact, we
found that the vitamin D-deficient subjects were 2.3 times more likely to develop GDM
compared to their healthy counterparts (OR=2.29, 95%; CI=0.79–6.65; P=0.016). Our
results are consistent with two previous studies that linked vitamin D deficiency with
GDM36,37 as well as a meta-analysis, which associated vitamin D deficiency in pregnancy
with a 1.6-times increased risk of GDM.38 However, in other studies, particularly in
Saudi Arabia,13 the Czech Republic,39 Turkey,32 India,40 and Britain,41 no associations
were reported between vitamin D deficiency and the risk of GDM. Other factors that can
potentially impact the results include geographical location, ethnicity, study design,
sample size, lack of adjustment for confounding factors, heterogeneity of dietary factors,
and differences in socio-economic status.42,43
GDM is considered a serious public health issue, as it has been associated with
higher incidences of perinatal mortality and morbidity.40 The prevalence of GDM in
Saudi Arabia has risen steadily over the past two decades, from 12.5% in 200011 to 18.7%
in 201344 and 24% in 2015.45 These alarmingly large increments were measured using the
2013 criteria of the ADA and the WHO.11,44,45 In our study, using the latest GDM
diagnosis criteria of the IADPSG, we identified 108 participants (29.3%) with GDM.
This rate appears to be high, and it corresponds well with the rising trend of GDM in
Saudi Arabia; however, it should be noted that the IADPSG criteria includes pregnant
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women with hyperglycemia as well as GDM patients, which may have affected the
prevalence of GDM observed in our study population.46,47 Three other studies conducted
in Saudi Arabia used the same IADPSG criteria and, congruent with our results, found a
high prevalence of GDM in their respective samples, amounting to 39.6%,48 36.6%,49 and
39.4%.16 These rates are extremely high when compared to the overall prevalence of
GDM (17.8 %) found in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO)
cohort.50 The HAPO was a large, multicenter, multinational, epidemiologic cohort study
of 23,957 pregnant women at 24–32 weeks’ gestation, who were similarly diagnosed
using the IADPSG criteria.4 According to the literature, GDM has genetic and
environmental influences.51 In addition to ethnic variation within a population, the most
commonly reported risk factors for GDM in pregnant women include weight, parity,
advanced maternal age, having delivered a macrosomic infant, having a previous history
of GDM, and having a family history of diabetes.49,54 Likewise, our study found that
having a previous history of GDM, fasting insulin, HOMA-IR, obesity, and vitamin D
deficiency (as discussed earlier) are strong, significant predicators of GDM. The
association between having a previous history of GDM and the recurrence of GDM has
been confirmed as well; as earlier studies found that GDM recurs in at least 30% of
women with prior history.53 Our findings are also supported by studies in different
countries that found a significant association between pre-pregnancy obesity and GDM
risk.49,54
The association between GDM and HbA1C has been previously documented as
well.14 While we also observed a strong, significant relationship between GDM and
HbA1C, statistical significance was lost after adjusting for confounders.
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We acknowledge that there are some limitations in our study, as cross-sectional
studies are incapable of proving causation. In addition, our sample size was relatively
small, especially in the group carrying the ff genotype of the FokI VDR polymorphism,
thus making it difficult to assess the interaction between VDR gene polymorphisms and
GDM risk. We also analyzed only one SNP of the VDR gene—albeit one that translates
structurally diverse VDR proteins, which have different potentials in eliciting vitamin Dmediated gene expression. While there are other documented risk factors that might have
masked the relationship between the FokI VDR polymorphism and GDM risk, such as
gestational weight gain,55 inflammation,56 low levels of vitamin B12,57 and low
adiponectin,58 we only controlled for the classical risk factors. Nevertheless, our study is
one of the few in Saudi Arabia that assesses the association between the FokI VDR
polymorphism and GDM while considering the confounding factors of age, BMI, parity,
obesity, vitamin D deficiency, previous history of GDM, and family history of diabetes.
We had strict standards for recruitment, as we excluded all patients taking vitamin D
supplements. The accuracy of our vitamin D measurements is assured through our use of
the ECLIA method, which is the gold standard in liquid chromatography–mass
spectrometry (LC–MS/MS), and our results were included in the Vitamin D External
Quality Assurance Scheme (DEQAS). We were also able to measure multiple outcomes
related to glucose intolerance, such as insulin and HbA1C, using the most accepted and
cost-effective criteria worldwide (the IADPSG criteria).59
5.6 Conclusion

Contradictory results exist in the prevailing literature on the associations between
VDR gene polymorphisms and GDM. While our study identified an effect on GDM risk
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caused by vitamin D deficiency, we found no associations between the ff genotype of the
FokI VDR polymorphism and the occurrence of GDM in the Saudi population.
Regardless, our study is very encouraging, as it demonstrates that the glucose-lowering
effects of a higher vitamin D level may be dependent upon the FokI genotype within the
Saudi population. Our findings also confirm a high prevalence of GDM and vitamin D
deficiency among pregnant Saudi women. A strong, significant association has been
detected between vitamin D deficiency and GDM risk, along with other classical risk
factors.
Potential interactions between vitamin D status and genetic polymorphisms in the
pathogenesis of GDM are far from being fully comprehended. Nevertheless, given the
role of vitamin D status in pregnancy outcomes and disease conditions other than GDM,
it would be prudent to recommend increased vitamin D supplementation among this
vulnerable population of women. Further studies are warranted, with sufficient statistical
power, subjects of diverse ethnic backgrounds, and the inclusion of both classical and
atypical risk factors for GDM as well as other genes in the vitamin D metabolic pathway,
to confirm the potential association of VDR gene polymorphisms with GDM in different
populations.
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Table 5.1: Demographic and biochemical characteristics of GDM vs. normal subjects

All

GDM

Non GDM

N

368

108 (29.3)

260 (70.7)

29.1 ± 5.6

30.6 ± 6.0

28.4 ± 5.2

2.0 (1.0-4.0)

2.0(1.0-5.0)

2.0(1.0-3.0)

0.369

28.2 ± 6.1

30.3 ± 6.4

27.3 ± 5.9

<0.001

------

26.9 ± 5.9

28.7 ± 5.9

25.9 ± 5.4

<0.001

------

5.3 (4.8-5.6)
10.1 (7.6-10.7)

4.3 (3.9-5.6)
6.7 (5.3-7.8)

<0.001

<0.001

OGTT_1hrs (mmol/L)

4.5 (4.1-5.0)
7.4 (5.8-8.9)

<0.001

<0.001

OGTT_2hrs (mmol/L)

6.3 (5.3-7.7)

8.8 (6.6-10.2)

5.9 (5.1-6.9)

<0.001

<0.001

4.8 ± 0.5

5.0 ± 0.6

4.7 ± 0.5

<0.001

<0.001

Fasting Insulin (uU/ml)

7.5 (4.5-13.1)

9.7 (6.2-17.2)

6.5 (4.1-12.1)

<0.001

0.003

HOMA_IR

1.5 (0.9-2.5)

2.2 (1.3-3.9)

1.2 (0.7-2.2)

<0.001

<0.001

HOMA_

141.9 (52.9325.6)
33.4 (213-53.7)

371 (163.1-658.9)

100 (44.6-216.5)

<0.001

<0.001

33.9 (21.7-56.9)

32.9 (20.9-52.8)

0.772

0.686

Age (years)
Parity
2

Current-BMI (kg/m )
Pre-Pregnancy-BMI
(kg/m2)
FBG (mmol/L)

HbA1C (%)

25(OH)D (nmol/l)

P-value

P-Value
adjusted
for Age
and BMI

Parameters

<0.001

Note: GDM: gestational diabetes mellitus, BMI: body mass index; FBG: fasting blood glucose; OGTT: Oral Glucose Tolerance Test;
HbA1C: haemoglobin A1c or glycated haemoglobin; HOMA_IR: homeostatic model assessment of insulin resistance;
HOMA_: homeostatic model assessment of beta cell function. Normally distributed variables are presented as Means ± SD.
Non-normally distributed variables such as parity, FBG, OGTT 1,and 2 hrs, Fasting Insulin, HOMA_IR, HOMA_, and vitamin D.
are presented as Medians (25th and 75th percentile). P-value denotes significance at <0.05 and <0.01
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Table 5.2: Predictors of GDM among pregnant women between 24-28 weeks gestation

Parameters

Univariate Analysis

Adjusted Model

OR (95% CI)

P-value

OR (95% CI) *

P-value*

Age (years)

1.05(1.00 - 1.10)

0.044

0.98(0.91 - 1.04)

0.448

Parity

1.11(0.96 - 1.30)

0.170

0.86 (0.68 – 1.08)

0.191

Current-BMI (kg/m2)

1.05(1.02 - 1.10)

0.002

1.04(0.99 - 1.09)

0.168

Pre-Pregnancy-BMI (kg/m2)

1.06(1.03 - 1.10)

0.001

1.05 (0.99 – 1.11)

0.072

Family history of Diabetes

1.13(0.63 - 2.00)

0.676

0.84(0.42 - 1.65)

0.607

Previous history of GDM

10.96 (4.14 – 29.0)

<0.001

9.25(3.14 - 27.22)

<0.001

History of Miscarriage

1.69(0.93 - 3.10)

0.087

1.36 (0.64 – 2.92)

0.426

HbA1C (%)

2.44(1.51 - 3.92)

<0.001

1.50 (0.74 – 3.02)

0.263

Fasting Insulin (uU/ml)

1.07(1.03 - 1.10)

0.000

1.07 (1.03 – 1.11)

<0.001

HOMA_IR

56.8(12.66 - 254.60)

<0.001

75.34 (15.32 – 370.60)

<0.001

HOMA_

0.48(0.24 - 0.96)

0.038

0.76 (0.36 – 1.57)

0.453

25(OH)D (nmol/l)

0.58(0.19 - 1.81)

0.352

1.00 (0.98 – 1.02)

0.966

Vitamin D deficiency (<50nmol/L)

2.96(1.22 – 7.19)

0.046

2.29(0.79 - 6.65)

0.016

Obesity

2.66(1.62– 4.36)

<0.001

2.08 (1.09 – 3.95)

0.026

Note: *P-value adjusted for age, pre-pregnancy BMI, family history of diabetes, previous history of GDM, HbA1C (%), and obesity.
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Table 5.3: Comparison of the genotype and allele frequencies of the VDR FokI polymorphism in GDM
and control groups

Parameters
N

GDM
N=108
(29.3%)

Non-GDM
N=160
(70.7%)

Odd Ratio (95%
CI)

FokI- rs10735810
FF
Ff
ff
Ff+ff

65 (60.2)
36 (33.3)
7 (6.5)
43 (39.8)

160 (61.1)
82 (31.5)
18 (6.9)
100 (38.4)

1
0.96 (0.38-2.40)
1.08 (0.66-1.76)
1.06 (0.66-1.68)

F
f

166 (76.9)
50 (23.1)

402 (77.3)
118 (22.7)

1
1.03 (0.70-1.50)

P-Value

Adjusted OR
(95% CI)

Adjusted PValue

0.926
0.755
0.808

1
1.26 (0.48-3.31)
1.28 (0.76-2.14)
1.29 (0.78-2.07)

0.426
0.289
0.256

0.704

1
1.51 (0.78-1.70)

0.368

Note: OR: Odds ratio (95% CI), P-value adjusted for Age, Pre-pregnancy BMI, family history of diabetes, obesity, previous history of GDM,
fasting serum insulin, Hbg A1c and vitamin D deficiency.
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Table 5.4: Clinical and biochemical characteristics of the subjects depending on
their alleles

Parameters
N

F

f

568

168

29.2 ± 5.9

28.3 ± 5.3

P-value

Age (years)
0.073
2.0 (1.0-4.0)

2.0(1.0-3.0)

0.755

Current-BMI (kg/m2)

28.5 ± 6.5

27.6 ± 5.7

0.121

Pre-Pregnancy-BMI (kg/m2)

27.2 ± 6.2

26.3 ± 5.2

0.080

FBG (mmol/L)

4.5 (4.1-4.9)

4.5 (4.1-4.9)

0.625

OGTT_1hrs (mmol/L)

7.3 (5.8-8.8)

8.0 (5.9-9.5)

0.122

OGTT_2hrs (mmol/L)

6.2 (5.2-7.7)

6.6 (5.8-7.8)

0.017

4.8 ± 0.5

4.9 ± 0.7

0.099

Fasting Insulin (uU/ml)

7.5 (4.4-12.9)

7.7 (5.6-15.6)

0.967

HOMA_IR

1.5 (0.9-2.6)

1.3 (0.9-2.8)

0.975

HOMA_

141.7 (52.6-315.9)

136.9 (57.1-360.1)

0.772

33.6 (22.4-53.7)

31.6 (19.3-52.2)

0.303

Parity

HbA1C (%)

25(OH)D (nmol/l)

Note: Data represented Mean ± SD and Median (1st and 3rd) percentile for Gaussian and non-Gaussian
variables. P-Value denotes significance at <=0.05 and 0.01.
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Table 5.5: Clinical characteristics of the vitamin D deficient and non-deficient
pregnant Saudi women

Parameters

Vitamin D deficient

Non- deficient

25(OH)D<50 nmol/l

25(OH)D >50
nmol/l

N

260 (85.3)

108 (14.7)

Age (years)

28.9 ± 5.7

29.4 ± 5.2

0.470

2.0 (1.0-4.0)

1.0 (1.0-3.0)

0.202

Current-BMI (kg/m2)

28.2 ± 6.5

28.1 ± 5.6

0.835

Pre-Pregnancy-BMI
(kg/m2)
FBG (mmol/L)

26.8 ± 6.1

26.9 ± 5.5

0.852

4.5 (4.1-4.9)

4.2 (3.9-5.1)

0.081

OGTT_1hrs (mmol/L)

7.3 (5.8-8.7)

8.4 (6.7-9.5)

0.114

OGTT_2hrs (mmol/L)

6.3 (5.3-7.4)

6.8 (5.6-9.1)

0.756

4.8 ± 0.5

4.8 ± 0.6

0.712

Fasting Insulin (uU/ml)

7.6 (4.6-13.1)

6.3 (4.5-12.9)

0.024

HOMA_IR

1.5 (0.9-2.5)

1.3 (0.9-2.7)

0.007

HOMA_

146.8 (59.3-319.9)

111.1 (56.8-348.3)

0.041

29.9 (20.1-46.7)

66.7 (43.4-85.3)

<0.001

Parity

HbA1C (%)

25(OH)D (nmol/l)

P-value

Note: Data represented Mean ± SD and Median (25th and 75th) percentile for Gaussian and non-Gaussian
variables. P-Value Denotes significance at P <0.05 and 0.01
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Figure 5.1 Demographic and biochemical parameters in relation to GDM status
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Figure 5.2 Correlations between Log vitamin D (nmol/L) in ff FokI genotypes versus (A) FBG, (B) HbA1C
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Figure 5.3 Correlation between Log vitamin D (nmol/L) in f FokI allele versus
HOMA_
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CHAPTER 6
MANUSCRIPT 3: VITAMIN D, VITAMIN D RECEPTOR POLYMORPHISM,
AND METABOLIC SYNDROME IN PREGNANT SAUDI WOMEN

6.1 Abstract
•

Background: Metabolic Syndrome (MS) is a serious health concern and its
prevalence is rising significantly in Saudi Arabia. It is also more common in females
than in males. Pregnant women with MS have a higher risk of developing gestational
diabetes (GDM) and preeclampsia during pregnancy and a great increased risk of
future chronic diseases such as cardiovascular disease (CVD) and Type 2 diabetes
mellitus (T2DM). In addition, it has been previously reported that complications
during pregnancy may contribute negatively to the health of the unborn infant from
gestation to adulthood and cause an increased risk for morbidity and mortality.
Previous studies have linked Vitamin D receptor (VDR) gene polymorphism to MS in
adults. However, the association between VDR gene polymorphisms with maternal
MS and its components in pregnancy has not yet been clarified.

•

Aim: The objective of this study was to investigate the association of the FokI VDR
genotype as a risk factor for MS and its components in pregnant Saudi women.

•

Materials and Method: A cross-sectional study of 368 pregnant Saudi women (44
with MS and 324 without MS) who visited antenatal clinics of three hospitals in
Riyadh, Saudi Arabia (King Khaled University Hospital [KKUH], King Salman bin
Abdulaziz Hospital, and King Fahad Medical City [KFMC]) between December 2013
and January 2016. Fasting serum glucose, HbgA1C, insulin, HDL-C, LDL-C, TG, TC,
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25(OH) D and blood pressure were measured in the second trimester (at 24-28 weeks
of pregnancy. The Fokl VDR genotype of each woman was determined by allelespecific polymerase chain reaction (PCR).
•

Results: About 12% of the study population had MS. FokI VDR genotyping
frequencies for FF, Ff, and ff genotypes were 62.7% (203), 31.5% (102), and 5.9%
(19), respectively, in healthy pregnancies and 50.0% (22), 36.4% (16), and 13.6% (6),
respectively, in patients with MS. The minor FokI ff genotype was a significant risk
factor for MS (OR = 2.91; 95% CI, 1.05-8.1; P= 0.039).

•

Conclusion: This observation suggests that the presence of the ff FokI VDR genotype
is genetic marker of MS risk in pregnant Saudi women. However, we did not find a
significant association between FokI VDR genotype and components of MS in these
pregnant women.

6.2 Introduction
Metabolic syndrome (MS) is a cluster of abnormal metabolic health disorders that
includes 3 or more of the following 5 characteristics: elevated blood pressure, central
obesity, dyslipidemia, high cholesterol and elevated fasting blood sugar.1 MS is a
growing worldwide health problem and is a risk factor for developing cardiovascular
disease (CVD) and type 2 diabetes mellitus (T2DM).2 The prevalence of MS has been
rising globally and increasing from about 20% to 40% in the adult population.3 In the
United States, for example, about 25% of the adult population suffers from MS,4 whereas
in Saudi Arabia, the prevalence of MS is much higher, ranging between 13.6 and 57%.5
Differences in the prevalence estimates of MS in different geographic areas may by
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affected by gender variations in the population studied, different targeted populations or
age groups studied, as well as possible differences in the criteria used in its definition.5
Moreover, a recent study from Saudi Arabia revealed that 43.42% of the total cohort of
12,126 study participants, aged 18 years and above, had two or more risk factor
components for MS.6
The prevalence of MS in general is higher in females than in males.4 Al-Nozha
and colleagues, found a higher ratio of MS in Saudi females than in males, 42%, and
37.2%, respectively.7 A systematic review conducted by Aljefree and Ahmed in the Gulf
countries found a high prevalence of CVD and its associated risk factors, particularly
obesity among women in this area.8 Another large cohort study in Saudi Arabia; Riyadh
Mother and Baby Study (RAHMA), found that more than 68% of the 14,568 pregnant
women studied were either overweight or obese and 24% of the total cohort developed
gestational diabetes. 9 The prevalence of these two risk factors for MS; namely, obesity
and gestational diabetes were among the highest in the world.9
Identification of MS in pregnant women is important because they are at
increased risk of developing maternal complications, such as preeclampsia and coma, as
well as adverse perinatal effects, such as malformations, neonatal hypoglycemia, neonatal
macrosomia, jaundice, and preterm birth.1,4,10 Moreover, Rodie et al. reviewed different
studies related to complications during pregnancy and their outcomes and reported that
multiple complications, such as preeclampsia, preterm birth and intra-uterine growth
restriction, carries a seven-fold additive risk of future diseases, including maternal
CVD.11 In addition, an increasing body of epidemiologic evidence indicates that offspring
of high-risk pregnancies accompanied by complications and adverse birth outcomes are
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at increased risk of developing MS, CVD, and T2DM later in life.1,10, Gosadi has
reported that “CVD is one of the leading causes of death in the adult Saudi population
where the increase in cardiovascular-related mortality is augmented by the rise in the
prevalence of MS.”12
The alarmingly pandemic rate of MS in Saudi Arabia and elsewhere can be
attributed to many etiological factors. For example, in Saudi Arabia, rapid urbanization,
globalization, and improvements in socioeconomic status have resulted in a significant
change in lifestyle.13 A recent systematic review also found a very high prevalence of
physical inactivity among Saudi women, ranging from 53.2% to 98.1%.14 These authors
attributed the high prevalence of sedentary lifestyle and obesity in Saudi women to sociocultural factors like the banning of driving and physical education in girls’ public
schools.14 The dietary pattern of the Saudi Arabian diet has also changed to a more
Westernized diet with increased consumption of high-energy-dense foods and processed
foods that are high in fat, sugar and salt.13 As a result, non-communicable diseases
(NCD) such as obesity, diabetes, hypertension and high cholesterol have emerged as a
significant problem, and are affecting a growing number of people in Saudi Arabia.13,15
Rahim et al. reported that in Arab countries there were more than one million deaths in
the year of 2008 from NCD, which accounted for 60% of all deaths.16 Although all these
risk factors in addition to aging are considered to be primary etiological factors for
developing MS, genetic predisposition could be another important factor in the prediction
of risk for MS.3
The activity of 1,25-dihydroxyvitamin D, the active hormonal form of vitamin D,
is mediated through the cellular vitamin D nuclear receptor (VDR) protein.17 VDR is
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expressed in most body tissues and has been shown to be important in calcium
homeostasis and bone metabolism, as well as other non-calcemic actions.18,19 Single
nucleotide polymorphisms (SNPs) are common in the genome and can sometimes affect
gene expression or function. The VDR gene has several recognized SNPs that could alter
the functioning of the VDR.20 Among these VDR polymorphisms, the FokI VDR gene
polymorphism has been of interest because it occurs in the transcription start codon, and
its polymorphic form (f) results in a change in the start codon position such that the
expression of the VDR protein is three amino acids longer than the wild-type (F) allele.17
The longer VDR protein has been shown to be less active than the shorter wild-type
version. This shorter FokI VDR allelic variation has also been found associated with
various adverse disease outcomes in some epidemiologic studies.21,22 The association of
FokI VDR genotypes with pregnancy complications has been studied, but has resulted in
mixed findings.23
Vitamin D status is largely dependent on sunlight exposure and is reflected in
higher serum 25-hydroxyvitamin (25(OH)D), a biomarker of vitamin D status. However,
it is evident that vitamin D deficiency is quite prevalent among pregnant women in Saudi
Arabia, despite the abundance of sunlight all year around.24 Vitamin D deficiency itself
has been linked to MS. Meta-analysis of cross-sectional studies found a significant
inverse association between the level of serum 25(OH)D and the risk of MS.25 In another
systematic review, it was observed that the highest levels of serum 25(OH)D were
associated with a 43% reduction in CVD, T2DM and MS.18
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Several studies have examined the relationship between VDR gene
polymorphisms and the risk for MS or its components in adults. These studies found that
FokI VDR gene polymorphisms were associated with blood pressure, insulin resistance,
BMI and lipid profile, but the findings from these studies in different ethnic groups
remained inconclusive. 2,3,21,22, 26,27 To our knowledge, there have been no studies that
have investigated the association between VDR gene polymorphisms and MS and its
components among pregnant Saudi women. Given the endemic nature of low vitamin D
status and vitamin D deficiency found in the Saudi population, this group may be
particularly susceptible to vitamin D-related adverse events due to the presence of the
relatively ineffective longer VDR protein found in women with the ff VDR genotype.
Therefore, our study was designed to investigate the association of VDR FokI genotypes
with the risk of MS and its individual components in pregnant Saudi women living in
Riyadh, the capital city of Saudi Arabia.

6.3 Methods
6.3.1 Study Design and Sample Population
This study is a part of a large prospective cohort study called “Vitamin D and
Pregnancy in Saudi Women”. Our cross-sectional study is a subset of these study
participants and consisted of 368 pregnant Saudi women, which included 324 healthy
pregnant women and 44 pregnant women with MS, among subjects who visited an
antenatal clinic in their second trimester (24-28 weeks of gestation) at one of three Saudi
hospitals; King Khaled University Hospital (KKUH), King Salman bin Abdulaziz
Hospital and King Fahad Medical City (KFMC) in Riyadh, the capital city of Saudi

129

Arabia, between December 2013 and January 2016. The study has full ethical approval
from the three hospitals to collect samples and patient data and approval from the Ethics
Committee of the College of Science, King Saud University in Riyadh. (Appendix A).
Written informed consent was obtained from each patient (Appendix B).
6.3.1.1 Inclusion and Exclusion Criteria
Healthy pregnant Saudi women, aged 18 to 40 years, with no previous history of
diabetes mellitus (type I or II) were enrolled in the study prior to 16 weeks of gestation.
Subject exclusion criteria included: non-Saudi subjects; gestational age of over 16 weeks;
if they were taking vitamin D supplements during pregnancy; unwillingness to deliver at
any of the three hospitals; taking oral glucocorticoids; using drugs known to interfere
with vitamin D or calcium absorption or parathyroid disorders; using any cardiac
medication or diuretics; suffering from chronic hypertension or malabsorption syndrome;
having chronic medical conditions or preexisting liver, kidney, calcium, and /or
parathyroid conditions; or serious chronic disease conditions (epilepsy, cancer, other
malignancy).
6.3.1.2 Recruitment and Medical Screening
Recruitment banners and brochures were placed in prenatal clinics in all three of
the hospitals. Obstetricians were asked to introduce the research to their pregnant patients
at their first prenatal appointment. Patients who met the criteria and consented to
contribute in the present study were given the appropriate information. At their early
pregnancy visit, prospective candidates were asked to sign consent forms that included
information about their participation in the study, such as answering a questionnaire
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about demographic data, procurement of blood samples for biomarker measurement and
DNA for genetic analyses, and anthropometric measurements. Permission for data
collection from their medical records and stored blood stocks from a bio-bank were also
obtained (Appendix A). The participants were also informed of their right to withdraw
from the study at any point without it affecting their usual medical care.

6.3.2 Anthropometric Measurements
Anthropometric measurements were taken from the participants between 24 and
28 weeks gestation. These measures included weight (kg) and height (cm), used for
calculating body mass index (BMI) (kg/m2); reported pre-pregnancy weight (kg) and prepregnancy BMI (kg/m2). Systolic and diastolic blood pressures (mmHg) were also
recorded.
Body weight, without shoes and wearing lightweight clothing, was measured to
the nearest 0.1 kg (Digital Pearson Scale, ADAM Equipment Inc., USA). Based on prepregnancy weight as self-reported during the prenatal visit, pregnant women were
classified according to the WHO BMI definitions as follows: underweight: <18.5 kg/m2;
normal weight: 18.5–24.9 kg/m2; overweight: 25.0 - 29.9 kg/m2; or obese: ≥ 30.0 kg/m2.28
Height, to the nearest 0.5 cm, was measured at the early pregnancy visit only
using a stadiometer (Digital Pearson Scale), while standing upright without shoes. Prepregnancy BMI was calculated from pre-pregnancy body weight recall and measured
height. Blood pressure (mm Hg) was measured using a mercury sphygmomanometer,
while the patient was relaxed and seated. Per the criteria set out by the International
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Society for the Study of Hypertension in Pregnancy, gestational HTN was identified as
BP140/90 mm Hg.29
6.3.3 Biochemical Assessment
During the antenatal visit between 24 and 28 weeks of gestation, participants were
asked to fast > 10 hours for blood withdrawal. Blood samples (10 ml) were collected
using sterile vacutainer blood collection apparatus. Whole blood, serum, and ethylene
diamine tetra-acetic acid (EDTA) plasma were collected from the participants. All
samples were aliquoted and stored in a -80ºC freezer for subsequent analyses. All the lab
tests were performed on serum, except hemoglobin A1C (HbA1C), which was performed
on whole blood. The blood samples were stored and analyzed at the King Saud University
Biomarkers Research Program (BRP) Laboratory. It should be noted that the Biomarker
Research Program (BRP) Laboratory is a participating entity in the vitamin D External
Quality Assessment Scheme (DEQAS), and Quality Assurance (QA) standards are
maintained by ISO 9000 and 17025. The QA department audits the BRP Laboratory at
regular intervals. Serum 25(OH)D was measured by electro-chemiluminescence binding
assay 2012 (ECLIA) (Roche Diagnostics GmbA, Mannheim, Germany) and
commercially available IDS kits (IDS Ltd, Boldon Colliery, Tyne & Wear, UK). The
inter- and intra-assay coefficients of variation (CV) for 25(OH)D ELISA is 5.3% and
4.6%, respectively, with 100% cross-reactivity to 25(OH)D3 and 75% cross-reactivity to
25(OH)D2. According to US Endocrine Society guidelines, the cutoff values for vitamin
D deficiency is defined as serum 25(OH)D less than 50 nmol/L, and for sufficiency
serum 25(OH)D more than 75nmol/L. 30
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6.3.3.1 Primary Outcome Measures
Our main outcome measure was to study the metabolic impact of the ff FokI VDR
genotype versus the FF wild type VDR genotype on the risk of MS. Participants were
divided into two groups, cases with MS and controls without MS, according to the
International Diabetes Federation (IDF) definition with some attention taken into
account to accommodate to our study population of pregnant women.4 In particular, for a
pregnant women to be defined as having MS according to IDF definition, she must have
3 or more of the following risk factors: pre-pregnancy body mass index (BMI) > 30
kg/m2; level of serum triglyceride(TG) ≥ 150 mg /dL; serum high-density lipoprotein
(HDL-cholesterol level < 50 mg/dL; fasting serum glucose level ≥ 100 mg/dL, and blood
pressure level ≥ 130/85 mm Hg. 4 Healthy pregnant control subjects were those who did
not match the criteria employed for the selection of MS subjects.
6.3.3.2 Other Measures
After an overnight fast (>10 h), participants were requested to return to their
prenatal clinics for blood withdrawal. A 6-mL sample of fasting venous blood was
collected and transferred immediately to a non-heparinized tube for centrifugation. Serum
was then transferred to a pre-labeled plain tube, stored in ice, and delivered to the
Biomarker Research Center in King Saud University on the same day. Fasting serum
samples were stored in a −20 °C freezer prior to analysis to facilitate availability for later
analysis.
Fasting serum glucose (FBG) and lipid profile (including total cholesterol (TC),
triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C) were all measured using a chemical analyzer (Konelab,
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Vantaa, Finland). Dyslipidemia is defined by presence of one or more abnormal serum
lipid biomarkers. The cut-off of dyslipidemia, according to IDF guidelines, was as
follows: TC ≥ 5.2 mmol/L (200 mg/dl), LDL ≥ 3.4 mmol/L (130 mg/dl), HDL
<1.3 mmol/L (50 mg/dl), or TG >1.7 mmol/L (150 mg/dl), or a combination thereof. 31
From the whole blood, HbA1C was measured using point-of-care (POC) devices
(Accu-Check Active, Roche Diagnostics, Mannheim, Germany).
Fasting serum insulin was measured by COBAS e 411 Analyzer (Roche
Diagnostics). The homeostasis model of insulin resistance (HOMA-IR) was calculated to
evaluate insulin resistance using the following equations: (HOMA-IR) = fasting insulin
(μU/ml) × fasting FPG (mmol/l)/22.5. Higher HOMA-IR values indicated greater insulin
resistance.31
6.3.3.3 DNA Extraction and Quantification
Genomic DNA was extracted from whole blood using innuPREP blood mini kits
(Analytik Jena, Germany) following the manufacturer’s instructions. Briefly, 200µl of
whole blood sample was added to a 1.5 ml reaction tube containing lysis buffer and
Proteinase K. The content was mixed by vortex and incubated at 60 0C for 10 minutes.
The required amount of binding solution was added to the tube and transferred to a spin
filter column with receiver tube and centrifuged for 1 minute at 12000 rpm. Washing of
the column-bound DNA was performed using the kit’s washing solution C followed by
washing solution BS. In a final step, the spin filter was placed into a 1.5ml elution tube
and 200µl of pre-warmed at 60 0C elution buffer was added. After centrifugation, the
collected DNA was stored at -20 0C for further analysis. DNA concentration and purity
(260/280) was determined using a Nano-Drop spectrophotometer.
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6.3.3.4 FokI SNP Genotyping
The FokI SNP is in the VDR coding region (rs 2228570); previously reported as
(rs10735810) and can be evaluated by allelic discrimination real-time PCR using predesigned TaqMan genotyping assay from Applied Biosystems, Foster City, CA, USA
(assay ID: C_12060045_20). Amplification reactions was performed in a volume of 10
µL containing 1X TaqMan genotyping Master Mix (Applied Biosystems), 1X mix of
unlabeled PCR primers and TaqMan MGB probes, and 30 ng of template DNA. All
amplification and detection was conducted in 96-well PCR plates using a Bio-Rad
CFX96 Real-Time PCR Detection System (Bio-Rad, Milan, Italy). Thermal cycling was
initiated with a denaturation step of 10 min at 95 °C, followed by 45 cycles of 15 s at 95
°C and 90 s at 60 °C. After PCR was completed, allelic discrimination was analyzed
using the Bio-Rad CFX Manager Software (Version 1.6, Bio-Rad). Genotype assignment
was determined by plotting the end point relative fluorescent units (RFU) for one
fluorophore (allele 1 on the x-axis) against the RFU for the other fluorophore (allele 2 on
the y-axis) on the allelic discrimination. All PCR reactions were set up in a dedicated
PCR area with dedicated PCR pipettes and reagents.
6.3.4 Statistical Analysis

Data were analyzed using SPSS (version 21.0, IBM). Continuous data are
presented as mean ± standard deviation (SD) for Gaussian variables and non-Gaussian
variables are presented as median (25th and 75th) percentiles. Categorical data are
presented as frequencies and percentages (%). All continuous variables were checked for
normality using Kolmogorov-Smirnov test. Non-Gaussian variables were log-
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transformed prior to parametric analysis. Independent T-test, analysis of variance
(ANOVA), Mann-Whitney and Kruskal-Walis H tests were used to compare mean
differences in Gaussian and non-Gaussian variables. Odds-ratio and X2 tests were done
using binary logistics and multinomial logistic regression. A p- value <0.05 was
considered statistically significant.

6.4 Results
6.4.1 General Characteristics and Components of MS
Table 6.1 presents the characteristics of the subjects with and without MS. In our
study, the prevalence of MS was 12%. Pregnant women with MS were significantly older
and have higher pre-pregnancy BMI than the controls (P< 0.02 and <0.01, respectively).
The mean age of the 44 women with MS was 31 (±7) years, and the mean age of 324
controls was 29 (±5) years. Moreover, median serum 25(OH)D was lower in the MS
subjects than controls (29.9 and 33.7 nmol/L, respectively), but did not reach statistical
significance (P=0.186), as both groups had high prevalence of vitamin D deficiency
(P=0.199). Compared with the controls, diastolic blood pressure, HbgA1C, fasting serum
glucose, HOMA_IR, insulin, and TG were significantly higher in pregnant women with
MS, while HDL cholesterol was significantly lower (1.6±0.4 vs. 1.3±0.5 mg/dl,
P<0.001). These findings remained significant even after adjusting for age and prepregnancy BMI.
6.4.2 FokI VDR Gene Polymorphisms and MS Risk
As shown in Table 6.2, the difference in the occurrence of the genotypes in FokI
between individuals with MS and the control group was statistically significant even after
136

the adjustment for age. The FokI VDR genotypes are normally expressed as dominant
homozygous genotype “FF”, heterozygous genotype “Ff”, and mutant homozygous
genotype “ff”. The frequencies of genotype FF, Ff, and ff in women with MS were 50%,
36%, and 14% respectively, while in the control group were 63%, 32%, and 6%,
respectively, which suggests that the genotype ff is a risk factor for MS (OR = 4.17; 95%
CI, 1.42-12.2, P=0.009) in pregnant Saudi women. The prevalence of F and f alleles for
the FokI VDR polymorphisms in the two groups were statistically significant (allele F vs.
f; P=0.017), which suggests that the f allele is a genetic risk factor for MS in this
population.
6.4.3 Clinical Characteristics of the FokI VDR Gene Polymorphisms in MS and
Control Group
The distribution of some clinical and biochemical variables according to FokI
VDR genotype that were observed in MS participants and pregnant controls are shown in
Table 6.3. The pregnant women without MS with the FF genotype had a higher prepregnancy and current BMI than pregnant women with either the Ff or ff genotypes (P=
0.021, 0.027, respectively). We did not observe any association between VDR genotype
and individual components of MS in pregnant women.
6.4.4 FokI VDR Gene Polymorphism x Components of MS
We conducted a multinomial logistic regression to better understand the
relationship between different genotypes and alleles of FokI VDR polymorphisms and
obesity, hypertension, low HDL, hypertriglyceridemia, hypercholesterolemia,
dyslipidemia, and GDM (Table 6.4). Taking the FF genotype as a reference, the odds

137

ratio for the risk of having any component of MS, was not significant among the different
FokI VDR genotypes. However, pregnant women carrying the mutant homozygous ff
genotype of the VDR FokI were more likely to have elevated blood pressure (OR = 1.85,
95% CI: 0.79, 4.34), low HDL (OR = 1.14, 95% CI: 0.70, 1.87), dyslipidemia (OR =
1.60, 95% CI: 0.63, 4.10), and GDM (OR = 1.08, 95% CI: 0.66, 1.76) suggesting that ff
genotype could be a risk factor for these variables. Although we did not see statistically
significant odds ratios, they were consistently in the same direction.
The prevalence of maternal obesity in Saudi women was 27%. Moreover, 12%,
29%, 63%, 55%, 34%, and 47% of participants had elevated blood pressure, GDM,
hypercholesterolemia, hypertriglyceridemia, low HDL, and dyslipidemia, respectively
(Figure 6.1).
6.4.5 MS and Its Components x Vitamin D Status
Pregnant women who had MS and carry ff genotype were found to have a very
strong significant and inverse association between serum 25(OH)D and fasting serum
glucose (r=-0.92) (Figure 6.2). In controls, we found a significant inverse association
between serum 25(OH)D and diastolic blood pressure (DBP) regardless of genotype (r=0.16) (Figure 6.3). Additionally, in all controls carrying FF genotype, serum 25(OH)D
was significantly associated with HDL-cholesterol, LDL-cholesterol, and total cholesterol
(r= 0.22, 0.19, 0.25, respectively) (Figure 6.4).
Table 6.5 presents the anthropometric and biochemical characteristics of vitamin
D deficient versus non-deficient subjects. Vitamin D deficiency was prevalent among
85% of our participants. Moreover, vitamin D deficient subjects had significantly higher
fasting insulin, HOMA_IR and systolic blood pressure (SBP) (P= 0.007, 0.024, 0.032,
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respectively). Whereas, HDL-C and TC were significantly higher among the nondeficient vitamin D women compared to their counterparts (P= 0.001, 0.049,
respectively).
6.5 Discussion
To our best knowledge, this study represents the first time that the associations
between the FokI VDR gene polymorphism and MS, as well as its components, have
been evaluated in pregnant Saudi women.
We found that the FokI VDR polymorphism may have a strong influence on the
emergence of MS. The f allele and the ff genotype seem to be risk factors for MS, while
the F allele and the FF genotype appear to play a protective role. Our findings are in line
with Aslani et al.,32 who found that the frequency of the ff genotype was two-fold in
postpartum Iranian women with MS compared to healthy participants during the
postpartum follow-up (OR=2.1; 95% CI: 0.90–4.89; P=0.09). On the contrary, another
recent study on the same population in Iran did not observe any significant associations
between the FokI VDR polymorphism and MS in adult males nor females.33 Results from
other studies in northern China3, the United Arab Emirates (UAE)26, and Brazil2 are also
consistent with this finding. The variations and inconsistencies between these studies
could be attributed to the environmental factors in different populations.25 Moreover, the
frequency of the VDR FokI genotypes and alleles differ substantially between ethnic
groups and even within the same population samples,26 as previously observed in the
contradictory findings regarding the Iranian population. Such heterogeneity in allele and
genotype distribution leads to varying susceptibility to diseases.22
There are very few studies on MS in pregnancy. In our study, the prevalence of
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MS among pregnant women was 12%. Another study recently conducted in the UAE
found that the prevalence of MS among adults was 14.6%.26 Furthermore, 66% of our
study population was either overweight or obese. This finding is congruent with another
large cohort study performed in Saudi Arabia, in which 68% of pregnant women were
found to be either overweight or obese.9 According to a recent report by the World Health
Organization (WHO), the prevalence of obesity and overweight among females aged 15
years or older in Saudi Arabia is approximately 65.9%, which is one of the highest in the
Eastern Mediterranean Region, and this figure is predicted to rise to 78% by the year
2022.34 The increasing prevalence of obesity among females in Saudi Arabia is
concerning due to the myriad of adverse health outcomes it can cause in mothers and
their offspring.35 Obesity is a risk factor for many maternal and neonatal complications,
including increased incidence of GDM, hypertension, cesarean-section delivery, fetal
macrosomia, shoulder dystocia, and perinatal mortality.1,36 In addition, obesity in
pregnancy has a negative effect on fetal metabolic programming, thereby causing a longterm, adverse metabolic condition in the child, such as obesity, diabetes, and CVD.36,37
A significant body of evidence has revealed associations between obesity and
vitamin D deficiency. Since vitamin D is fat-soluble, it becomes sequestered in fat cells
in a form that is not bioavailable.38 Obese individuals tend to have a higher body fat
percentage, thus reducing the circulating level of serum 25(OH)D.21,38 Another known
causation linked to obesity and vitamin D deficiency is the reduction of cutaneous
vitamin D synthesis as a result of decreased sunlight exposure due to clothing habits or
limited outdoor activity.39,40 In our study, 85% of pregnant women were found deficient
in vitamin D (25[OH]D <50 nmol/L). This rate exceeds Al-Faris’s report in 201624 that
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50% of pregnant Saudi women living in Riyadh were vitamin D deficient, but Al-Ajlan et
al.’s41 results contained the highest rate; they found that 94% of pregnant Saudi women
had vitamin D deficiency or insufficiency (25[OH]D <50 nmol/L).
Previous studies have reported a link between the FokI VDR polymorphism and
obesity. In Egypt, Mackawy and Badawi27 found that the ff genotype was associated with
higher waist circumference in diabetic patients with MS, compared to the FF genotype in
the same group. Similarly, Zaki et al.21 reported higher frequencies of the mutant allele f
in obese Egyptian women with vitamin D deficiency, compared to healthy obese women
with sufficient levels of vitamin D. In their preliminary study on obese Pakistanis, Haris
and Baig42 observed a potential association between the ff genotype and obesity. Zhao et
al.3 also found that the FF genotype was associated with lower BMI, compared to the ff
and Ff genotypes, in Chinese adults with MS. Aslani et al.32 also found a significant
association between the f allele and pre-pregnancy obesity in pregnant Iranian women. In
our study, however, the control-group carriers of the FF genotype presented higher prepregnancy BMI than the pregnant women carrying the Ff and ff genotypes. This indicates
that the ff genotype may be a protective factor against obesity, but the level of association
did not reach statistical significance. A possible explanation for the variation between
these studies could be related to ethnicity and environmental factors.
It is well known that vitamin D plays a powerful role in regulating blood pressure
by suppressing renin biosynthesis for the modulation of the renin–angiotensin system
(RAS).43 Vitamin D also has anti-hypertensive properties by enhancing endothelial
vasodilation as well as reducing advanced glycation products and oxidative stress.41 We
found that vitamin D deficient subjects had significantly higher systolic blood pressure
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than non deficient (P=0.032). Similarly, a cross-sectional study found that low levels of
serum 25(OH)D may be correlated with high blood pressure and increased rates of
incident hypertension.44 We also found a significant inverse correlation between serum
25(OH)D and diastolic blood pressure across all genotypes in the control group (non-MS
patients) (r=-0.16). It is also notable that carriers of the mutant genotype ff demonstrated
a higher incidence of hypertension (>130/85) compared to carriers of the homozygous
and heterozygous genotypes. While these results are not statistically significant, they are
consistent with Zaki et al.’s 21 findings, who reported that obese Egyptian women
carrying both genotypes Ff and ff showed significantly higher blood pressure compared to
those with the common homozygous genotype FF. Two studies found a significant
association between the FF genotype and the risk of high blood pressure; one study
linked the FF genotype to higher systolic blood pressure in Emirati women,26 while the
other study associated the FF genotype with hypertension in Indian adults.19 Both studies
attributed the cause of hypertension or elevated blood pressure to the effect of FF
homozygotes enhancing the production of renin and angiotensin II. In contrast to these
findings, Cottone et al.45 did not detect any significant associations between blood
pressure and the FokI VDR polymorphism, nor between blood pressure and serum
25(OH)D levels, in hypertensive Italian patients. A meta-analysis concluded that vitamin
D supplementation is ineffective in lowering systolic or diastolic blood pressure and thus
should not be used as an anti-hypertensive agent.46 Such discrepancies in previous studies
may be related to genetic differences in the sample populations or their exposure to
different environmental factors. Until future research determines a significant association
between the FokI VDR polymorphism and maternal hypertension, it should be stressed
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that pregnant women with hypertension are at increased risk of delivering a premature
baby as well as other serious complications, such as a defect in endothelial-dependent
vascular function, compared to healthy pregnant women.10 These issues should be
carefully addressed when defining high risk pregnancies, and preventative measures
should be undertaken.
The expression of VDR has been detected in various human tissues and cells,
including adipocytes.27 Vitamin D is known to interact with VDR in adipose tissue,
thereby forming the vitamin D-VDR axis, which is important for the metabolic activation
of vitamin D.26 Any change in the axis caused by, for example, vitamin D deficiency or
VDR polymorphism could affect the lipid profile through many different mechanisms.47
Vitamin D can directly affect adipocyte differentiation and metabolism through the
stimulation of parathyroid hormone secretion, thus depressing lipolysis.39,48 Additionally,
vitamin D increases intestinal calcium absorption, which reduces the formation and
secretion of TG by the liver, thereby causing a decrease in serum TG levels.49 It has also
been found that vitamin D raises the concentrations of apolipoprotein A-1, which is the
main protein component in HDL-C.50 Vitamin D can also indirectly influence lipid
metabolism by improving insulin secretion and sensitivity.51 All these hypothesized
mechanisms contribute to a favorable lipid profile with a decreased risk of CVD. 52
Consistent with this notion, many studies have associated VDR gene
polymorphism with dyslipidemia.26,27,50,52 Schuch et al.2 found that participants who did
not have MS and who were carrying the mutant, homozygous genotype (ff) had
significantly higher TG levels and lower HDL levels compared to those with the
heterozygous (Ff) or normal homozygous (FF) genotypes. Other authors have reached
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reciprocal outcomes. Mackawy et al.27 observed higher plasma TC, TG, and LDL-C with
lower HDL-C levels in diabetic, non-MS carriers of the ff genotype compared to carriers
of the FF genotype. Additionally, Hasan et al.26 reported higher serum TC levels in
Emirati carriers of the ff genotype compared to other genotypes of the FokI VDR
polymorphism. These previous studies are in line with our findings, which revealed that
all participants carrying the mutant, homozygous genotype were at higher risk of
developing dyslipidemia compared with those carrying the normal homozygous and
heterozygous genotypes. However, these results are not statistically significant.
Moreover, all pregnant women with MS, regardless of their genotypes, expressed
significant associations between HDL and serum 25(OH)D levels. Similarly, in the
control group (non-MS), the serum 25(OH)D level was found to be significantly
associated with HDL, LDL, and TC in all pregnant carrying FF genotypes. Surprisingly,
we found that non-deficient vitamin D women had higher lipid profile compared to
vitamin D deficient women. Our unexpected result was similar to the finding of Al-Ajlan
et al,41 who reported that in the subgroup of vitamin D-deficient, pregnant Saudi women,
their serum vitamin D levels were significantly and positively correlated with their serum
TG and TC levels. One possible explanation for this outcome, as speculated by the
researchers, could be the combination of vitamin D deficiency, which was highly
prevalent among the study sample, with the high metabolic demands of pregnancy.41 It
has been known that as pregnancy progresses, there is a marked increase in plasma lipid
concentrations, which mimics the markers of MS.4, 35 While increased lipid levels are
considered normal physiological changes during pregnancy, maternal hyperlipidemia
could cause serious health issues in the fetus by disrupting normal placentation and
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damaging the vessel wall via increased oxidative stress.11 Previous studies have shown a
strong relationship between hyperlipidemia and increased incidence of preterm birth,
which is considered a leading cause of prenatal morbidity and mortality.53,54
As previously mentioned, the presence of VDR in human tissue, including
pancreatic -cells, inspired many researchers to study the association between VDR gene
polymorphism and glucose homeostasis.26,32 In Brazil, Schuch et al.2 observed
significantly higher -cell secretion (HOMA-) in individuals carrying the f allele than
those carrying the F allele. Both Schuch et al.2 and Zaki et al.21 reported a significant
association between the ff genotype and a higher HOMA-IR, compared to the FF and Ff
genotypes of the FokI VDR polymorphism, in Brazilian and Egyptian populations,
respectively. Similarly, Mackawy et al.27 found that diabetic Egyptian patients with MS
who carried the ff genotype presented higher insulin levels and HOMA-IR than those
with the FF and Ff genotypes. These outcomes support our finding of a statistically
significant and inverse correlation between serum 25(OH)D levels and fasting serum
glucose in pregnant women carrying ff genotype in MS group.
There are very few studies available that examined the effect of the FokI VDR
polymorphism on GDM. A link between the FokI VDR polymorphism and GDM risk
was conducted among Iranian32 and Saudi populations,55 with contradictory results. In
Iran, Aslani et al.32 found that the frequency of the ff genotype in GDM patients was
higher than in normal pregnant women (10.6% vs. 6.2%). A higher frequency of the F
allele was also observed in healthy subjects (P=0.06), suggesting that the F allele may
represent a protective factor against GDM.33 In Saudi Arabia, El-Beshbishy et al.55 also
found a higher frequency of the F allele (56.4% vs. 35.7%) and a lower frequency of the f
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allele (43.6% vs. 64.3%) in their control group compared to their GDM group, but the
results were not statistically significant (P=0.100). The authors concluded that there was
no significant association between the FokI VDR polymorphism and GDM in the Saudi
population.55 The present results agree with El-Beshbishy et al.,55 as we did not observe
any statistically significant associations between GDM and the FokI VDR polymorphism.
However, a logistic regression analysis revealed that carriers of the ff genotype are at
higher risk of developing GDM, compared to carriers of other genotypes of the FokI
VDR polymorphism (odds ratio=1.27; 95% CI: 0.76–2.14; P=0.360, after adjustments for
age and BMI). In support of the present findings, Al-Daghri et al.56 found a statistically
significant association between the F allele and a reduced risk of developing T2DM
among the Saudi population (P=0.02). It is well known that GDM mimics T2DM in its
pathology, as both conditions cause defects in insulin secretory response.57 We speculate
that a larger cohort study with sufficient statistical power is necessary to affirm the
potential of VDR genetic variation in predicting GDM.
The pathophysiological mechanisms of the previous associations are still unclear.
It has been hypothesized that vitamin D plays a role in glucose homeostasis through
several underlying pathways; for example, the active hormonal metabolite of vitamin D
(1,25-dihydroxyvitamin D) binds to the VDRs of pancreatic β-cells, which stimulates
insulin secretion and regulates the balance between the extracellular and intracellular
calcium pools.57 Thus, calcium is an important co-factor for insulin-mediated intracellular
functions in insulin-responsive tissues, as any changes in intracellular calcium may cause
peripheral insulin resistance.58 In addition, the VDR affects glucose homeostasis via the
insulin-like growth factor system;23 any genetic changes in the VDR might contribute to
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the pathogenesis of GDM via alterations in calcium metabolism and modulation of
insulin secretion.27 GDM can have serious consequences with lasting metabolic changes
for both mother and offspring.1 Long-term cohort studies have reported that women with
GDM have an 35–65% increased risk of developing T2DM later in life, and their
offspring are more likely to develop obesity and T2DM in childhood and adulthood.1,57
In our study, vitamin D deficiency was evident in 85% of the sample population.
Our results are in line with Al Foda et al.59 and Al-Sheikh et al.60 who reported a high
prevalence of vitamin D deficiency amounting to 86%. We did not detect any significant
difference between MS and controls in regards to vitamin D deficiency, as both groups
had high prevalence of vitamin D deficiency.
We acknowledge that there are some limitations in our study. Due to the limited
frequency of mutant ff genotype, we were not able to observe an association between
FokI and components of MS. We strongly believe for future prospective studies, a
sufficient statistical power is vitally needed, especially when studying the effect of
mutant ff FokI genotype on MS and its components. In addition, we analyzed the VDR
gene at only one SNP—albeit one that translates structurally diverse VDR proteins,
which vary in their potential to elicit vitamin D-mediated gene expression. Unfortunately,
we did not control for confounding factors such as dietary habits, physical activity or
other lifestyle factors, which may impact the risk of MS. Despite these limitations, and to
our best knowledge, this study is the first to examine the relationships between the FokI
VDR polymorphism and MS, as well as its components, among pregnant Saudi women;
in fact, no previous study has investigated such associations in pregnancy among any
population. Accuracy can also be assured in our vitamin D measurements, as we
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investigated the role of vitamin D status and correlated it with different variables related
to the components of MS in all FokI genotypes. Unlike previous epidemiological studies,
detailed and valid data for each MS component, such as blood pressure, and the fasting
serum samples, including the lipid, glucose, and insulin concentrations, were precisely
measured and not self-reported.

6.6 Conclusion
The past few years have seen dramatic changes to the lifestyle of Saudi Arabians,
which have led to notable increases in the prevalence of MS, especially among pregnant
women, associated with an increased incidence of CVD, T2DM, GDM, and dyslipidemia
in the Saudi population. Despite this, there is a marked lack of research on the genetic
risk factors, such as VDR gene polymorphism, in MS occurrence among this population,
and no study has examined such associations during pregnancy.
To address this issue, we conducted a study to observe the effect of the FokI VDR
polymorphism on the pathology of MS and its components among pregnant Saudi
women. We found a statistically significant association between the FokI VDR
polymorphism, specifically in carriers of the ff genotype, and an increased risk of MS
among the sample. This association could be a prognostic tool for predicting the risk of
developing MS in pregnancy.
Knowledge of the associations between the FokI VDR polymorphism and the risk
of MS is crucial for many reasons. One is that the early diagnosis of MS during
pregnancy allows for the identification of patients who are at risk of developing CVD and
other adverse metabolic changes.61 Another reason is that early intervention, such as
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vitamin D supplementation, can be used to treat this condition and mitigate its adverse
effects on mothers and their offspring.
The results of our study suggest that the FokI VDR polymorphism may affect the
components of MS, namely obesity, dyslipidemia, and GDM, but the correlation is not
statistically significant. Our findings warrant further investigations using larger cohorts as
well as future associative studies on other VDR gene polymorphisms.
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Table 6.1 Demographic and biochemical characteristics of MS vs. normal subjects
Parameters

All

Metabolic
Syndrome

Control

368

44 (12.0)

324 (88.0)

Age (years)

29.1±5.6

31.3±6.9

28.7±5.3

0.02

Pre-pregnancy
BMI
(kg/m2)
Current BMI
(kg/m2)
Parity

26.9±5.9

33.3±4.1

25.9±5.5

<0.001

28.2±6.2

34.7±4.5

27.5±5.9

<0.001

0.956

2 (1-4)

2(1-5)

2(1-4)

0.210

0.539

SBP (mmHg)

113.3±12.9

119.1±15.7

112.3±12.1

0.020

0.272

DBP (mmHg)

66.9±9.2

71.7±11.4

66.1±8.5

0.010

0.030

HbA1C (%)

4.8±0.5

5.1±0.7

4.8±0.8

<0.001

0.005

FBG (mmol/L)

4.6 ± 1.0

5.6±1.5

4.5±0.8

<0.001

<0.001

1.5 (0.9-2.5)

3.1 (1.7-5.2)

1.3 (0.9-2.3)

<0.001

<0.001

14.2(7.9-22.8)

6.9(4.1-11.9)

<0.001

0.003

HDL-C (mmol/L)

7.5 (4.513.1)
1.5±0.4

1.3±0.5

1.6±0.4

<0.001

<0.001

LDL-C (mmol/L)

3.9±1.3

3.9±1.4

3.9±1.3

0.698

0.269

TC (mmol/L)

6.2±1.2

6.4±1.3

6.2±1.5

0.271

0.084

TG (mmol/L)

1.8(1.4-2.3)

2.6(2.1-3.4)

1.7(1.3-2.2)

<0.001

<0.001

25(OH)D
(nmol/L)

33.4(21.353.7)

29.9(17.9-44.6)

33.7(21.7-54.4)

0.232

0.186

Vitamin D
deficiency
(<50nmol/L)

314 (85.3)

38 (86.4)

276 (85.2)

0.291

0.199

N

HOMA_IR
Insulin (uU/ml)

P-value*

P-value**

Note: Pre-preg BMI: Pre-pregnancy body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood
pressure; FBG: fasting blood glucose; HbA1C: haemoglobin A1c or glycated haemoglobin; HDL: Highdensity lipoprotein Cholesterol; LDL: low-density lipoprotein Cholesterol; TC: Total Cholesterol, TG:
Triglycerides. Data Presented as Mean ± SD and Median (25th -75th) percentiles for Gaussian and Non
Gaussian variables. *P-value adjusted for age & pre-pregnancy BMI; significant at 0.05 and 0.01 levels.
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Table 6.2 The genotype distribution of VDR FokI polymorphisms in MS and control groups
FokI
Genotype

All

MS

Control

β

OR (95 % CI)

*PValue

Adjusted OR

** P-Value

FF
Ff
ff
Ff+ff

225 (61.1)
118 (32.1)
25 (6.8)
143 (38.9)

22 (50.0)
16 (36.4)
6 (13.6)
22 (50.0)

203 (62.7)
102 (31.5)
19 (5.9)
121 (37.3)

0.37
1.07
0.52

1
1.45 (0.73-2.88)
2.91 (1.05-8.1)
1.68 (0.89-3.16)

0.291
0.039
0.109

1
1.42 (0.71-2.9)
4.17 (1.42-12.2)
1.76 (0.92-3.36)

0.307
0.009
0.090

F
f

568 (77.2)
168 (22.8)

60 (68.2)
28 (31.8)

508 (78.4)
140 (21.6)

0.53

1
1.69 (1.04-2.75)

0.034

1
1.84 (1.05-1.14)

0.017

Note: ORs: Odds ratio (95% CI); *P-value significant at < 0.05, **P-value adjusted for age and significant at <0.05,0.01
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Table 6.3 Clinical characteristics of the FokI VDR genes polymorphisms in MS and
control groups
Parameters

FF

Ff

ff

P-value

Metabolic Syndrome
N

22

16

6

Age (years)

29.1±5.4

28.5±5.3

26.8±3.6

0.190

Pre-preg BMI
(kg/m2)
Current BMI
(kg/m2)
Parity

34.2±4.8

33.3±2.6

30.3±4.3

0.127

35.3±4.8

34.8±3.1

32.6±6.3

0.430

2.0(1.0-5.0)

3.0(1.0-7.0)

4.0(2.0-6.0)

0.635

SBP (mmHg)

111.9±12.3

112.9±11.4

112.3±14.2

0.870

DBP (mmHg)

65.6±8.3

67.2±9.1

65.3±7.9

0.471

HbA1C (%)

4.7±0.4

4.8±0.6

4.8±0.4

0.645

FBG (mmol/L)

4.5±0.9

4.4±0.7

4.5±0.3

0.594

HOMA_IR

3.7 (1.9-5.3)

3.7(1.7-5.9)

2.1(1.1-2.7)

0.132

Insulin (uU/ml)

7.4 (4.1-12.3)

6.4 (4.2-10.9)

6.4 (3.6-17.9)

0.907

HDL-C (mmol/L)

1.6±0.4

1.5±0.4

1.6±0.4

0.949

LDL-C (mmol/L)

3.8±1.3

3.9±1.2

3.7±1.0

0.749

TC (mmol/L)

6.2±0.6

6.2±1.4

6.2±1.2

0.996

TG (mmol/L)

2.7 (2.1-3.2)

2.5 (2.2-3.4)

3.3 (2.2-3.4)

0.761

29.9 (18.0-46.9)

37.3(20.4-60.6)

22.2(15.7-28.3)

0.234

25(OH)D
(nmol/l)

Control
N

203

102

19

Age (years)

32.4±7.1

31.8±6.6

26.3±5.5

0.144

Pre-pregnancy BMI
(kg/m2)
Current BMI
(kg/m2)
Parity

26.6±5.9

24.7±4.3

25.9±5.7

0.021

27.9±6.3

25.9±4.7

27.0±5.9

0.027

2.0(1.0-4.0)

2.0(1.0-3.0)

1.0(1.0-2.0)

0.439

SBP (mmHg)

120.1±15.3

119.3±15.5

112.0±22.5

0.720

DBP (mmHg)

70.8±11.6

73.4±10.3

69.7±18.5

0.796

152

HbA1C (%)

5.1±0.6

5.0±0.8

5.2±0.9

0.840

FBG (mmol/L)

5.4±1.5

6.2±1.6

5.0±0.9

0.156

1.4 (0.8-2.3)

1.2 (0.8-2.1)

1.3 (0.8-3.6)

0.616

16.2 (9.3-22.7)

15.5 (6.7-24.7)

7.9 (6.0-11.7)

0.081

HDL-C (mmol/L)

1.3±0.5

1.4±0.5

1.2±0.2

0.802

LDL-C (mmol/L)

4.1±1.6

3.7±1.2

4.1±0.9

0.744

TC (mmol/L)

6.4±1.3

6.4±1.4

6.6±0.9

0.922

TG (mmol/L)

1.7 (1.3-2.2)

1.7 (1.2-2.2)

1.6 (1.4-2.3)

0.729

HOMA_IR
Insulin (uU/ml)

25(OH)D
34.3(23.2-54.5)
31.4(18.8-52.1)
40.4(23.2-85.1)
0.090
(nmol/l)
Note: Data represented Mean ± SD and Median (25th and 75th) percentile for Gaussian and nonGaussian variables. P-value significance at 0.05.
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Table 6.4 Risk predictions for different genotypes and alleles of FokI VDR gene polymorphisms in relation to metabolic
syndrome and its components
Yes

β

OR (95 % CI)

P-Value

Obesity (≥ 30 kg/m2)
FF
Ff
ff
Ff+ff

101
66 (65.3)
28 (27.4)
7 (7.4)
35 (34.8)

0.030
-0.363
-0.291

1
1.03 (0.40-2.63)
0.70 (0.41-1.18)
0.75 (0.46-1.22)

0.950
0.179
0.245

F
f

160 (28.3)
42 (25.1)

-0.169

1
0.84 (0.56-1.27)

0.844

Elevated Blood Pressure (> 130/85)
FF
Ff
ff
Ff+ff

44
19 (46.2)
19 (46.2)
6 (7.7)
25 (53.9)

0.464
0.616
0.592

1
1.59 (0.32-7.89)
1.85 (0.79-4.34)
1.81 (0.79-4.11)

0.571
0.157
0.157

F
f
Low HDL-C (< 1.3 mmo/l)
FF
Ff
ff
Ff+ff

57 (10.3)
31 (14.7)
126
76 (60.0)
42 (33.0)
8 (7.0)
50 (40.0)

0.409

1
1.51 (0.80-2.83)

0.205

0.072
0.133
0.122

1
1.07 (0.44-2.66)
1.14 (0.70-1.87)
1.13 (0.71-1.79)

0.877
0.595
0.604

F
f

194 (33.8)
58 (35.8)

0.087

1
1.09 (0.75-1.59)

0.652

Parameters
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Hypertriglyceridemia (> 1.7 mmol/l)
FF
Ff
ff
Ff+ff

202
127 (62.8)
60 (29.6)
15 (7.5)
75 (37.1)

F
f
Hypercholesterolemia ( > 5.7 mmol/l)
FF
Ff
ff
Ff+ff

314 (55.6)
90 (53.6)
233
137 (58.5)
78 (33.6)
18 (7.9)
96 (41.5)

F
f
Dyslipidemia
FF
Ff
ff
Ff+ff

352 (62.1)
114 (68.1)
171
88 (51.5)
69 (40.5)
14 (8.0)
83 (48.5)

F
f

GDM
FF
Ff
ff
Ff+ff

0.131
-0.240
-0.175

1
1.14 (0.49-2.65)
0.79 (0.50-1.23)
0.84 (0.55-1.28)

0.761
0.297
0.419

-0.079

1
0.92 (0.65-1.31)

0.656

0.501
0.237
0.282

1
1.65 (0.66-4.12)
1.27 (0.79-2.03)
1.33 (0.85-2.07)

0.283
0.324
0.214

0.265

1
1.31 (0.90-1.89)

0.158

-0.004
0.470
0.088

1
1.00 (0.57-1.75)
1.60 (0.63-4.10)
1.09 (0.65-1.84)

0.324
0.989
0.740

245 (71.6)
97 (29.4)

0.101

1
1.11 (0.72-1.71)

0.648

108
65 (60.2)
36 (33.3)
7 (6.5)
43 (39.8)

-0.04
0.06
0.06

1
0.96 (0.38-2.40)
1.08 (0.66-1.76)
1.06 (0.66-1.68)

0.926
0.755
0.808

F
166 (76.9)
1
f
50 (23.1)
0.03
1.03 (0.70-1.50)
Note: Data Represented unstandardized β, odd ratio and (95 % CI). P-value significant at < 0.05.
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0.704

Table 6.5: Clinical characteristics of the vitamin D deficient vs. non-deficient
pregnant Saudi women

Parameters

Vitamin D deficient

Non-deficient

25(OH)D<50 nmol/l

25(OH)D >50
nmol/l

260 (85.3)

108 (14.7)

Age (years)

28.9 ± 5.7

29.4 ± 5.2

0.470

Pre-preg BMI
(kg/m2)
Current BMI
(kg/m2)
Parity

26.8 ± 6.1

26.9 ± 5.5

0.852

28.2 ± 6.5

28.1 ± 5.6

0.835

2.0 (1.0-4.0)

1.0 (1.0-3.0)

0.202

SBP (mmHg)

114.6 ± 12.9

110.8 ± 12.4

0.032

DBP (mmHg)

67.7 ± 9.1

65.5 ± 9.2

0.070

HbA1C (%)

6.3 (5.3-7.4)

6.8 (5.6-9.1)

0.756

FBG (mmol/L)

4.5 (4.1-4.9)

4.2 (3.9-5.1)

0.081

HOMA_IR

7.6 (4.6-13.1)

6.3 (4.5-12.9)

0.024

Insulin (uU/ml)

1.5 (0.9-2.5)

1.3 (0.9-2.7)

0.007

HDL-C (mmol/L)

1.5 ± 0.4

1.6 ± 0.4

0.001

LDL-C (mmol/L)

3.8 ± 1.3

3.9 ± 1.3

0.671

TC (mmol/L)

6.1 ± 1.5

6.4 ± 1.4

0.049

TG (mmol/L)

1.80(1.4-2.3)

1.90 (1.5-2.4)

0.684

29.9 (20.1-46.7)

66.7 (43.4-85.3)

<0.001

N

25(OH)D
(nmol/l)

P-value

Note: Data represented Mean ± SD and Median (25th and 75th) percentile for Gaussian and non-Gaussian
variables. P-Value Denotes significance at P <0.05 and 0.01.
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Figure 6.1 Presence of metabolic disorders among pregnant Saudi women in their
second trimester

85%

63%
55%
47%
34%
27%
12%

29%

12%

Figure 6.2 Correlation between Log vitamin D (nmol/L) in ff FokI genotypes versus
FBG in MS subjects
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Figure 6.3 Correlation between Log vitamin D (nmol/L) and diastolic blood pressure (DBP) in controls,
regardless of their FokI genotype
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Figure 6.4 Correlations between Log vitamin D (nmol/L) in FF FokI genotypes
versus (A) HDL-C, (B) LDL-C, (C) TC in controls

A

B

C
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CHAPTER 7
CONCLUSION AND FUTURE DIRECTIONS

7.1 Conclusion
This is the first study to examine the metabolic impact of the ff VDR genotype
versus the FF wild type VDR in pregnant Saudi women, who are known to be vitamin D
deficient. We thoroughly investigated the genetic influence of FokI VDR polymorphism
on vitamin D deficiency, gestational diabetes, glucose intolerance, and metabolic
syndrome while controlling for classic confounders that may mask the findings of our
results. Our findings are important and encouraging because, if replicated and proved
correct, they will advance the medical field by determining the possible culprit or
predictor of adverse outcomes for both mother and infant. This new knowledge is
significant because it will lead to significant changes in current obstetric and pediatric
practice, facilitating early identification of any at-risk pregnancy and supplementing
pregnant women with vitamin D. This in turn will reduce the risk of morbidity and
mortality as well as reduce the economic burden of these chronic diseases. The following
section highlights our major research results.
❖ We have successfully identified unique predictors according to the following
health problems Saudi women face during pregnancy:
o Vitamin D Deficiency: FokI FF genotype and the F allele might be
important predictors of an individual’s susceptibility to vitamin D
deficiency in pregnant Saudi women, thus leaving them unprotected and at
risk of developing adverse skeletal and non-skeletal health problems.

167

Other identified risk factors for vitamin D deficiency in our study sample
included full-body clothing coverage, lower levels of physical activity,
residence in areas other than North Riyadh, working indoors, and the
amount of sunlight exposure.
o Gestational Diabetes (GDM): vitamin D deficiency appeared to be a
major risk for GDM in Saudi women. Although we did not detect any
association between FokI VDR gene polymorphism and GDM, we found
that the glucose-lowering effects of a higher vitamin D level may be
dependent upon the FokI genotype within the Saudi population. Other
identified risk factors for GDM in our study sample included previous
history of GDM, fasting insulin, HOMA_IR, and obesity.
o Metabolic Syndrome (MS): Our results indicate that the presence of the
ff FokI VDR genotype is a genetic marker for MS risk in pregnant Saudi
women. However, we did not find any significant association between
FokI VDR genotype and components of MS in our subjects. This
meaningful association could be a potential prognostic tool for predicting
development of MS in pregnancy.

❖ We have observed an alarmingly high prevalence of the following metabolic
disorders in Saudi women:
o Vitamin D deficiency was prevalent among 79% of pregnant Saudi
women in their first trimester. Full-body clothing coverage, lower levels of
physical activity, residence in areas other than North Riyadh, working
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indoors, and the amount of exposure to sunlight were found to be major
risk factors for vitamin D deficiency in pregnant Saudi women.
o We noticed that in the second trimester, the prevalence of vitamin D
deficiency increased to 85%.
o Using IADPSG criteria, we found that about 29% of our participants were
diagnosed with GDM. This rate is extremely high when compared to the
overall prevalence of GDM (17.8 %) found in the Hyperglycemia and
Adverse Pregnancy Outcome (HAPO) cohort using the same diagnostic
criteria as ours.
o Metabolic Syndrome was evident in 12% of our study population. To the
best of our knowledge, no study has examined the prevalence of MS in
pregnancy.
▪

Prevalence of the components of MS: 66% of our study population
were either overweight or obese. Moreover, 63%, 55%, 34% of
participants had hypercholesterolemia, hypertriglyceridemia, and
low HDL, respectively.

7.2 Future Directions
Based on our study results, we believe that a more thorough understanding of the
association between FokI VDR gene polymorphism and metabolic health disorders
during pregnancy, especially in a population with a high rate of vitamin D deficiency, is
vital to improving current diagnoses and intervention strategies for both mother and
child. Therefore, we recommend the following be addressed in future research:
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❖ Our study indicates the need for sufficient statistical power, especially when
studying the effect of mutant ff FokI genotype. Unlike the wild FF FokI genotype,
mutant ff FokI genotype has a limited frequency, thus the role of genotype ff is
still unclear. The results of our study suggest that FokI VDR gene polymorphism
may influence MS components, namely obesity, dyslipidemia, and GDM,
although the correlation was not statistically significant. Our findings warrant
further investigation in larger cohorts to confirm the potential association. We
believe that we could have observed a significant association between FokI VDR
genotype and components of MS if the frequency of mutant ff were high.
❖ Further research is warranted for investigating the association between FokI VDR
genotype polymorphism and metabolic outcomes in pregnancy, with substantial
need to adjust for important classical and non-classical confounders that are
known to be risk factors for GDM, vitamin D deficiency, and MS. Controlling for
such covariates will reveal the independent effects of genotype on adverse
perinatal outcomes, if in fact any association truly exists.
❖ We call for interventional trials such as supplementing pregnant women,
especially deficient subjects, with high and safe doses of vitamin D while
studying the responsiveness of different VDR genotypes. These kinds of trials are
important as they help to better identify which genotype carrier will benefit the
most from supplementation. Because we assume that carriers of the mutant ff
genotype are considered high-risk patients, or “low responders,” they need higher
doses of vitamin D supplements than non-carriers to achieve sufficient levels and
benefit the most from treatment.

170

❖ Further studies on healthy subjects are required to identify the genetic predictors
of 25(OH)D concentrations, as most of the research that investigated such an
association was conducted with patients who had different diseases. There is a
possibility that a specific disease could have masked the genetic influence of
VDR on vitamin D status.
❖ Through our literature review, we noticed that there are numerous genes involved
in the vitamin D metabolic pathway, aside from VDR gene, that significantly
impact vitamin D status and are worth studying. Vitamin D binding protein as
well as 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1) are among those genes
that showed significant association with vitamin D status.
❖ We would like to shed light on a neglected issue yet to be assessed. No studies to
date have investigated the genetic risk factors, such as VDR gene polymorphism,
on the occurrence of MS during pregnancy. Examining such a relationship is vital
for preventing short- and long-term adverse effects on both mother and baby.
❖ Saudi Arabia has a young population, with more than half of the population
younger than 25 years. Therefore, research is needed among this age group to
develop strategies for primary care intervention. If these current high rates of
vitamin D deficiency, GDM, obesity, MS, and dyslipidemia that we observed in
our population are not reversed early in life, the future disease burden will soar in
Saudi Arabia.
❖ No genome-wide association studies (GWAS) have been conducted in Saudi
Arabia. These kinds of studies are important for the detection of novel genetic
variants that may play a role in the occurrence of adverse health outcomes in the
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Saudi population. Understanding the pathophysiological mechanisms of genes
related to the vitamin D metabolic pathway might bring insight into the genetic
components of different diseases in the Saudi population, especially in women of
child-bearing age.
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APPENDIX B
CONSENT FORM
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APPENDIX C
QUESTIONNAIRES

First and Second visit questionnaires

Research code:
Name:
Tel or Mobile No:

Date of filling of the
form:

Date of filling of the
form:

Place of birth:
Date of Birth (age):

Week of
gestation……

Mother anthropometrics
❖ Ht....................cm
Current Wt.................kg
Prepregnancy Wt.................. kg

Current BMI…………. kg/ m2
Before pregnancy BMI…………. kg/ m2

❖ Blood Pressure:....................

Sociodemographic Measurements
Education Level

Family Income Per
month

Illiterate Primary Intermediate
Secondary
University
Post
graduate
No Income less than 5000 S.R  500010000 S.R
10000-20000 S.R
R
 House wife
Teacher

Occupation

 More than 20000 S.

Retired

Student

Employee Physician Businesswomen
Other (………)
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Marital
status
Does your
husband a
relative?
Living area

Skin color

 Married

Single

Divorced

Widow

Yes

No

Relative degree

First degree

Second degree

 North Riyadh

West Riyadh

East Riyadh

South Riyadh

 North Riyadh

West Riyadh

East Riyadh

South Riyadh

Center Riyadh

Center Riyadh

Clinical Measurements
Medical history: Family
HTN
Osteoporosis

Hyperlipidemia

 Heart disease

 Asthma
 Cancer
 Kidney Disease

Liver Disease

Others: ………………………………….
Diabetes
children

1st degree relatives

2nd degree relatives
uncle(father) grandchildren

 GDM

1st degree relatives

mother

father

grandparents

grandmother

 Obesity
children

mother

1st degree relatives

2nd degree relatives
uncle(father) grandchildren

uncle(mother)

mother sister

2nd degree relatives
aunt(father) grandchildren

siblings

daughter
aunt(mother)

father

siblings

grandparents uncle(mother)

Medical history: Subject
HTN
syndrome

Hyperlipidemia
Osteoporosis

 Asthma
 Obesity

Anemia

 GDM

178

Polycystic ovarian
 IGT

Others: ………………………………….
Age of menarche: ………….
 Regular

Menstrual cycle

 Irregular

Age at first pregnancy: ………….
LMP (last menstrual period): …… EDD (expected date of delivery) by date:
………
Risk Factors:
-The head circumference of last baby…………………
-Usage of insulin or its alternatives Yes  NO
-Parity (how many times she got pregnant): …………… Number of
children……………
- Previous caesarean section Yes  No, how many……….
-Miscarriages if occurs? Yes
 No
times?...............Reasons……………
 Yes

-Preeclampsia
 No

If any occurred in the past: 
Protein urea

 No

Poly urea

If yes, how many
-Gestational HTN

 Glycosuria

 Yes



-Pregnancy symptoms:
Nausea
headache

 vomiting
 mood swings

abdominal bloating
 tender swallow breast

 frequent urination

 morning sickness
constipation

-Pregnancy complications: ……………………………………………..

List of medications:
Please a check on all medications used by the subject
AntiHyperlipidemics
[ ] Atorvastatin
– Lipitor, Torvast

[

] Mexiletine – Novo – Mexiletine

[

] Procainamide – Procan

[

] Propafenone – Rhythrnol, Nu, Apo, Gen, PMS
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[ ] Cerivastatin –
Lipobaby
[ ] Fluvastatin –
Lescol, Lescol XL
[ ] Lovastatin –
Mevacor, Altocor,
Altoprev
[ ] Mevastatin [
] Pitavastatin –
Livalo, Pitava
[ ] Pravastatin –
Pravachol,
Selektine, Lipostat
[ ] Rosuvastatin
– Crestor
[ ] Simvastatin –
Zocor, Lipex
[ ] Simvastatin +
Ezetimibe –
Vytorin
[ ] Atorvastatin
+ Amlodipine –
Caduet
[ ] Simvastatin +
Niacin – Simcor
[ ]
Cholestyramine [
] Gemfibrozil
[ ] Colestipol [
] Benzafibrate,
fenofibrate

[

] Digoxin

[

] Clonidine

[

] Methyldopa

[

] Diazoxide

[

] Hydralazine

[

] Isosarbide dinitrate

[

] Nitroglycerin

[

] Prazosin, Terazosin, Dozazosin

[ ] Atenolol, Acebutolol, Bisoprolol, Labetalol,
Metaoprolol, Nadolol, Oxprenolol, Pndolol,
Propranolol, Sotalol, Timolol
[

] Amlodipine, Felodipine, Nifedipine

[

] Diltiazem, Verapamil

[

] Captopril, Benazepril, Enalapril, Cilazapril,

Perindopril, Quinapril, Ramipril, Lisinopril
[ ] Candesartan, Irbesartan, Losartan, Telmisartan,
Valsartan,
[

] Spironolactone [ ] Hydrochlorothiazide

[

] Furosemide

[

] Pentoxyphylline

Other (Please specify)
1.
__
2.
__
3.
__

_______________________________
_______________________________
_______________________________

Cardiovascular
drugs
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[ ] Aspirin
[ ] Warfarine
[ ] Heparin
[ ] Clopidogrel
[ ] Amiodarone –
Amiodarone,
Cordarone
[ ]
Disopyramide –
Rythmodan
[ ] Flecainide
acetate – Apo –
Flecainide

Second visit questionnaires
Research code:
Name:
Tel or Mobile No:

Date of filling of
the form:

Date of filling of the form:

Place of birth:
Week of
gestation……

Date of Birth (age):

Anthropometric Measurements

❖ Ht....................cm
Current Wt.................kg
Prepregnancy Wt.................. kg

Current BMI…………. kg/ m2
Before pregnancy BMI…………. kg/ m2

❖ Blood Pressure:....................
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Clinical Measurements
o Pregnancy symptoms:
Nausea
 vomiting
mood swings
abdominal bloating
tender swallow breast

 morning sickness

 frequent urination

headache

constipation





o Any complains or diagnosis………………………………
Gestational HTN
Preeclampsia
bacterial vaginosis

 Anemia

Viral or Bacterial illnesses

Respiratory

 Gastrointestinal



Food Frequency Questionnaire
Dietary intake of vitamin D and calcium Questionnaire
Breakfast cereals and bread
Daily

Weekly

Amount

Cornflakes

1 2 3

1 2 3 4 5 6 M

R No

.......…
Cup/ week

Cornflakes
with sugar and
Coco Pops

1 2 3

1 2 3 4 5 6 M

R No

……… Cup/
week

 Weciabix,
Shredded wheat

1 2 3

1 2 3 4 5 6 M

R No

…........
Cup/ week

 Bran flakes,
Wheat flakes or
Sultana

1 2 3

1 2 3 4 5 6 M

R No

…........
Cup/ week

 Brown Bread

White Bread

1 2 3

1 2 3

1 2 3 4 5 6 M

1 2 3 4 5 6 M
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R No

R No

………..toas
t/ week or
………..1/4
loaf
………..toas
t/ week or
………..1/4
loaf

White
Bread(Samoli,bu
rger)

1 2 3

1 2 3 4 5 6 M

R No

Shaboorah
(bran or white)

1 2 3

1 2 3 4 5 6 M

R No

………..toas
t/ week or
………..1/4
loaf
………..piec
es/week

*M (1-3 times per month), R(rarely), NO (don’t take it at all)
Meat and Fish
Daily
White fish
(hamoor), fish
fingers
Oysters, shrimp

Canned fish
(canned salmon,
sardines,)

Tuna fresh or
canned

Weekly

Amount

1 2 3

1 2 3 4 5 6 M

R No

.......… gm
Fried /
Grilled

1 2 3

1 2 3 4 5 6 M

R No

.......… gm
Fried /
Grilled

R No

.......…
piece
With oil /
water

R No

Can/large
/small
With oil /
water

1 2 3

1 2 3

1 2 3 4 5 6 M

1 2 3 4 5 6 M

….gm/wee
k
Red meat (
.............)

1 2 3

1 2 3 4 5 6 M

R No

With fat
Little fat
Without fat

Chicken Type
..............) )

1 2 3

1 2 3 4 5 6 M

R No

….gm/wee
k
Skin/with
out skin
….gm/wee
k

Liver, brain
and kidneys

1 2 3

1 2 3 4 5 6 M

R No

With fat
Little fat
Without fat

Egg
How many eggs
do you eat?

1 2 3

1 2 3 4 5 6 M
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R No

………Egg/
week

What kind of eggs do you eat?

yolk

White

Both

Fats
What kind of fats used in your food?
 Vegetables oil

 Ghee

Daily

 Margarine

Weekly

How many
times do you use
veg oil?

 Butte
Amount

1 2 3

1 2 3 4 5 6 M

R No

1 2 3

1 2 3 4 5 6 M

R No

........Spoon
/ week

Type….
How many
times do you use
olive oil?
How many
times do you use
butter or ghee?

1 2 3

1 2 3 4 5 6 M

R No

........Spoon
/ week
........Spoon
/ week

Type….
How many
times do you eat
Tahini?

1 2 3

1 2 3 4 5 6 M

R No

........Spoon
/ week

Type….
How many
times do you
usually have
almonds or
peanuts?

...........Cup
/ week
1 2 3

1 2 3 4 5 6 M

R No

Type……
*Table spoon (15 ml), cup (240 ml)

Dairy And its Products
Do you usually drink milk?
 No

Yes

If milk is liquid of which type?
 Cow

 Camel

 Goat

 Sheep

 Other

How many times do you drink fresh milk?
Daily
Full fat

Weekly
1

2

3

1 2

3

4
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5

6

Amount
M

R

No

.......…
Cup/ week

Low fat

1

2

3

1 2

3

4

5

6

M

R

No

………Cup/
week

Skim fat

1

2

3

1 2

3

4

5

6

M

R

No

…........Cup
/ week

 How many times do you drink dried milk?
Daily

Weekly

Amount

Full fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Low fat

1

2

3

1 2

3

4

5

6

M

R

No

………Cup/
week

Skim fat

1

2

3

1 2

3

4

5

6

M

R

No

…........Cup
/ week

 How many time do you drink canned milk?
Daily

Weekly

Amount

Full fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Low fat

1

2

3

1 2

3

4

5

6

M

R

No

………Cup/
week

Full fat

1

2

3

1 2

3

4

5

6

M

R

No

…........Cup
/ week

Concentra
ted milk

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Chocolate

1

2

3

1 2

3

4

5

6

M

R

No

………Cup/
week

With
Strawberry

1

2

3

1 2

3

4

5

6

M

R

No

…........Cup
/ week

With
Banana

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

other

1

2

3

1 2

3

4

5

6

M

R

No

………Cup/
week

How many times do you drink Laban?
Daily

Weekly

Amount

Full fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Low fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Skim fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week
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How many times do you have yoghurt?
Daily

Weekly

Amount

Full fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Low fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

Skim fat

1

2

3

1 2

3

4

5

6

M

R

No

.......…
Cup/ week

How many times do you have these products?
Daily

Weekly

Amount

Triangle
Cheese

1

2

3

1 2

3

4

5

6

M

R

No

……Piece/
week

Kerry
Cheese

1

2

3

1 2

3

4

5

6

M

R

No

……Piece/
week

White
Cheese

1

2

3

1 2

3

4

5

6

M

R

No

……Spoon
/ week

Yellow
cheese

1

2

3

1 2

3

4

5

6

M

R

No

……Spoon
/ week

Fatty
cheese

1

2

3

1 2

3

4

5

6

M

R

No

……Spoon
/ week

Geshtah

1

2

3

1 2

3

4

5

6

M

R

No

……Spoon
/ week

Labnah

1

2

3

1 2

3

4

5

6

M

R

No

……Spoon
/ week

Cream

1

2

3

1 2

3

4

5

6

M

R

No

……Spoon
/ week

1

2

3

1 2

3

4

5

6

M

R

No

……..gm/
week

1

2

3

1 2

3

4

5

6

M

R

No

……Piece /
week

Mozzarell
a
Tofu

* Food spoon= 15 gm

Vegetables and Fruits
How many times do you eat the following?
Daily
Orange

1

Weekly
2

3

1 2

3

4
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5

6

M

Amount
R

No

………One/
week

1

2

3

1 2

3

4

5

6

M

R

No

………One/
week

Dried
fruits
(raisins,pea
che)

1

2

3

1 2

3

4

5

6

M

R

No

….......Cup
/ week

(fresh or
cooked)
kale

1

2

3

1 2

3

4

5

6

M

R

No

……...Cup /
week

(fresh or
cooked)
celery

1

2

3

1 2

3

4

5

6

M

R

No

……...Cup /
week

Spinach
(fresh or
cooked)

1

2

3

1 2

3

4

5

6

M

R

No

…...…Cup /
week

(fresh or
cooked)
broccoli

1

2

3

1 2

3

4

5

6

M

R

No

…...…Cup /
week

Mashroom
(fresh or
sundried)

1

2

3

1 2

3

4

5

6

M

R

No

……...Cup /
week

Potatoes
(fried or
cooked)

1

2

3

1 2

3

4

5

6

M

R

No

………One/
week

Homos,len
tis

1

2

3

1 2

3

4

5

6

M

R

No

...……Cup /
week

Fool
(black
beans)

1

2

3

1 2

3

4

5

6

M

R

No

…..….Cup /
week

Fig

*Cup = 240 m
Cultural Food and others
Weekly

Amount

How many times do
you have Greesh per
week?

1

2

3

4

5

6

M

R

No

……...Cup/
week

How many times do
you have Saleeq per
week?

1

2

3

4

5

6

M

R

No

……...Cup/
week

How many times do
you have Harees per
week?

1

2

3

4

5

6

M

R

No

….......Cup/
week
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How many times do
you have Marase or
msabeb per week?

1

2

3

4

5

6

M

R

No

……...Cup/
week

How many times do
you have Pasta with
cheese or milk
(lasagna, fettuccine,
bashamel( per week?

1

2

3

4

5

6

M

R

No

……...Cup/
week

How many times do
you have pizza per
week?

1

2

3

4

5

6

M

R

No

...…...piece
s/week

Sweets
Daily
How many
times do
you have
Ice cream?
How many
times do
you have
carbonated
beverages?
How many
times do
you have
chocolate?
How many
times do
you have
muffins or
cake or
donuts?
How many
times do
you have
biscuits?
How many
times do
you have
cream
caramel or
custard?

Weekly

1

2

3

1 2 3 4

5 6

M

Amount

R

No

……Piece/
week
Type………
…
……Piece/
week

1

1

2

2

3

3

1 2 3 4

1 2 3 4

5 6

5 6

M

M

R

R

No

No

Type………
…
……Piece/
week
Type………
…
……Piece/
week

1

1

2

2

3

3

1 2 3 4

1 2 3 4

5 6

5 6

M

M

R

R

No

No

Type………
…
…....Piece/
week
Type………
…
……Piece/
week

1

2

3

1 2 3 4

5 6

Tea and Coffee
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M

R

No

Type………
…

Daily
How many
times do
Current
Season1
you drink
red tea?

Weekly

2

3

1 2 3 4

5 6

What
How many
is the extent of your exposure to the sun?
times do
1 2 3
1 2 3 4 5 6
you drink
green tea?
What is the time of exposure to the sun?

Water

Amount

Summer
M
R
No
Winter

…..Cup/
week
Type
(……………)

 No exposure

Daily Minutes (….…)
……Cup/
week
Weekly
Minutes
(…….)
M R
No
Type

(……………)
 at sunrise
at noon
 before sunset

under
Daily Outside/ directly
Amount
How many
1-3
What
is thetimes
naturedoofyou
your work?

drink water?
Kind?

cups

Bottled Water

3-6
cups
water from
Tanks

What are the parts of the body most exposed to
the sun?

the sun

More than

6-12 cups
Inside
(in covered
12 cups
rooms/ paces)
Tape water

Face

hands
Face and hands
Face, hands and feet
Body except face

What is the extent of clothing cover to the
body during exposure to the sun?

Body except face and
hands
 Body except face,
hands and feet
The whole body
Body except hands and
feet
 Yes
(type………………)

Do you use sun protection creams?

 No
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Physical activity (International Physical Activity Questionnaire) (IPAQ)
READ: I am going to ask you about the time you spent being physically active in the last 7
days. Please answer each question even if you do not consider yourself to be an active
person. Think about the activities you do at work, as part of your house and yard work, to
get from place to place, and in your spare time for recreation, exercise or sport.
READ: Now, think about all the vigorous activities which take hard physical effort that you
did in the last 7 days. Vigorous activities make you breathe much harder than normal and
may include heavy lifting, digging, aerobics, or fast bicycling. Think only about those
physical activities that you did for at least 10 minutes at a time.
1.

During the last 7 days, on how many days did you do vigorous physical activities?

_____
8.
9.
2.
days?

Days per week [VDAY; Range 0-7, 8,9]
Don't Know/Not Sure
Refused
How much time did you usually spend doing vigorous physical activities on one of those

__ __ Hours per day [VDHRS; Range: 0-16]
__ __ Minutes per day [VDMIN; Range: 0-960, 998, 999]
998. Don't Know/Not Sure
999. Refused
➔Interviewer probe: An average time for one of the days on which you do vigorous activity
is being sought. If the respondent can't answer because the pattern of time spent varies
widely from day to day, ask: "How much time in total would you spend over the last 7 days
doing vigorous physical activities?”
__ __ Hours per week
[VWHRS; Range: 0-112]
__ __ Minutes per week [VWMIN; Range: 0-6720, 9998, 9999]
9998. Don't Know/Not Sure
9999. Refused
READ: Now think about activities which take moderate physical effort that you did in the
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last 7 days. Moderate physical activities make you breathe somewhat harder than normal
and may include carrying light loads, bicycling at a regular pace, or doubles tennis. Do not
include walking. Again, think about only those physical activities that you did for at least
10 minutes at a time.
3.

During the last 7 days, on how many days did you do moderate physical activities?

____
8.
9.

Days per week
[MDAY; Range: 0-7, 8, 9]
Don't Know/Not Sure
Refused

4. How much time did you usually spend doing moderate physical activities on one of those days?
__ __ Hours per day
[MDHRS; Range: 0-16]
__ __ Minutes per day [MDMIN; Range: 0-960, 998, 999]
998. Don't Know/Not Sure
999. Refused
➔[Interviewer probe: An average time for one of the days on which you do moderate
activity is being sought. If the respondent can't answer because the pattern of time spent
varies widely from day to day, or includes time spent in multiple jobs, ask: “What is the total
amount of time you spent over the last 7 days doing moderate physical activities?”
__ __ Hours per week
[MWHRS; Range: 0-112]
__ __ Minutes per week [MWMIN; Range: 0-6720, 9998, 9999]
9998. Don't Know/Not Sure
9999. Refused
READ: Now think about the time you spent walking in the last 7 days. This includes at
work and at home, walking to travel from place to place, and any other walking that you
might do solely for recreation, sport, exercise, or leisure.
5.

During the last 7 days, on how many days did you walk for at least 10 minutes at a time?
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____ Days per week [WDAY; Range: 0-7, 8, 9]
8. Don't Know/Not Sure
9. Refused
6. How much time did you usually spend walking on one of those days?
__ __ Hours per day [WDHRS; Range: 0-16]
__ __ Minutes per day [WDMIN; Range: 0-960, 998, 999]
998. Don't Know/Not Sure
999. Refused
➔[Interviewer probe: An average time for one of the days on which you walk is being
sought. If the respondent can't answer because the pattern of time spent varies widely from
day to day, ask: “What is the total amount of time you spent walking over the last 7 days?”
__ __
__ __
9998.
9999.

Hours per week
[WWHRS; Range: 0-112]
Minutes per week
[WWMIN; Range: 0-6720, 9998, 9999]
Don't Know/Not Sure
Refused
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READ: Now think about the time you spent sitting on week days during the last 7 days.
Include time spent at work, at home, while doing course work, and during leisure time.
This may include time spent sitting at a desk, visiting friends, reading or sitting or lying
down to watch television.
7. During the last 7 days, how much time did you usually spend sitting on a week day?
__ __ Hours per weekday [SDHRS; 0-16]
__ __ Minutes per weekday [SDMIN; Range: 0-960, 998, 999]
998. Don't Know/Not Sure
999. Refused
➔[Interviewer probe]: An average time per day spent sitting is being sought. If the
respondent can't answer because the pattern of time spent varies widely from day to day,
ask: “What is the total amount of time you spent sitting last Wednesday?”
__ __ Hours on Wednesday [SWHRS; Range 0-16]
__ __ Minutes on Wednesday [SWMIN; Range: 0-960, 998, 999]
998. Don't Know/Not Sure
999. Refused
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